

# CITATION REPORT

List of articles citing

## The 2016 revision of the World Health Organization classification of lymphoid neoplasms

DOI: 10.1182/blood-2016-01-643569  
Blood, 2016, 127, 2375-90.

**Source:** <https://exaly.com/paper-pdf/64170812/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2204	Mature B-Cell Neoplasms Overview. <b>2008</b> , 429-442		
2203	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Monoclonal B-Cell Lymphocytosis. <b>2008</b> , 443-466		
2202	Mature T- and NK-Cell Neoplasms Overview. <b>2008</b> , 665-672		
2201	Reply to: Correspondence Regarding the Study by Chen-Lu Yang et al. Published in the Chinese Medical Journal, 129(18):2258-9. <b>2016</b> , 129, 2898		
2200	Correspondence Regarding the Study by Chen-Lu Yang et al. Published in the Chinese Medical Journal, 129(18):2258-9. <b>2016</b> , 129, 2897		
2199	Monoclonal B-cell Lymphocytosis in a Patient with Wegener Granulomatosis: A Case Report and Update on 2016 World Health Organization Classification. <b>2016</b> , 129, 2258-9		1
2198	Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How. <b>2016</b> , 8, e2016062		3
2197	Pathology Image-Sharing on Social Media: Recommendations for Protecting Privacy While Motivating Education. <b>2016</b> , 18, 817-25		45
2196	Follicular Lymphoma: The Management of Elderly Patient. <b>2017</b> , 9, e2017009		11
2195	The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era. <b>2016</b> , 8, e2016045		2
2194	Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. <b>2016</b> , 5,		7
2193	Burkitt lymphoma in adolescents and young adults: management challenges. <b>2017</b> , 8, 11-29		37
2192	Towards Stratified Medicine in Plasma Cell Myeloma. <b>2016</b> , 17,		6
2191	Hereditary Predispositions to Myelodysplastic Syndrome. <b>2016</b> , 17,		47
2190	Enteropathy-Associated T-Cell Lymphoma. <b>2016</b> , 11, 504-513		29
2189	B-Zell-Lymphome der Haut - Pathogenese, Diagnostik und Therapie. <b>2016</b> , 14, 1207-1225		0
2188	Breast implant-associated anaplastic large cell lymphoma vs. anaplastic large cell lymphoma in a patient with breast implant effusion history: a diagnostic dilemma. <b>2016</b> , 9, 173-177		

2187	Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss. <b>2016</b> , 4, 2324709616683721		
2186	T-cell Lymphoma Epidemiology: the Known and Unknown. <b>2016</b> , 11, 492-503		25
2185	PD-L1 is upregulated by EBV-driven LMP1 through NF- $\kappa$ B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. <b>2016</b> , 9, 109		150
2184	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <b>2016</b> , 108,		44
2183	Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy. <b>2016</b> , 14, 1207-1224		13
2182	Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. <b>2016</b> , 2016, 432-436		2
2181	Starry Sky Pattern in Hematopoietic Neoplasms: A Review of Pathophysiology and Differential Diagnosis. <b>2016</b> , 23, 343-355		1
2180	Plasmablastic lymphoma: oral presentation in patient suffering from osteoradionecrosis of the jaw. <b>2016</b> , 29, 94-97		
2179	The role of HGF/c-MET signaling pathway in lymphoma. <b>2016</b> , 9, 135		29
2178	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. <i>Blood</i> , <b>2016</b> , 128, 1101-11	2.2	76
2177	Targetable gene fusions in T-cell lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1161-2	2.2	
2176	Pediatric-type FL: simply different. <i>Blood</i> , <b>2016</b> , 128, 1030-1	2.2	2
2175	Current therapy guidelines for Waldenstrom's macroglobulinaemia. <b>2016</b> , 29, 194-205		4
2174	MYC rearranged B-cell neoplasms: Impact of genetics on classification. <b>2016</b> , 209, 431-439		12
2173	Formulating a novel prognostic index for diffuse large B-cell lymphoma: T cells break the Silence. <b>2016</b> , 57, 2733-2735		
2172	EBV, an inhibited receptor kinase, and lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1542-3	2.2	1
2171	Precision medicine in diffuse large B-cell lymphoma: Hype or hope?. <b>2016</b> , 68, 22-26		1
2170	Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival. <i>Blood</i> , <b>2016</b> , 128, 1578-89	2.2	11

2169	The Pathology of Reactive Lymphadenopathies: A Discussion of Common Reactive Patterns and Their Malignant Mimics. <b>2016</b> , 140, 881-92	9
2168	Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. <b>2016</b> , 15, 2241-7	5
2167	[Hemato-oncological imaging : Importance of hybrid procedures]. <b>2016</b> , 56, 597-604	
2166	Lack of association between cytotoxic T-lymphocyte antigen-4 gene polymorphisms and lymphoid malignancy risk: evidence from a meta-analysis. <b>2016</b> , 95, 1685-94	5
2165	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. <b>2016</b> , 58, 72-77	26
2164	Practice changing information in aggressive lymphoma, ASH 2015. <b>2016</b> , 9, 124-126	0
2163	Rewired NFB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. <b>2016</b> , 97, 499-510	14
2162	Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?. <b>2016</b> , 30, 1163-1177	15
2161	The Spectrum of Double Hit Lymphomas. <b>2016</b> , 30, 1239-1249	7
2160	Pathology of Transplantation. <b>2016</b> ,	1
2159	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. <b>2016</b> , 38, 346-357	17
2158	Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. <b>2016</b> , 16, 1093-1102	3
2157	Transplantation and Malignancy. <b>2016</b> , 451-476	
2156	New mutations for nodal lymphomas of TFH origin. <i>Blood</i> , <b>2016</b> , 128, 1446-7	2.2 1
2155	2016 US lymphoid malignancy statistics by World Health Organization subtypes. <b>2016</b> , 66, 443-459	504
2154	¿Hacia dónde vamos con la patologí moderna? La patologí personalizada. <b>2016</b> , 49, 205-207	2
2153	Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases. <b>2016</b> , 4, 199-210	13
2152	Ectopic extra-nodal in situ follicular neoplasia (ISFN). <b>2016</b> , 9, 151-153	2

2151	Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. <b>2016</b> , 11, 514-527	94
2150	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. <b>2016</b> , 6, e491	4
2149	Contributions of Dr. Louis "Pepper" Dehner to the art of cutaneous pathology, the first pediatric dermatopathologist. <b>2016</b> , 33, 441-449	1
2148	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. <b>2016</b> , 7, 12602	102
2147	Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma: Current Understanding and Differential Diagnosis. <b>2016</b> , 56, 109-118	28
2146	The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship. <b>2016</b> , 40, e94-e102	177
2145	Discussion: Anaplastic Large Cell Lymphoma in the Plastic Surgery Practice: Has It Influenced Practice Patterns?. <b>2016</b> , 138, 819e-820e	2
2144	Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. <b>2016</b> , 29, 1173-82	21
2143	A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. <b>2016</b> , 29, 1212-20	27
2142	Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. <b>2016</b> , 95, 1271-80	7
2141	Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. <b>2017</b> , 102, e148-e151	89
2140	Treatment approaches of hard-to-treat non-Hodgkin lymphomas. <b>2017</b> , 10, 259-273	7
2139	Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of $\beta_2$ -microglobulin yields a more accurate GELTAMO-IPI. <b>2017</b> , 176, 918-928	50
2138	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <b>2017</b> , 47, 35-49	7
2137	Epstein-Barr virus-positive mucocutaneous ulcer. <b>2017</b> , 33, 50-51	9
2136	Sensitivity of fine-needle aspiration biopsy for diagnosing and grading follicular lymphomas using a multiparameter approach in a cancer center. <b>2017</b> , 6, 80-88	4
2135	Nódulo de la hermana María José y linfoma difuso de células grandes B. <b>2017</b> , 50, 268-272	
2134	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <b>2017</b> , 34, 324-356	79

2133	Clinicopathologic Variants of Mycosis Fungoides. <b>2017</b> , 108, 192-208	19
2132	[Mysterious gingival ulcers]. <b>2017</b> , 37, 198-201	
2131	Epidemiology and environmental aspects of marginal zone lymphomas. <b>2017</b> , 30, 84-91	20
2130	Functional proteomic insights in B-cell chronic lymphocytic leukemia. <b>2017</b> , 14, 137-146	5
2129	Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. <b>2017</b> , 12, 3	8
2128	Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <b>2017</b> , 10, 239-249	60
2127	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. <b>2017</b> , 15, 541-552	17
2126	Non-Hodgkin lymphoma. <b>2017</b> , 390, 298-310	225
2125	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. <b>2017</b> , 64, 19-27	31
2124	Outcome of Referrals for Non-Responsive Celiac Disease in a Tertiary Center: Low Incidence of Refractory Celiac Disease in the Netherlands. <b>2017</b> , 8, e218	23
2123	Cost-effective approach to the diagnostic workup of B cell lymphoproliferative disorders via optimal integration of flow cytometric data. <b>2017</b> , 39, 137-146	2
2122	Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. <b>2017</b> , 177, 67-71	27
2121	Primary mediastinal large B-cell lymphoma. <b>2017</b> , 113, 318-327	45
2120	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. <b>2017</b> , 30, 745-760	39
2119	Infection in Organ Transplantation. <b>2017</b> , 17, 856-879	326
2118	Welcome to the 9th Volume of Immunotherapy. <b>2017</b> , 9, 1-3	1
2117	Clinicopathological analysis of 12 patients with Epstein-Barr virus-positive primary intestinal T/natural killer-cell lymphoma (EBV ITNKL). <b>2017</b> , 70, 1052-1063	11
2116	Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. <b>2017</b> , 30, 761-772	58

2115 [Immune-checkpoint and hemopathies]. **2017**, 37, 101-110

2114 Primary central nervous system natural killer/T-cell lymphoma: An atypical case of chronic meningitis. **2017**, 44, 228-230 1

2113 CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma. **2017**, 71, 81-88 9

2112 Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells. **2017**, 71, 89-97 15

2111 How we treat chronic active Epstein-Barr virus infection. **2017**, 105, 406-418 47

2110 Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols. **2017**, 102, 1091-1098 27

2109 Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. **2017**, 17, 193-200 18

2108 Diagnostic Liquid-Based Cytology. **2017**, 13

2107 Die Diagnostik und Therapie kutaner Lymphome erfordert spezielle klinische und dermatohistologische Kenntnisse. **2017**, 15, 249-250 2

2106 Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6. **2017**, 213, 659-665 4

2105 Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours. **2017**, 11, 96-109 15

2104 Peripheral T-cell lymphoma, not otherwise specified. *Blood*, **2017**, 129, 1103-1112 2.2 42

2103 LGL leukemia: from pathogenesis to treatment. *Blood*, **2017**, 129, 1082-1094 2.2 137

2102 Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. *Blood*, **2017**, 129, 1095-1102 2.2 77

2101 T cell-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach. **2017**, 70, 187-201 6

2100 Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. *Blood*, **2017**, 129, 2143-2147 2.2 36

2099 Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. **2017**, 3, 1253-1256 37

2098 Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sżary syndrome?. **2017**, 27, 49-53 4

2097	Ocular adnexal lymphomas: a review. <b>2017</b> , 12, 133-148	3
2096	Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review. <b>2017</b> , 58, 2403-2418	11
2095	Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma. <b>2017</b> , 13, 859-862	4
2094	Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). <b>2017</b> , 70, 461-468	8
2093	Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression. <b>2017</b> , 102, 1238-1246	7
2092	Book Review Hematopathology, 2nd edition. <b>2017</b> , 470, 353-354	
2091	Lymphoma classification update: B-cell non-Hodgkin lymphomas. <b>2017</b> , 10, 405-415	32
2090	MYD88 L265P mutation in cutaneous involvement by Waldenström macroglobulinemia. <b>2017</b> , 44, 625-631	7
2089	Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment. <b>2017</b> , 282, 395-414	8
2088	Case 11-2017 - A 61-Year-Old Woman with Leg Swelling, Back Pain, and Hydronephrosis. <b>2017</b> , 376, 1461-1471	1
2087	Immunophenotypic Shifts in Primary Cutaneous T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. <b>2017</b> , 41, 431-445	10
2086	Commentary on: CD30+ T Cells in Late Seroma May Not Be Diagnostic of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <b>2017</b> , 37, 776-778	4
2085	Cyclin D1 overexpression in proliferation centres of small lymphocytic lymphoma/chronic lymphocytic leukaemia. <b>2017</b> , 70, 899-902	10
2084	Diffuse Large B-Cell Lymphoma in a Patient With Necrotizing Fasciitis Secondary to Silicone Biopolymer Implants in Buttock. <b>2017</b> , 25, 606-607	0
2083	Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. <b>2017</b> , 10, 90	72
2082	Die histologischen Typen der lymphomatoiden Papulose - Ein Vorschlag für die Vereinfachung des Buchstabenchaos. <b>2017</b> , 15, 390-394	1
2081	Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics. <b>2017</b> , 125, 604-614	22
2080	Clinicopathological Study of 30 Cases of Peripheral T-cell Lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan. <b>2017</b> , 41, 506-516	16



2079	Emergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK's population-based Haematological Malignancy Research Network. <b>2017</b> , 78, 53-60	11
2078	Mutational landscape of B-cell post-transplant lymphoproliferative disorders. <b>2017</b> , 178, 48-56	38
2077	The diagnosis and management of NK/T-cell lymphomas. <b>2017</b> , 10, 85	152
2076	Pediatric-type Follicular Lymphoma and Pediatric Nodal Marginal Zone Lymphoma: Recent Clinical, Morphologic, Immunophenotypic, and Genetic Insights. <b>2017</b> , 24, 128-135	10
2075	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. <b>2017</b> , 214, 1371-1386	83
2074	Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. <b>2017</b> , 17, 623-632	2
2073	Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. <b>2017</b> , 123, 3550-3567	48
2072	Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms. <b>2017</b> , 31, 425-436	7
2071	Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation. <b>2017</b> , 44, 703-712	2
2070	Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. <b>2017</b> , 49, 695-714	166
2069	Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews. <b>2017</b> , 99, 51-55	
2068	Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation. <b>2017</b> , 40, 262-269	7
2067	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features. <b>2017</b> , 41, 1322-1332	18
2066	The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. <b>2017</b> , 178, 739-746	15
2065	Role of plasma cells in Waldenström macroglobulinaemia. <b>2017</b> , 49, 337-345	8
2064	Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. <b>2017</b> , 19, 43	18
2063	Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?. <b>2017</b> , 123, 3222-3225	7
2062	Intravascular large B cell lymphoma diagnosed in random duodenal biopsies. A case report and a literature review. <b>2017</b> , 471, 429-431	4

2061	Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritis. <b>2017</b> , 96, 1061-1063	
2060	PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature. <b>2017</b> , 25, 333-338	6
2059	2016 WHO Classification update-What's new in lymphoid neoplasms. <b>2017</b> , 39 Suppl 1, 14-22	14
2058	Flow cytometry-Recognizing unusual populations in leukemia and lymphoma diagnosis. <b>2017</b> , 39 Suppl 1, 86-92	11
2057	Management of Lymphomas: A Case-Based Approach. <b>2017</b> ,	
2056	Epstein-Barr virus-positive mucocutaneous ulcer in Crohn's disease. A condition to consider in immunosuppressed IBD patients. <b>2017</b> , 49, 934-937	26
2055	Past, present and future of cutaneous lymphomas. <b>2017</b> , 34, 3-14	10
2054	The Landscape of Cutaneous Lymphomas in 2016, An Introduction. <b>2017</b> , 34, 1-2	
2053	Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. <b>2017</b> , 41, 216-224	39
2052	Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology. <b>2017</b> , 41, 1155-1166	25
2051	Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. <b>2017</b> , 147, 124-128	8
2050	EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1. <b>2017</b> , 147, 129-152	54
2049	Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 5. <b>2017</b> , 147, 204-216	10
2048	Hodgkin lymphoma classification: Are we at a crossroads?. <b>2017</b> , 123, 3654-3655	4
2047	Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes. <b>2017</b> , 39, 1010428317706227	13
2046	Primary Cutaneous CD4 Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. <b>2017</b> , 21, 502-506	10
2045	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. <b>2017</b> , 41, 998-1004	28
2044	Preparing pathology for precision medicine: challenges and opportunities. <b>2017</b> , 471, 141-146	6

2043	BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. <i>Blood</i> , <b>2017</b> , 130, 489-500	2.2	43
2042	Comparison of clinicopathologic characteristics of gastric follicular lymphomas and duodenal follicular lymphomas. <b>2017</b> , 65, 201-208		5
2041	The aggressive peripheral T-cell lymphomas: 2017. <b>2017</b> , 92, 706-715		47
2040	and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. <i>Blood</i> , <b>2017</b> , 130, 554-557	2.2	68
2039	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <b>2017</b> , 28, 2169-2178		157
2038	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous T-Cell Lymphomas. <b>2017</b> , 41, 204-215		41
2037	Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). <b>2017</b> , 9, 74-79		5
2036	Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study. <b>2017</b> , 21, 507-512		8
2035	Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. <b>2017</b> , 10, 277-284		18
2034	Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. <b>2017</b> , 282, 371-394		41
2033	Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma. <b>2017</b> , 42, 595-602		18
2032	The 2016 updated WHO classification of lymphoid neoplasias. <b>2017</b> , 35 Suppl 1, 37-45		51
2031	Molecular genetics of aggressive B-cell lymphoma. <b>2017</b> , 35 Suppl 1, 76-79		6
2030	B-cell lymphomas with discordance between pathological features and clinical behavior. <b>2017</b> , 471, 439-451		4
2029	How I treat double-hit lymphoma. <i>Blood</i> , <b>2017</b> , 130, 590-596	2.2	85
2028	Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. <b>2017</b> , 31, 705-719		14
2027	Mutations of are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. <i>Blood</i> , <b>2017</b> , 130, 323-327	2.2	34
2026	SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. <i>Blood</i> , <b>2017</b> , 130, 501-513	2.2	62

2025	Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. <b>2017</b> , 242, 387-390	8
2024	Syndrome lymphoprolifatif induit par le virus EBV dans le contexte d'une maladie rhumatismale : revue systématique de la littérature. <b>2017</b> , 84, 378-384	
2023	Hematolymphoid lesions of the breast. <b>2017</b> , 34, 462-469	2
2022	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. <b>2017</b> , 41, 877-886	13
2021	Autopsy case of systemic EBV-positive T-cell lymphoma of childhood with marked hepatomegaly in a middle-aged man. <b>2017</b> , 67, 431-433	2
2020	Epstein-Barr Virus-Positive Mucocutaneous Ulcer Mimicking Rectal Carcinoma at 18F-FDG PET/CT. <b>2017</b> , 42, 645-646	7
2019	Diagnosis and classification of hematologic malignancies on the basis of genetics. <i>Blood</i> , <b>2017</b> , 130, 410-423	113
2018	Pathology and classification of aggressive mature B-cell lymphomas. <b>2017</b> , 35 Suppl 1, 80-83	2
2017	The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. <b>2017</b> , 99, 627-633	37
2016	Imaging features of myeloproliferative neoplasms. <b>2017</b> , 72, 801-809	8
2015	Evolution of lymphoma staging and response evaluation: current limitations and future directions. <b>2017</b> , 14, 631-645	19
2014	Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia. <b>2017</b> , 147, 596-603	7
2013	NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <b>2017</b> , 37, 285-289	127
2012	CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival. <b>2017</b> , 39, 552-556	8
2011	[Granulomatous reaction pattern of the skin : Interstitial granulomatous dermatitis - lymphoma - vasculitis]. <b>2017</b> , 68, 553-559	4
2010	B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2. <b>2017</b> , 147, 153-170	28
2009	HIV-associated Kaposi sarcoma and related diseases. <b>2017</b> , 31, 1903-1916	65
2008	The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. <i>Blood</i> , <b>2017</b> , 130, 433-439	2.2 38

2007	TP53 mutation and survival in aggressive B cell lymphoma. <b>2017</b> , 141, 1381-1388	39
2006	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Szary syndrome - Update 2017. <b>2017</b> , 77, 57-74	240
2005	Coeliac disease and other intraepithelial lymphocytic disorders of the upper gastrointestinal tract. <b>2017</b> , 23, 62-72	1
2004	It Takes a Village to Unmask HSTL. <b>2017</b> , 7, 352-353	1
2003	[The value of blood immunophenotyping and clonality testing in the management of cutaneous T-cell lymphomas]. <b>2017</b> , 144, 315-322	0
2002	Concomitant chronic myeloid leukemia and monoclonal B cell lymphocytosis - a very rare condition. <b>2017</b> , 39, 167-169	1
2001	Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. <b>2017</b> , 19, 29	14
2000	Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Review of Current Disease Understanding and Therapeutic Approaches. <b>2017</b> , 31, 189-207	12
1999	Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin. <b>2017</b> , 10, 429-453	10
1998	Epidemiology of Nasopharyngeal Lymphoma in the United States: A Population-Based Analysis of 1119 Cases. <b>2017</b> , 156, 870-876	13
1997	Angioimmunoblastic T-Cell Lymphoma. <b>2017</b> , 31, 223-238	13
1996	Management of Anaplastic Large Cell Lymphoma. <b>2017</b> , 31, 209-222	15
1995	Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T/NK-cell Lymphomas: A Histology-Specific Review. <b>2017</b> , 31, 335-357	8
1994	Uncommon Variants of T-Cell Lymphomas. <b>2017</b> , 31, 285-295	2
1993	Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma. <b>2017</b> , 57, 89-96	13
1992	Non-Hodgkin lymphoma. <b>2017</b> , 45, 297-304	9
1991	PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. <b>2017</b> , 31, 1633-1637	97
1990	Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma. <b>2017</b> , 28, 918-920	1

1989	Genetic profiling of and in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , <b>2017</b> , 129, 2760-2770	2.2	82
1988	Cutaneous Lymphomas with Cytotoxic Phenotype. <b>2017</b> , 10, 409-427		10
1987	Managing post-transplant lymphoproliferative disorder. <b>2017</b> , 5, 19-35		8
1986	Rare B Cell Lymphoproliferative Disorders. <b>2017</b> , 760-775		
1985	Rare T Cell Lymphomas. <b>2017</b> , 830-839		
1984	Clinicopathologic Variants of Mycosis Fungoides. <b>2017</b> , 108, 192-208		3
1983	Bacteria associated with marginal zone lymphomas. <b>2017</b> , 30, 32-40		19
1982	Waldenström Macroglobulinemia: Review of Pathogenesis and Management. <b>2017</b> , 17, 252-262		25
1981	Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. <b>2017</b> , 10, 289-297		21
1980	Genetic Landscape and Classification of Peripheral T Cell Lymphomas. <b>2017</b> , 19, 28		32
1979	Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. <b>2017</b> , 92, E114-E117		20
1978	Lymphomatoid papulosis - making sense of the alphabet soup: a proposal to simplify terminology. <b>2017</b> , 15, 390-394		6
1977	Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110 as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies. <b>2017</b> , 361, 312-321		5
1976	Primary central nervous system lymphoma: essential points in diagnosis and management. <b>2017</b> , 34, 61		18
1975	Intravascular T-cell lymphoma: A rare, poorly characterized entity with cytotoxic phenotype. <b>2017</b> , 37, 365-370		7
1974	New targeted therapies for malignant lymphoma based on molecular heterogeneity. <b>2017</b> , 10, 39-51		12
1973	Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. <i>Blood</i> , <b>2017</b> , 129, 280-288	2.2	98
1972	BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. <b>2017</b> , 105, 465-469		17

1971 [Update on nodular lymphocyte predominant Hodgkin's lymphoma and related lesions]. **2017**, 38, 3-10

1970 Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 Revision of the World Health Organization Classification. **2017**, 116, 620-625 18

1969 Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. **2017**, 52, 650-652 15

1968 A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. **2017**, 34, 22-35 38

1967 Cutaneous extranodal NK/T-cell lymphoma mimicking cellulitis in an HIV positive patient without lymphopenia. **2017**, 44, 296-299 3

1966 Sinusoidal CD30+ diffuse large B-cell lymphoma can masquerade as anaplastic large cell lymphoma in pediatric posttransplant lymphoproliferative disorders. **2017**, 64, e26403 4

1965 The Microscope as a Tool for Disease Discovery-A Personal Voyage. **2017**, 12, 1-24 1

1964 Révision 2016/2017 de la classification OMS des hémopathies lymphoïdes matures : ce qui va changer dans la pratique quotidienne. **2017**, 2017, 39-48

1963 Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. **2017**, 23, 2232-2244 53

1962 Pathology of nodal marginal zone lymphomas. **2017**, 30, 50-55 10

1961 Cutaneous lymphomas with a panniculitic presentation. **2017**, 34, 36-43 21

1960 T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. **2017**, 109, 21

1959 Marginal zone lymphomas: Reconsidering similarities and differences while moving towards personalized treatment. **2017**, 30, 1-4 1

1958 Cutaneous EBV-related lymphoproliferative disorders. **2017**, 34, 60-75 36

1957 Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. **2017**, 10, 137-146 10

1956 Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications. **2017**, 10, 123-135 2

1955 Erythema multiforme-like cutaneous lesions in monomorphic epitheliotropic intestinal T-cell lymphoma: a rare case report. **2017**, 44, 183-188 9

1954 Clonal B-cell lymphocytosis of marginal zone origin. **2017**, 30, 77-83 9

1953	Epstein-Barr virus-positive follicular lymphoma. <b>2017</b> , 30, 519-529		26
1952	Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma. <b>2017</b> , 34, 85-98		17
1951	How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. <b>2017</b> , 176, 851-866		36
1950	Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma. <b>2017</b> , 10, 1179545X17705863		4
1949	[Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences]. <b>2017</b> , 158, 1635-1641		1
1948	Comparison of IGH Profile Signals Using t(4;14) and IGH Break-Apart Probes by FISH in Multiple Myeloma. <b>2017</b> , 153, 18-21		3
1947	Checkpoint Inhibition in Non-Hodgkin's Lymphoma. <b>2017</b> , 40, 662-672		1
1946	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. <b>2017</b> , 49, 731-739		12
1945	Primary Cutaneous Acral CD8 T-Cell Lymphoma. <b>2017</b> , 141, 1469-1475		13
1944	A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type. <b>2017</b> , 25, 41-49		23
1943	Primary splenic low-grade follicular lymphoma presenting with leukaemia and large cell transformation in the marrow. <b>2017</b> , 49, 649-652		2
1942	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <b>2017</b> , 117, 1685-1688		9
1941	Hemomath. <b>2017</b> ,		14
1940	70 years of the -highly cited papers: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. <b>2017</b> , 70, 909-910		1
1939	KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. <i>Blood</i> , <b>2017</b> , 130, 2900-2902	2.2	22
1938	[The role of autologous hemopoietic stem cell transplantation in T-cell lymphoma. Hungarian data]. <b>2017</b> , 158, 1615-1619		
1937	Ultrasound features of Primary Cutaneous CD4+ Small/Medium-Sized T-Cell Lymphoproliferative Disorder. <b>2017</b> , 108, 792-794		1
1936	Flow Cytometry of T'cells and T-cell Neoplasms. <b>2017</b> , 37, 725-751		5



1935	Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. <b>2017</b> , 62, 12-16	23
1934	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer. <b>2017</b> , 69, 129-139	17
1933	Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. <b>2017</b> , 108, 2022-2029	44
1932	Genetic, Hematologic and Psychological Aspects of Leukemia. <b>2017</b> , 667-755	1
1931	Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas. <b>2017</b> , 41, 1581-1592	11
1930	Double-Hit Large B Cell Lymphoma. <b>2017</b> , 19, 74	5
1929	Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. <b>2017</b> , 60, 120-129	26
1928	Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review. <b>2017</b> , 10, 1179545X17692544	16
1927	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study. <b>2017</b> , 19, 892-904	27
1926	Understanding lymphoma molecular complexity. <i>Blood</i> , <b>2017</b> , 130, 1780-1781	2.2 2
1925	Cutaneous atypical papular CD8+ lymphoproliferative disorder at acral sites in a renal transplant patient. <b>2017</b> , 42, 902-905	8
1924	[WHO classification and clinical spectrum of cutaneous lymphomas]. <b>2017</b> , 68, 682-695	4
1923	Unravelling biology and shifting paradigms in cancer with single-cell sequencing. <b>2017</b> , 17, 557-569	157
1922	Monoclonal antibodies against cutaneous T-cell lymphomas. <b>2017</b> , 17, 1503-1510	5
1921	From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. <b>2017</b> , 7, e591	14
1920	Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200. <b>2017</b> , 179, 480-487	38
1919	The clinicopathologic spectrum of mature aggressive B cell lymphomas. <b>2017</b> , 471, 453-466	19
1918	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <b>2017</b> , 23, 2199-2204	6

1917	Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis. <b>2017</b> , 96, e7781	1
1916	J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. <b>2017</b> , 68, 47-53	4
1915	Advances in the Pathology of High Grade B Cell Lymphomas. <b>2017</b> , 17, S51-S53	
1914	CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. <b>2017</b> , 102, 1923-1930	69
1913	Radiation Therapy in Peripheral T-Cell and Cutaneous Lymphomas. <b>2017</b> , 1-14	
1912	Intravascular large B-cell lymphoma presenting as Richter's syndrome with cerebral involvement in a patient with chronic lymphocytic leukemia. <b>2017</b> , 5, 1444-1449	3
1911	Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact. <b>2017</b> , 7, 10813	27
1910	Differences between chronic lymphocytic leukaemia and small lymphocytic lymphoma cells by proteomic profiling and SNP microarray analysis. <b>2017</b> , 218-219, 20-38	3
1909	Non-Hodgkin Lymphoma State of the Art and Next Questions. <b>2017</b> , 17, S160-S164	
1908	Epstein-Barr virus-associated lymphomas. <b>2017</b> , 372,	181
1907	Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?. <b>2017</b> , 30, 669-676	10
1906	Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia. <b>2017</b> , 9, 709-714	0
1905	Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997-2016. <b>2017</b> , 106, 675-680	11
1904	Flow Cytometry of B-Cell Neoplasms. <b>2017</b> , 37, 697-723	8
1903	Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis. <b>2017</b> , 37, 753-769	24
1902	The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections. <b>2017</b> , 282, 360-370	26
1901	Lymphadenectomy Specimens in a Large Retrospective Cohort of Pediatric Patients Reveal No in situ Lymphomas but a Broad Spectrum of Reactive Changes. <b>2017</b> , 84, 139-143	2
1900	Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region. <b>2017</b> , 135, 1062-1068	15

1899	Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. <b>2017</b> , 61, 39-43	2
1898	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <b>2017</b> , 10, 761-774	11
1897	Indolent T-cell lymphoproliferative disease of the gastrointestinal tract in a renal transplant patient: diagnostic pitfalls and clinical challenges. <b>2017</b> , 49, 547-550	7
1896	What's Your Micromort? A Patient-Oriented Analysis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). <b>2017</b> , 37, 887-891	32
1895	Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms. <b>2017</b> , 14, 567-574	2
1894	Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia. <b>2017</b> , 142, 163-178	44
1893	Epstein-Barr virus (EBV) provides survival factors to EBV diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV DLBCL. <b>2017</b> , 152, 562-573	11
1892	Anaplastic large-cell lymphoma and peripheral T-cell lymphoma: What can pediatricians and adult oncologists learn from each other?. <b>2017</b> , 35 Suppl 1, 70-75	3
1891	Ultrasound Appearance of Primary Cutaneous CD4+ Small/Medium-Sized T-Cell Lymphoproliferative Disorder. <b>2017</b> , 108, 792-794	2
1890	Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia. <b>2017</b> , 39, 237-243	2
1889	Transient abnormal myelopoiesis: A case series and review of the literature. <b>2017</b> , 2, 14-18	2
1888	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. <b>2017</b> , 21, 568-571	1
1887	Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. <b>2017</b> , 83, 146-153	14
1886	Acral angiokeratoma-like pseudolymphoma in a middle-aged woman. <b>2017</b> , 44, 878-881	4
1885	Role of endoscopic ultrasound-guided-fine needle aspiration biopsy in the diagnosis of lymphoma of the pancreas: A clinicopathological study of nine cases. <b>2017</b> , 28, 536-541	8
1884	MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. <b>2017</b> , 71, 960-971	16
1883	Monomorphic epitheliotropic intestinal T-cell lymphoma in pleural effusion: A case report. <b>2017</b> , 45, 1050-1054	8
1882	The clinical significance of c-MYC expression, rearrangement, and copy number gain in extranodal NK/T-cell lymphoma: A retrospective study in China. <b>2017</b> , 103, 38-43	2

1881	Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. <b>2017</b> , 17, 857-862	9
1880	MYC rearrangement in aggressive B-cell lymphomas: A major therapeutic challenge. <b>2017</b> , 149, 343-344	
1879	AEDV Primary Cutaneous Lymphoma Registry. <b>2017</b> , 108, 181-183	3
1878	Primary gastrointestinal anaplastic large cell lymphoma. <b>2017</b> , 49, 479-485	8
1877	Cytogenetics with flow cytometry in lymph node/extranodal tissue biopsies is sensitive to assist the early diagnosis of suspected lymphomas. <b>2017</b> , 96, 1673-1680	1
1876	Management of Patients With Histologic Transformation. <b>2017</b> , 17S, S100-S104	1
1875	Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. <b>2017</b> , 88, 238-246	8
1874	Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. <b>2017</b> , 178, 871-887	31
1873	Pediatric intracerebral histiocytic sarcoma with rhabdoid features: Case report and literature review. <b>2017</b> , 37, 560-568	3
1872	SOX11 holds mantle cell lymphoma's key to home. <i>Blood</i> , <b>2017</b> , 130, 389-391	2.2
1871	Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder: Report of a case and review of the literature. <b>2017</b> , 44, 944-947	11
1870	Post-transplant lymphoproliferative disorder after solid-organ transplant in children. <b>2017</b> , 26, 257-266	17
1869	miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. <b>2017</b> , 405, 79-89	16
1868	Exome sequencing identifies recurrent alterations and the absence of , and mutations in splenic diffuse red pulp small B-cell lymphoma. <b>2017</b> , 102, 1758-1766	32
1867	Specific immunotypes of canine T cell lymphoma are associated with different outcomes. <b>2017</b> , 191, 5-13	22
1866	Clinical applications of genome studies. <b>2017</b> , 35 Suppl 1, 67-69	
1865	[Treatment of mycosis fungoides and Sřary syndrome]. <b>2017</b> , 68, 702-710	6
1864	[Treatment of indolent cutaneous B-cell lymphoma]. <b>2017</b> , 68, 721-726	3

1863	Indeterminate Dendritic Cell Tumor in Thoracic Spine: A Case Report. <b>2017</b> , 108, 543-547		2
1862	["Indolent" pigmented skin tumor for more than 20 years]. <b>2017</b> , 68, 855-858		
1861	CD5-negative mantle cell lymphoma shows a less aggressive outcome and variable SOX11 staining. <b>2017</b> , 10, 49-53		4
1860	Distinguishing Between Hepatosplenic T-cell Lymphoma and T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. <b>2017</b> , 41, 82-93		29
1859	Cutaneous intravascular natural killer/T cell lymphoma with peculiar immunophenotype. <b>2017</b> , 71, 994-1002		11
1858	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , <b>2017</b> , 130, 1832-1844	2.2	44
1857	Cutaneous T-cell Lymphoma. <b>2017</b> , 37, 527-546		32
1856	Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: A long-standing case with an unexpected progression. <b>2017</b> , 44, 964-968		17
1855	Current and emerging treatment options for mantle cell lymphoma. <b>2017</b> , 8, 223-234		16
1854	[Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities]. <b>2017</b> , 68, 727-739		2
1853	[Diagnostics of primary cutaneous lymphomas]. <b>2017</b> , 68, 696-701		1
1852	Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies. <b>2017</b> , 31, 426-435		6
1851	[Treatment of rare cutaneous T-cell lymphoma and blastic plasmacytoid dendritic cell neoplasm]. <b>2017</b> , 68, 711-715		
1850	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <b>2017</b> , 23, 1826-1838		89
1849	Survival for patients with rare haematologic malignancies: Changes in the early 21st century. <b>2017</b> , 84, 81-87		7
1848	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , <b>2017</b> , 130, 1819-1831	2.2	42
1847	Primary Cutaneous B-cell Lymphomas. <b>2017</b> , 37, 547-574		18
1846	. <b>2017</b> , 159, 14		

1845	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. <b>2017</b> , 30, 1688-1697		34
1844	Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. <b>2017</b> , 8, 153		29
1843	Check this checkpoint inhibitor in lymphoma. <i>Blood</i> , <b>2017</b> , 130, 234-235	2.2	2
1842	Incidence and survival of Hodgkin lymphoma patients in Girona (Spain) over three decades: a population-based study. <b>2017</b> , 26 Joining forces for better c, S164-S169		2
1841	Primary ovarian Burkitt's lymphoma: a rare oncological problem in gynaecology: a review of literature. <b>2017</b> , 296, 653-660		8
1840	Nanotechnology, nanosurfaces and silicone gel breast implants: current aspects. <b>2017</b> , 4, 99-113		36
1839	Diagnostik lymphatischer Neoplasien. <b>2017</b> , 41,		0
1838	Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. <b>2017</b> , 7, 647		6
1837	[Primary Intraocular Lymphoma: Relevance of Diagnostic Vitrectomy]. <b>2017</b> , 234, 1524-1532		5
1836	Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers. <b>2017</b> , 179, 724-738		28
1835	Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. <b>2017</b> , 15, 1429-1437		10
1834	S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86). <b>2017</b> , 15, 1266-1273		6
1833	Current Issues in Histology, Biology and Prognosis of Hodgkin Lymphoma. <b>2017</b> , 34, 89-98		
1832	Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. <b>2017</b> , 17, 783-796		23
1831	Primary, non-germinal center, double-expressor diffuse large B cell lymphoma confined to a uterine leiomyoma: A case report. <b>2017</b> , 22, 78-81		1
1830	Primary cutaneous aggressive epidermotropic cytotoxic CD8 T-cell lymphoma: long-term remission after brentuximab vedotin. <b>2017</b> , 56, 1448-1450		4
1829	Lymphoproliferative Diseases of the Gut: A Survival Guide for the General Pathologist. <b>2017</b> , 10, 1021-1037		0
1828	Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. <b>2017</b> , 92, 1382-1390		31

1827	A multicenter study of malignant oral and maxillofacial lesions in children and adolescents. <b>2017</b> , 75, 39-45	12
1826	Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. <b>2017</b> , 96, 1471-1475	24
1825	The discovery and development of romidepsin for the treatment of T-cell lymphoma. <b>2017</b> , 12, 859-873	28
1824	Erythema multiforme-like lesions in primary cutaneous aggressive cytotoxic epidermotropic CD8+ T-cell lymphoma: A diagnostic and therapeutic challenge. <b>2017</b> , 44, 867-873	7
1823	PD-1 signaling and inhibition in AML and MDS. <b>2017</b> , 96, 1441-1448	19
1822	Distinct subtype distribution and somatic mutation spectrum of lymphomas in East Asia. <b>2017</b> , 24, 367-376	5
1821	Tocilizumab in patients with multisystem Erdheim-Chester disease. <b>2017</b> , 6, e1318237	23
1820	Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. <b>2017</b> , 66, 1103-1111	15
1819	Pathobiology and Diagnosis of Multiple Myeloma. <b>2017</b> , 33, 225-236	64
1818	Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. <b>2017</b> , 471, 467-489	38
1817	Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features. <b>2017</b> , 7, 2577	6
1816	Extrafollicular PD1 and Intrafollicular CD3 Expression Are Associated With Survival in Follicular Lymphoma. <b>2017</b> , 17, 645-649	4
1815	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , <b>2017</b> , 130, 1007-1013	2.2 69
1814	Brentuximab vedotin in a patient with enteropathy-associated T-cell lymphoma of the small bowel. <b>2017</b> , 10, 111-114	2
1813	Hematopoietic Tumors Primarily Presenting in Bone. <b>2017</b> , 10, 675-691	6
1812	Observation as the initial management strategy in patients with mantle cell lymphoma. <b>2017</b> , 28, 2489-2495	48
1811	Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. <b>2017</b> , 18, 45	23
1810	Spindle-Cell Variants of Primary Cutaneous Follicle Center B-Cell Lymphomas Are Germinal Center B-Cell Lymphomas by Gene Expression Profiling Using a Formalin-Fixed Paraffin-Embedded Specimen. <b>2017</b> , 137, 2450-2453	12

1809	ALK-positive anaplastic large cell lymphoma undiagnosed in a patient with tuberculosis: a case report and review of the literature. <b>2017</b> , 11, 132	
1808	Gamma-delta (γδ) T-cell lymphoma - another case unclassifiable by World Health Organization classification: a case report. <b>2017</b> , 11, 163	5
1807	CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. <b>2017</b> , 36, 43	19
1806	Oral Manifestations of Hematologic Disease. <b>2017</b> , 25, 149-162	11
1805	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. <b>2017</b> , 30, 1338-1366	27
1804	Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. <b>2017</b> , 10, 697-705	24
1803	Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a Transgender Woman. <b>2017</b> , 37, NP83-NP87	36
1802	Primary Breast Lymphoma-Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma. <b>2017</b> , 109,	4
1801	Emerging Strategies in Treating Double Hit Lymphomas. <b>2017</b> , 17, 563-568	6
1800	Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide. <b>2017</b> , 96, 513-515	0
1799	The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. <b>2017</b> , 140, 1233-1245	34
1798	Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia. <b>2017</b> , 31, 1355-1362	9
1797	Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders. <b>2017</b> , 470, 205-215	9
1796	Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders. <b>2017</b> , 56, 221-230	7
1795	Impact of Double-Hit and Double-Expressor Phenotypes in Relapsed Aggressive B-Cell Lymphomas Treated With Autologous Hematopoietic Stem Cell Transplantation. <b>2017</b> , 35, 1-3	32
1794	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). <b>2017</b> , 70, 595-621	32
1793	Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. <b>2017</b> , 176, 16-36	13
1792	Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?. <b>2017</b> , 58, 30-36	



1791	Methylation patterns in marginal zone lymphoma. <b>2017</b> , 30, 24-31	5
1790	Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. <b>2017</b> , 17, 291-304	24
1789	Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ). <b>2017</b> , 35, 542-547	9
1788	Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. <b>2017</b> , 59, 94-101	6
1787	High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. <b>2017</b> , 31, 37-42	119
1786	Refractory hairy cell leukemia-variant. <b>2017</b> , 92, 1398-1399	2
1785	Epidemiology of Hematologic Malignancies. <b>2017</b> , 543-569	7
1784	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <b>2017</b> , 92, E1-E2	22
1783	Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. <b>2017</b> , 58, 822-833	16
1782	Indolent T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: a review and update. <b>2017</b> , 35, 3-16	43
1781	EBV-associated but HHV8-unrelated double-hit effusion-based lymphoma. <b>2017</b> , 45, 257-261	7
1780	Nivolumab in the Treatment of Hodgkin Lymphoma. <b>2017</b> , 23, 1623-1626	38
1779	Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. <b>2017</b> , 44, 517-532	17
1778	Different predictive values of interim F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. <b>2017</b> , 31, 1-11	7
1777	Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology. <b>2017</b> , 58, 788-796	0
1776	Linfoma Nasal de Células T/Natural Killer Extranodal Refractario Mal Diagnosticado, Tratado de Manera Exitosa: Informe de Caso. <b>2017</b> , 10, 1092-1097	
1775	CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration. <b>2017</b> , 148, 485-493	8
1774	Diagnosis and treatment of neoplastic post-transplant lymphoproliferative disorder following hematopoietic stem cell transplant in $\beta$ -thalassemia: A pediatric case report. <b>2017</b> , 96, e9055	

1773	Das pathologische Blutbild. <b>2017</b> , 14, 46-58	
1772	Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. <b>2017</b> , 7, 660	19
1771	Aggressive lymphoma 2016: revision of the WHO classification. <b>2017</b> , 10, 248-254	23
1770	Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. <b>2017</b> , 7, 653	3
1769	MYC rearrangement in aggressive B-cell lymphomas: A major therapeutic challenge. <b>2017</b> , 149, 343-344	
1768	CNS Erdheim-Chester Disease: A Challenge to Diagnose. <b>2017</b> , 76, 986-996	14
1767	S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86). <b>2017</b> , 15, 1266-1273	6
1766	IgA plasmablastic large B-cell lymphoma. <b>2017</b> , 4, 105-107	2
1765	KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. <b>2017</b> , 148, 465-476	6
1764	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2017</b> , 28, iv62-iv71	134
1763	Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. <b>2017</b> , 57, 109-119	17
1762	The pathobiology and treatment of Hodgkin lymphoma. Where do we go from Gianni Bonadonna's lesson?. <b>2017</b> , 103, 101-113	2
1761	A case of AIDS-related plasmablastic lymphoma of the upper gingiva. <b>2017</b> , 29, 233-239	
1760	Current treatment approaches for NK/T-cell lymphoma. <b>2017</b> , 57, 98-108	19
1759	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <b>2017</b> , 37, 535-546	14
1758	Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?. <b>2017</b> , 2017, 284-294	16
1757	Health Disparities and the Global Landscape of Lymphoma Care Today. <b>2017</b> , 37, 526-534	7
1756	Leukemia Clusters. <b>2017</b> , 1-12	

1755	Lymphoproliferative Tumors of the Ocular Adnexa. <b>2017</b> , 6, 132-142	27
1754	Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. <b>2017</b> , 2017, 371-378	10
1753	Extramedullary haematopoiesis presenting with cardiac tamponade in a patient with polycythaemia vera. <b>2017</b> , 2017,	
1752	Small lymphocytic lymphoma with Reed Sternberg cells: a diagnostic dilemma. <b>2017</b> , 2017,	
1751	Anatomic pathology. <b>2017</b> , 23, 5-12	
1750	Chronic neutropenia in LGL leukemia and rheumatoid arthritis. <b>2017</b> , 2017, 181-186	14
1749	The clinical spectrum of Erdheim-Chester disease: an observational cohort study. <b>2017</b> , 1, 357-366	105
1748	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <b>2017</b> , 1, 2600-2609	43
1747	Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. <b>2017</b> , 1, 1945-1958	16
1746	Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas. <b>2017</b> , 9,	17
1745	Primary hepatic peripheral T-cell lymphoma mimicking hepatocellular carcinoma: a case report. <b>2017</b> , 93, 110-114	6
1744	Viral Oncology: Molecular Biology and Pathogenesis. <b>2017</b> , 6,	70
1743	Epstein-Barr Virus-Associated Vesiculopapular Eruption on the Face of a Patient with Natural Killer T Cell Lymphoma. <b>2017</b> , 29, 618-620	1
1742	From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL). <b>2017</b> , 9,	5
1741	Role of MYC in B Cell Lymphomagenesis. <b>2017</b> , 8,	14
1740	The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. <b>2017</b> , 8,	66
1739	Impact of Chronic Viral Infection on T-Cell Dependent Humoral Immune Response. <b>2017</b> , 8, 1434	5
1738	EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in , , , , and. <b>2017</b> , 2017, 5083463	3

1737	Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Ileum. <b>2017</b> , 2017, 5981013	0
1736	Primary Cutaneous Follicle Centre Lymphoma with Hodgkin and Reed-Sternberg Like Cells: A Case Report and Review of the Literature. <b>2017</b> , 2017, 9549428	5
1735	A Rare Case of Angioimmunoblastic T-Cell Lymphoma with Epstein-Barr Virus-Negative Reed-Sternberg-Like B-Cells, Chylous Ascites, and Chylothorax. <b>2017</b> , 2017, 1279525	6
1734	Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature. <b>2017</b> , 2017, 6230138	9
1733	High-Grade B-Cell Neoplasm with Surface Light Chain Restriction and Tdt Coexpression Evolved in a -Rearranged Diffuse Large B-Cell Lymphoma: A Dilemma in Classification. <b>2017</b> , 2017, 6891957	7
1732	Pediatric Pulmonary Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Review of the Literature. <b>2017</b> , 2017, 8946807	3
1731	Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. <b>2017</b> , 2017, 2861596	5
1730	Plasmacytoma as a Mimicker of Colonic Carcinoma in an Elderly Man. <b>2017</b> , 2017, 4846018	2
1729	T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases and Its Distinction from Other Mature T-Cell Malignancies. <b>2017</b> , 2017, 5873015	4
1728	Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. <b>2017</b> , 12, e0181097	51
1727	CNS relapse of diffuse large B cell Lymphoma A single centre experience. <b>2017</b> , 33, 1454-1458	0
1726	HHV8/EBV Coinfection Lymphoproliferative Disorder: Rare Entity with a Favorable Outcome. <b>2017</b> , 2017, 1578429	5
1725	Unusual Presentation of a Small-Cell Variant of Anaplastic Large-Cell Lymphoma Case: When a Septic Picture Is Not Sepsis. <b>2017</b> , 2017, 7292148	1
1724	Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review. <b>2017</b> , 2017, 2676254	4
1723	B-cell lymphomas involving Waldeyer's ring characterized by distinctive clinical and histopathological features: a comparison of pediatric to adult patients. <b>2017</b> , 8, 11544-11554	8
1722	Miscellaneous Tumors. 186-211	
1721	Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report. <b>2017</b> , 103, e41-e43	3
1720	Signal Pathway in Precursor B-Cell Lymphoblastic Leukemia/Lymphoma. <b>2017</b> ,	

1719	Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A. <b>2017</b> , 50, e6019	2
1718	T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. <b>2017</b> , 18, 71-83	10
1717	Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. <b>2017</b> , 10,	1
1716	Eye swelling and lacrimal gland lymphoma. <b>2017</b> , 110, 195-196	
1715	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. <b>2017</b> , 12, e0186983	8
1714	Evaluation of Opportunities to Improve Hematopathology Diagnosis for Vietnam Pathologists. <b>2017</b> , 148, 529-537	3
1713	3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. <b>2017</b> , 56, 2407-2413	2
1712	De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with and and/or rearrangements: a case report and literature review. <b>2017</b> , 17, 21	8
1711	The role of B cell antigen receptors in mantle cell lymphoma. <b>2017</b> , 10, 164	12
1710	Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). <b>2017</b> , 10, 171	25
1709	Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. <b>2017</b> , 6, 26	25
1708	Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier. <b>2017</b> , 57, 54-63	11
1707	Therapie seltener kutaner T-Zell-Lymphome und der blastären plasmazytoiden dendritischen Zellneoplasie. <b>2017</b> , 12, 316-322	
1706	Inflammatory pseudotumor-like follicular dendritic cell tumor: an underdiagnosed neoplasia. <b>2017</b> , 37,	4
1705	Smoldering mantle cell lymphoma. <b>2017</b> , 36, 185	24
1704	Epstein-Barr virus-positive diffuse large B-cell lymphoma. <b>2017</b> , 30, 443-444	8
1703	Hodgkin Lymphoma Mimicking Osteomyelitis. <b>2017</b> , 10, 542-547	2
1702	Follicular lymphoma: are we ready for a risk-adapted approach?. <b>2017</b> , 2017, 358-364	11

1701	Primary Non-Hodgkin Lymphomas of the Uterus and Uterine Cervix. <b>2017</b> , 03,	2
1700	Flow cytometry of lymph node aspirate can effectively differentiate the reactive lymphadenitis from the nodal non-Hodgkin lymphoma. <b>2017</b> , 10, 219	
1699	Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. <b>2017</b> , 6, 169-184	66
1698	Updated classification and novel treatment prospective for nodal peripheral T-cell lymphomas. <b>2017</b> , 6, 1-4	
1697	[Hypercalcemia, monoclonal peak and leukemic presentation of a High-grade B-cell lymphoma with MYC, BCL-2 and BCL-6 translocations (triple hit). Report of one case]. <b>2017</b> , 145, 1485-1489	0
1696	Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. <b>2017</b> , 11, 771	10
1695	An Unusual Case of Primary Extranodal Lymphoma of the Gallbladder. <b>2017</b> , 9, 6972	3
1694	Cutaneous Gamma-delta T-cell Lymphoma with an Initially Indolent Course Mimicking Lupus Panniculitis. <b>2017</b> , 97, 665-666	2
1693	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. <b>2017</b> , 8, 44960-44975	57
1692	Differential diagnosis of primary cutaneous CD4+ small/medium T-cell lymphoproliferative lesions: A report of three cases. <b>2017</b> , 52, 326-329	5
1691	"Double trouble" - synchronous mantle cell lymphoma and metastatic squamous cell carcinoma in an inguinal lymph node. <b>2017</b> , 68, 270-274	1
1690	A young man with acute respiratory distress syndrome: eosinophilia is not always "benign". <b>2017</b> , 52, 329-332	
1689	Primary Central Nervous System Lymphoma. <b>2017</b> ,	
1688	Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. <b>2017</b> , 38, 2535-2542	8
1687	Unravelling the genomic landscape of leukemia using NGS techniques: the challenge remains. <b>2017</b> , 52, 237-239	1
1686	Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma. <b>2017</b> , 35, 955-962	32
1685	Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick. <b>2017</b> , 35, 1872-1878	3
1684	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <b>2017</b> , 35, 2008-2017	98

1683	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <b>2017</b> , 35, 4019-4026	35
1682	Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. <b>2017</b> , 35, 2515-2526	137
1681	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <b>2017</b> , 35, 1668-1677	67
1680	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <b>2017</b> , 35, 3529-3537	234
1679	Bariatric Implant-Associated Anaplastic Large-Cell Lymphoma. <b>2017</b> , 13, 838-839	9
1678	Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. <b>2017</b> , 35, 2708-2715	42
1677	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. <b>2017</b> , 37, 512-525	11
1676	Chronic Lymphocytic Leukemia; Pathology and Genetics. <b>2017</b> ,	
1675	Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells. <b>2018</b> , 188, 1289-1299	4
1674	An Uncommon Mimic of Acute Coronary Syndrome: Infiltrating Non-Hodgkins Lymphoma. <b>2018</b> , 131, e257-e258	
1673	The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. <b>2018</b> , 67, 82-85	7
1672	Immunophenotyping of Mature B-Cell Lymphomas. 105-127	0
1671	Mature T-Cell Neoplasms and Natural Killer-Cell Malignancies. 140-160	
1670	Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. <b>2018</b> , 98, 609-619	60
1669	Expression of activating natural killer-cell receptors is a hallmark of the innate-like T-cell neoplasm in peripheral T-cell lymphomas. <b>2018</b> , 109, 1254-1262	6
1668	Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. <b>2018</b> , 59, 2715-2718	1
1667	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. <b>2018</b> , 181, 77-85	28
1666	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <b>2018</b> , 103, 849-856	12

1665	Evaluation of CD307a expression patterns during normal B-cell maturation and in B-cell malignancies by flow cytometry. <b>2018</b> , 94, 588-595	2
1664	Updated Results of Rituximab Pre- and Post-BEAM with or without Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. <b>2018</b> , 24, 2304-2311	5
1663	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. <b>2018</b> , 20, 203-214	42
1662	Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance. <b>2018</b> , 93, 356-362	4
1661	The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study. <b>2018</b> , 7, 953-965	7
1660	Targeting BCL-2 in Hematologic Malignancies. <b>2018</b> , 13, 257-267	19
1659	Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. <b>2018</b> , 78, 2407-2418	40
1658	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. <b>2018</b> , 103, e151-e153	9
1657	Venetoclax: A new wave in hematooncology. <b>2018</b> , 61, 10-25	53
1656	Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. <b>2018</b> , 138, 1573-1581	21
1655	A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases. <b>2018</b> , 97, e9418	7
1654	A Retrospective Study of Double-hit Lymphomas in Elderly Patients (Aged > 70 Years): Overall Outcomes. <b>2018</b> , 18, 280-285	1
1653	Quantitative proteomics of CSF reveals potential predicted biomarkers for extranodal NK-/T-cell lymphoma of nasal-type with ethmoidal sinus metastasis. <b>2018</b> , 198, 94-98	6
1652	Pediatric-Type Follicular Lymphoma in the Dura: A Case Report and Literature Review. <b>2018</b> , 115, 176-180	1
1651	CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. <b>2018</b> , 71, 795-801	6
1650	Novel insights into the pathogenesis of T-cell lymphomas. <i>Blood</i> , <b>2018</b> , 131, 2320-2330	2.2 26
1649	Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis. <b>2018</b> , 8, 6267	18
1648	Pathological features of intestinal T-cell lymphoma in Shiba dogs in Japan. <b>2018</b> , 16, 417-423	5



1647	Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. <i>Blood</i> , <b>2018</b> , 131, 2283-2296	2.2	59
1646	Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. <b>2018</b> , 23, 1039-1053		28
1645	Morphology and Immunophenotype of Chronic Lymphocytic Leukemia. <b>2018</b> , 79-98		
1644	Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL). <b>2018</b> , 482, 191-198		11
1643	Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. <b>2018</b> , 40, e59-e62		11
1642	Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI. <b>2018</b> , 48, 897-906		15
1641	Bronchial brush cytology of primary anaplastic large cell lymphoma of lung. <b>2018</b> , 46, 760-763		4
1640	The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. <b>2018</b> , 93, 874-881		2
1639	Cutaneous Hematolymphoid and Histiocytic Proliferations in Children. <b>2018</b> , 21, 208-251		3
1638	Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma. <b>2018</b> , 97, 1445-1452		4
1637	Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience. <b>2018</b> , 50, 2154-2158		3
1636	Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. <b>2018</b> , 109, 1682-1689		12
1635	Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma. <b>2018</b> , 32, e373-e376		3
1634	Duodenal-Type Follicular Lymphoma: A Clinicopathologic Review. <b>2018</b> , 142, 542-547		21
1633	Novel acquisitions on biology and management of transformed follicular lymphoma. <b>2018</b> , 36, 617-623		2
1632	Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20 years. <b>2018</b> , 20, 1289-1301		4
1631	T-cell lymphomas associated gene expression signature: Bioinformatics analysis based on gene expression Omnibus. <b>2018</b> , 100, 575-583		1
1630	Oral juvenile xanthogranuloma in a child: Clinical, histological and immunohistochemical profile of a rare entity. <b>2018</b> , 45, 515-521		5

- 1629 The Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. **2018**, 11, 1179545X18762799<sup>1</sup>
- 1628 Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma. **2018**, 6, 750-752 4
- 1627 CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. **2018**, 36, 543 16
- 1626 How we manage patients with Waldenström macroglobulinaemia. **2018**, 181, 737-751 5
- 1625 CAR T cell therapy for B-cell lymphomas. **2018**, 31, 135-146 24
- 1624 Usefulness of endoscopic ultrasound-guided fine needle aspiration for lymphadenopathy. **2018**, 15, 4759-47667
- 1623 Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. **2018**, 29, 1120-1129 11
- 1622 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Introduction-Definition, Diagnosis, Cell of Origin. **2018**, 1-33
- 1621 Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. **2018**, 42, 672-678 21
- 1620 Primary cutaneous small/medium-sized pleomorphic T-cell lymphoproliferative disorder shows a common vascular pattern at dermoscopy. **2018**, 32, e318-e321 6
- 1619 Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. **2018**, 9, 697 51
- 1618 World Health Organisation Classification of Lymphoid Tumours in Veterinary and Human Medicine: a Comparative Evaluation of Gastrointestinal Lymphomas in 61 Cats. **2018**, 159, 1-10 8
- 1617 Non-Hodgkin Lymphoma in Adults. **2018**, 444-462
- 1616 Pediatric Cancers. **2018**, 683-727
- 1615 ImmunoPET imaging of CD38 in murine lymphoma models using Zr-labeled daratumumab. **2018**, 45, 1372-1381 18
- 1614 GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. **2018**, 151, 39.e1-39.e17 4
- 1613 Management of Acute Hematological Malignancy in Pregnancy. 309-319
- 1612 Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. **2018**, 144, 697-706 6

1611	Crystal-Storing Histiocytosis in Bone Marrow: A Clinicopathologic Study of Eight Cases and Review of the Literature. <b>2018</b> , 149, 148-163		22
1610	F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. <b>2018</b> , 59, 1380-1385		10
1609	Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci. <b>2018</b> , 222-223, 25-31		1
1608	The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). <b>2018</b> , 13, 13-24		15
1607	Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. <b>2018</b> , 65, 41-46		20
1606	Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy. <b>2018</b> , 100, 1126-1132		7
1605	Checkpoint-Inhibition bei Non-Hodgkin-Lymphom. <b>2018</b> , 5, 12-20		
1604	Extranodal lymphoma arising within the maxillary alveolus: a systematic review. <b>2018</b> , 34, 113-126		9
1603	Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification. <b>2018</b> , 13, 25-36		9
1602	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , <b>2018</b> , 131, 2413-2425	2.2	122
1601	Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL. <b>2018</b> , 14, e252-e258		8
1600	Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas. <b>2018</b> , 42, 342-350		8
1599	Epidermotropic presentation by splenic B-cell lymphoma: The importance of clinical-pathologic correlation. <b>2018</b> , 45, 299-304		4
1598	Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. <b>2018</b> , 72, 1156-1163		33
1597	Therapeutic synergy between tigecycline and venetoclax in a preclinical model of / double-hit B cell lymphoma. <b>2018</b> , 10,		27
1596	CT imaging of primary pancreatic lymphoma: experience from three referral centres for pancreatic diseases. <b>2018</b> , 9, 17-24		11
1595	Harmonization of interpretative comments in laboratory hematology reporting: the recommendations of the Working Group on Diagnostic Hematology of the Italian Society of Clinical Chemistry and Clinical Molecular Biology (WGDH-SIBioC). <b>2018</b> , 57, 66-77		7
1594	Poor performance status, urban residence and female sex predict inferior survival in pediatric advanced stage mature B-NHL in an Indian tertiary care center. <b>2018</b> , 35, 23-32		5

1593	Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. <b>2018</b> , 1869, 85-96	9
1592	Post-Transplantation Lymphoproliferative Disorders in Adults. <b>2018</b> , 378, 549-562	187
1591	From genetics to the clinic: a translational perspective on follicular lymphoma. <b>2018</b> , 18, 224-239	66
1590	Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?. <b>2018</b> , 59, 2509-2511	5
1589	Chronic Lymphocytic Leukemia. <b>2018</b> ,	2
1588	Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. <b>2018</b> , 8, 6	6
1587	Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngsters. <b>2018</b> , 8, 1088	8
1586	The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. <b>2018</b> , 37, 1830-1844	53
1585	Characterization of skin blister fluids from children with Epstein-Barr virus-associated lymphoproliferative disease. <b>2018</b> , 45, 444-449	1
1584	Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. <b>2018</b> , 97, 725-726	1
1583	Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial. <b>2018</b> , 107, 395-404	17
1582	The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. <b>2018</b> , 180, 391-394	13
1581	A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome. <b>2018</b> , 93, 504-510	21
1580	Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. <b>2018</b> , 59, 2096-2104	
1579	Effective management strategies for patients with marginal zone lymphoma. <b>2018</b> , 14, 1213-1222	10
1578	Precision Molecular Pathology of Hodgkin Lymphoma. <b>2018</b> ,	1
1577	Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?. <b>2018</b> , 18, 91-97	4
1576	In situ neoplasia in lymph node pathology. <b>2018</b> , 35, 76-83	6

1575	Unilateral Lung Infiltrate: A Rare Form of Presentation of Primary Pulmonary Lymphoma. <b>2018</b> , 54, 103-104	
1574	Lymphomatoid Granulomatosis: A Rare Tumor with Poor Prognosis. <b>2018</b> , 54, 108-109	1
1573	Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma. <b>2018</b> , 138, 1204-1206	14
1572	Primary pediatric lymphoma of the larynx: An unusual presentation of a rare histologic subtype. <b>2018</b> , 19, 3-5	
1571	TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. <b>2018</b> , 98, 566-576	23
1570	MBN 2016 Aesthetic Breast Meeting BIA-ALCL Consensus Conference Report. <b>2018</b> , 141, 40-48	33
1569	Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. <b>2018</b> , 65, e26932	9
1568	Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. <b>2018</b> , 73, 408-412	1
1567	Epstein-Barr Virus (EBV) associated reactive and indeterminate lymphoid proliferations in the lymph node. <b>2018</b> , 35, 54-60	3
1566	Non-neoplastic histiocytic and dendritic cell disorders in lymph nodes. <b>2018</b> , 35, 20-33	8
1565	Re-Defining 'Reactive' lymphadenopathies: How molecular lessons have changed our minds. <b>2018</b> , 35, 1-3	
1564	Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling. <b>2018</b> , 31, 553-561	9
1563	A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. <b>2018</b> , 31, 732-743	23
1562	Treatment of mantle cell lymphoma in older adults. <b>2018</b> , 9, 308-314	4
1561	CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. <b>2018</b> , 31, 718-731	22
1560	Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide. <b>2018</b> , 97, 363-366	0
1559	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. <b>2018</b> , 103, 679-687	34
1558	Follicular lymphoma: 2018 update on diagnosis and management. <b>2018</b> , 93, 296-305	64

1557	Minimal residual disease in chronic lymphocytic leukaemia. <b>2018</b> , 150, 144-149		
1556	Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. <b>2018</b> , 29, 715-723		55
1555	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <b>2018</b> , 42, 492-499		5
1554	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <b>2018</b> , 23, 454-460		13
1553	The 2016 revision of the WHO classification of lymphoid neoplasms: The clinician's view. <b>2018</b> , 150, 64-66		0
1552	Gastrointestinal follicular lymphoma: Current knowledge and future challenges. <b>2018</b> , 68, 1-6		20
1551	ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. <i>Blood</i> , <b>2018</b> , 131, 1094-1105	2.2	69
1550	Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. <b>2018</b> , 4, 335-341		168
1549	The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS. <b>2017</b> , 149, 17-28		22
1548	The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. <b>2018</b> , 59, 2159-2174		4
1547	A Case of Diffuse Large B-Cell Lymphoma Mimicking Primary Effusion Lymphoma-Like Lymphoma. <b>2017</b> , 10, 1013-1022		2
1546	The Basics of Cancer Immunotherapy. <b>2018</b> ,		2
1545	Next-Generation Immunotherapy in Lymphoma: Checkpoint Blockade, Chimeric Antigen Receptor T Cells, and Beyond. <b>2018</b> , 95-114		
1544	Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). <b>2018</b> , 50, 124-131		18
1543	Epstein-Barr virus positive peripheral T cell lymphoma with novel variants in STAT5B of a pediatric patient: a case report. <b>2018</b> , 18, 373		0
1542	Artesunate shows potent anti-tumor activity in B-cell lymphoma. <b>2018</b> , 11, 23		49
1541	Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration. <b>2018</b> , 7, 8		7
1540	Letter to Editor: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management, APS 2018. <b>2018</b> , 42, 1164-1166		6

1539	The First Year of the AEVD Primary Cutaneous Lymphoma Registry. <b>2018</b> , 109, 610-616	7
1538	Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies. <b>2018</b> , 7, 5	2
1537	A case of HTLV-1 associated adult T-cell lymphoma presenting with cutaneous lesions and tropical spastic paresis. <b>2018</b> , 7, 61-64	3
1536	Reduced lymphotoxin-beta production by tumour cells is associated with loss of follicular dendritic cell phenotype and diffuse growth in follicular lymphoma. <b>2018</b> , 4, 124-134	11
1535	Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <b>2018</b> , 181, 760-769	26
1534	Linfomas T cutáneos excepto la micosis fungoide y el sîndrome de Sary. <b>2018</b> , 52, 1-8	
1533	Adult-onset hydroa vacciniforme-like lymphoma in a long-term resident of the United States. <b>2018</b> , 4, 314-317	1
1532	Hodgkin lymphoma cell lines: to separate the wheat from the chaff. <b>2018</b> , 399, 511-523	14
1531	Pulmonary mass: never judge a book by its cover. <b>2018</b> , 11, 158-160	
1530	Resistance to Ibritumomab in Lymphoma. <b>2018</b> ,	
1529	Genetic convergence of rare lymphomas. <b>2018</b> , 25, 307-314	1
1528	Ethnic disparity in primary cutaneous CD30 T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database. <b>2018</b> , 181, 752-759	3
1527	L265P Mutation in Lymphoid Malignancies. <b>2018</b> , 78, 2457-2462	52
1526	Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. <i>Blood</i> , <b>2018</b> , 132, 245-253	2.2 31
1525	How to Diagnose and Treat Breast Implant-Associated Anaplastic Large Cell Lymphoma. <b>2018</b> , 141, 586e-599e	97
1524	Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. <b>2018</b> , 59, 2727-2730	2
1523	SATB1 Defines a Subtype of Cutaneous CD30 Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile. <b>2018</b> , 138, 1795-1804	18
1522	Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN). <b>2018</b> , 181, 215-228	26

1521	Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. <i>Blood</i> , <b>2018</b> , 131, 2670-2681	49
1520	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. <b>2018</b> , 103, 1182-1190	15
1519	Highly sensitive mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. <b>2018</b> , 103, 1029-1037	32
1518	Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. <b>2018</b> , 31, 1332-1342	23
1517	Primary testicular natural killer/T-cell lymphoma: A CARE-case report and review of literature. <b>2018</b> , 97, e0181	1
1516	Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. <b>2018</b> , 32, 400-415	28
1515	The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. <b>2018</b> , 32, 1994-2007	34
1514	Epstein-Barr Virus-Positive Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue in the Posttransplant Setting: An Immunodeficiency-Related (Posttransplant) Lymphoproliferative Disorder?. <b>2017</b> , 149, 42-49	8
1513	Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF mutation. <b>2018</b> , 28, 3751-3759	19
1512	Hepatic Lymphoma Diagnosis. <b>2018</b> , 11, 389-402	11
1511	Intravascular Large B-Cell Lymphoma Within a Thyroid Nodule: A Diagnostic Pitfall. <b>2018</b> , 26, 428-431	4
1510	[Follow-up Care in Cancer: Selected Solid Tumors and Hematological Neoplasias]. <b>2018</b> , 143, 334-342	0
1509	Non-Hodgkin Lymphoma of Childhood. <b>2018</b> , 975-998	
1508	SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement. <b>2018</b> , 35, 49	2
1507	Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2018</b> , 24, 1341-1349	16
1506	Orbital Tumors and Inflammatory Disorders: Diagnosis and Management. <b>2018</b> , 58, 181-195	3
1505	Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. <b>2018</b> , 180, 741-744	71
1504	Age-related heterogeneity of Burkitt lymphoma: response to Mbulaiteye and Anderson. <b>2018</b> , 180, 155-156	



1503	How in-depth histological look may allow challenging diagnosis: The case of a primary in situ mantle cell neoplasm of the appendix. <b>2018</b> , 36, 376-378	2
1502	The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations. <b>2018</b> , 94, 159-168	14
1501	EBV-induced lymphoproliferative disorders in rheumatic patients: A systematic review of the literature. <b>2018</b> , 85, 35-40	14
1500	Histiocytic sarcoma with bladder involvement: Case report and literature review. <b>2018</b> , 51, 23-26	3
1499	PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma. <b>2018</b> , 181, 564-566	8
1498	Destructive soft tissue mass in the maxilla/maxillary sinus. <b>2018</b> , 125, 510-515	2
1497	The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry. <b>2018</b> , 94, 451-458	11
1496	Prognostic significance of morphotypes in canine lymphomas: A systematic review of literature. <b>2018</b> , 16, 12-19	10
1495	Increased frequencies of circulating and tumor-resident V $\alpha$ T cells in patients with diffuse large B-cell lymphoma. <b>2018</b> , 59, 187-195	9
1494	Unilesional locally recurrent lymphomatoid papulosis with variable histological presentation. <b>2018</b> , 59, 262-264	0
1493	Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. <b>2018</b> , 59, 249-252	1
1492	A pattern-based approach to reactive lymphadenopathies. <b>2018</b> , 35, 4-19	14
1491	A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. <b>2018</b> , 32, 263-272	25
1490	Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. <b>2018</b> , 36, 93-97	18
1489	Monoclonal B-cell lymphocytosis in blood donors in Turkey. <b>2018</b> , 23, 25-29	1
1488	MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. <b>2018</b> , 59, 505-508	10
1487	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <b>2018</b> , 32, 353-363	22
1486	Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma. <b>2018</b> , 178, 215-221	7

1485	What is the optimal initial management of the older MCL patient?. <b>2018</b> , 31, 99-104	7
1484	Epstein-Barr virus lytic cycle involvement in diffuse large B cell lymphoma. <b>2018</b> , 36, 98-103	19
1483	The 2016 revision of the WHO classification of lymphoid neoplasms: The clinician's view. <b>2018</b> , 150, 64-66	3
1482	Distribution of lymphoid neoplasms in Northwest China: Analysis of 3244 cases according to WHO classification in a single institution. <b>2018</b> , 34, 60-65	9
1481	Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. <b>2018</b> , 36, 166-173	17
1480	Transformed follicular lymphoma. <b>2018</b> , 97, 17-29	33
1479	Lifetime alcohol intake and risk of non-Hodgkin lymphoma: Findings from the Melbourne Collaborative Cohort Study. <b>2018</b> , 142, 919-926	5
1478	Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue. <b>2018</b> , 18, 151-163	15
1477	SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma. <b>2018</b> , 31, 505-516	17
1476	Long-Term Safety of Textured and Smooth Breast Implants. <b>2017</b> , 38, 38-48	67
1475	[Lymphomatoid papulosis]. <b>2018</b> , 145, 65-67	1
1474	Differential expression of CCR4 in primary cutaneous gamma/delta (T) cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. <b>2018</b> , 89, 88-91	9
1473	Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines. <b>2018</b> , 59, 1710-1716	5
1472	Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma. <b>2018</b> , 43, 1-8	14
1471	A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation. <b>2018</b> , 12, 324-329	
1470	Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88 Mutation. <b>2017</b> , 10, 813-818	2
1469	PET/CT for Staging; Past, Present, and Future. <b>2018</b> , 48, 4-16	31
1468	Recurrent scarring papulovesicular lesions on sun-exposed skin in a 22-year-old man. <b>2018</b> , 78, 637-642	2

1467	Cutaneous Richter Syndrome Mimicking Primary Cutaneous CD4-Positive Small/Medium T-cell Lymphoma: Case Report and Review of the Literature. <b>2018</b> , 40, 286-290	2
1466	High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. <b>2018</b> , 93, 40-46	15
1465	Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. <b>2018</b> , 59, 1375-1383	17
1464	First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. <b>2018</b> , 43, 137-143	18
1463	Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. <b>2018</b> , 32, 565-569	10
1462	Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas. <b>2018</b> , 103, 126-135	14
1461	Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation. <b>2018</b> , 24, 294-300	11
1460	Extranodal Marginal Zone Lymphoma of the Central Nervous System. <b>2018</b> , 18, 34-37.e8	22
1459	Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. <b>2018</b> , 31, 313-326	28
1458	CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. <b>2018</b> , 31, 327-336	33
1457	Immunohistochemistry in Tumor Diagnostics. <b>2018</b> , 1-9	
1456	Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis. <b>2018</b> , 23, 228-234	20
1455	Primary Cutaneous CD8+ T-cell Lymphoma, an Indolent and Locally Aggressive Form Mimicking Paronychia. <b>2018</b> , 40, e52-e56	4
1454	A pediatric-type follicular lymphoma with marginal zone and monotypic intracytoplasmic plasmacytic differentiation. <b>2018</b> , 11, 25-31	0
1453	Lymphoproliferative Disorders of the Gastrointestinal Tract. <b>2018</b> , 142, 44-52	13
1452	PhenoGraph and viSNE facilitate the identification of abnormal T-cell populations in routine clinical flow cytometric data. <b>2018</b> , 94, 588-601	15
1451	MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. <b>2018</b> , 59, 1391-1398	7
1450	Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma. <b>2018</b> , 183, 142-146	3

1449	Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. <b>2018</b> , 59, 434-447	16
1448	Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. <b>2018</b> , 32, 694-702	60
1447	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. <b>2018</b> , 59, 1213-1221	11
1446	Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the fore. <b>2018</b> , 59, 1244-1247	2
1445	22 Cases of Breast Implant-Associated ALCL: Awareness and Outcome Tracking from the Italian Ministry of Health. <b>2018</b> , 141, 11e-19e	35
1444	Lymphomatoid Granulomatosis: A Rare Tumor with Poor Prognosis. <b>2018</b> , 54, 108-109	0
1443	Minimal residual disease in chronic lymphocytic leukaemia. <b>2018</b> , 150, 144-149	1
1442	DNMT1 is associated with cell cycle and DNA replication gene sets in diffuse large B-cell lymphoma. <b>2018</b> , 214, 134-143	24
1441	Epstein-Barr virus-positive mucocutaneous ulcer with a background of Crohn's disease and Waldenström macroglobulinaemia: a case report highlighting diagnostic pitfalls. <b>2018</b> , 72, 874-877	8
1440	Recurrent gastrointestinal bleeding in a patient with IgM paraproteinaemia. <b>2018</b> , 71, 284-285	0
1439	Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female. <b>2018</b> , 42, 451-455	23
1438	Initial flow cytometric evaluation of the Clearlab lymphoid screen. <b>2018</b> , 94, 707-713	6
1437	ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population. <b>2018</b> , 97, 149-159	1
1436	Diffuse large B-cell lymphoma. <b>2018</b> , 50, 74-87	233
1435	Pathology of Histiocytic Disorders and Neoplasms and Related Disorders. <b>2018</b> , 3-50	6
1434	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <b>2018</b> , 59, 1814-1828	15
1433	Comprehensive review of post-organ transplant hematologic cancers. <b>2018</b> , 18, 537-549	47
1432	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <b>2018</b> , 103, 297-303	14

1431	Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. <b>2018</b> , 109, 490-496	23
1430	Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. <b>2018</b> , 18, e85-e93	5
1429	B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients. <b>2018</b> , 42, 269-276	15
1428	[Extranodal abdominal lymphomas]. <b>2018</b> , 58, 45-55	1
1427	Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing. <b>2018</b> , 45, 1-7	8
1426	Quantitative Analysis of a Multiplexed Immunofluorescence Panel in T-Cell Lymphoma. <b>2018</b> , 23, 252-258	5
1425	Lymphomas and Histiocytic Tumors. <b>2018</b> , 405-422	0
1424	A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. <b>2018</b> , 103, 1018-1028	31
1423	Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. <b>2018</b> , 7, 114-122	19
1422	Hematolymphoid Disorders. <b>2018</b> , 527-572.e5	
1421	Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study. <b>2018</b> , 18, 91-100	6
1420	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. <b>2018</b> , 103, 1065-1072	6
1419	Clinical significance of tryptophan catabolism in Hodgkin lymphoma. <b>2018</b> , 109, 74-83	11
1418	Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia. <b>2018</b> , 134-135, 32-40	10
1417	PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. <b>2018</b> , 48, 37-49	18
1416	Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. <b>2018</b> , 59, 1884-1889	14
1415	Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour. <b>2018</b> , 16, 246-252	22
1414	Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. <b>2018</b> , 97, 255-266	18

1413	Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin. <b>2018</b> , 97, 551-554	7
1412	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <b>2018</b> , 24, 486-493	2
1411	Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. <b>2018</b> , 103, 278-287	46
1410	Transformation of follicular lymphoma - Why does it happen and can it be prevented?. <b>2018</b> , 31, 49-56	4
1409	Pathogenesis of follicular lymphoma. <b>2018</b> , 31, 2-14	29
1408	What is the optimal initial management of the younger mantle cell lymphoma patient?. <b>2018</b> , 31, 90-98	2
1407	Epstein-Barr virus positive diffuse large B-cell lymphoma presenting with vaginal sloughing and ulcerated skin nodule. <b>2018</b> , 45, 162-166	2
1406	F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. <b>2018</b> , 59, 774-779	30
1405	Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?. <b>2018</b> , 31, 65-72	6
1404	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <b>2018</b> , 59, 2318-2326	2
1403	Epstein-Barr virus-positive mucocutaneous ulcer in a patient with polycythemia vera treated with oral hydroxyurea. <b>2018</b> , 45, e82-e83	0
1402	Overview on the management of non-gastric MALT lymphomas. <b>2018</b> , 31, 57-64	24
1401	Malignant Histiocytoses. <b>2018</b> , 361-381	2
1400	Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. <b>2018</b> , 22, 45-57	12
1399	Definition of a SNOMED CT pathology subset and microglossary, based on 1.17 million biological samples from the Catalan Pathology Registry. <b>2018</b> , 78, 167-176	6
1398	Epidemiologic, clinical and demographic features of primary cutaneous lymphomas in Castilla-La Mancha, Spain: are we different?. <b>2018</b> , 32, e168-e171	
1397	PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <b>2018</b> , 42, 326-334	27
1396	Positron emission tomography computed tomography features of monomorphic epitheliotropic intestinal T-cell lymphoma. <b>2018</b> , 23, 10-16	13

1395	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <b>2018</b> , 32, 774-787	56
1394	Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients. <b>2018</b> , 59, 679-689	2
1393	Tumor Heterogeneity in Lymphomas: A Different Breed. <b>2018</b> , 85, 130-145	23
1392	Acute Leukemia in Horses. <b>2018</b> , 55, 159-172	20
1391	Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. <b>2018</b> , 65, e26753	10
1390	Novel epigenetic therapies in hematological malignancies: Current status and beyond. <b>2018</b> , 51, 198-210	18
1389	Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation?. <b>2018</b> , 59, 758-762	3
1388	Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia. <b>2018</b> , 71, 215-220	9
1387	Unilateral lung infiltrate: A rare form of presentation of primary pulmonary lymphoma. <b>2018</b> , 54, 103-104	2
1386	Double Hit Lymphoma (DHL)::Triple Hit Lymphoma (THL). <b>2018</b> ,	1
1385	Relapsed subcutaneous panniculitis-like T cell lymphoma evaluated by FDG PET/CT: A clinical case report. <b>2018</b> , 97, e12980	2
1384	ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?. <b>2018</b> , 2, e43	9
1383	High-resolution architecture and partner genes of rearrangements in lymphoma with DLBCL morphology. <b>2018</b> , 2, 2755-2765	38
1382	Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. <b>2018</b> , 2, 1-13	18
1381	Hematopoietic Neoplasia. <b>2018</b> , 363-395	
1380	Informatics Approaches to Address New Challenges in the Classification of Lymphoid Malignancies. <b>2018</b> , 2,	2
1379	Diffuse large B-cell lymphoma—Who should we FISH?. <b>2018</b> , 2, 8-8	0
1378	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). <b>2018</b> , 36, 2593-2602	40

1377	Maligne Lymphome - es bewegt sich was!. <b>2018</b> , 5, 6-9	
1376	Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. <b>2018</b> , 38, 616-625	30
1375	Gastric Follicular Lymphomas Presenting as Subepithelial Tumors: Two Cases. <b>2018</b> , 18, 258	1
1374	Transplantationsassoziierte lymphoproliferative Erkrankungen (PTLD) bei Kindern. <b>2018</b> , 32, 502-509	
1373	T Cell Therapy of Burkitt's Lymphoma in Nude Mice Model Tumorized with Ramos Cell Line. <b>2018</b> , 09,	
1372	Molecular Hematopathology. <b>2018</b> , 712-760.e18	0
1371	Friday 26 October 2018. <b>2018</b> , 62, 30-55	
1370	Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016. <b>2017</b> , 2,	3
1369	Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV. <b>2018</b> , 25, e592-e596	6
1368	Review of Hematopathology Consult Cases: A Two-Year Experience in a Tertiary Referral Center in Lebanon. <b>2018</b> , 2018, 3028625	1
1367	The Expression of Human Telomerase Reverse Transcriptase Gene and Its Activity in Patients with B-Cell Chronic Lymphocytic Leukemia and Its Impact on Clinical Staging. <b>2018</b> , 10, 167	0
1366	Primary Colorectal Lymphoma: Institutional Experience and Review of a National Database. <b>2019</b> , 62, 1167-1176	4
1365	Angiogenesis in cutaneous T-cell lymphoma - proteomic approaches. <b>2019</b> , 17, 4060-4067	2
1364	Challenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases. <b>2018</b> , 6, 320	
1363	Epidemiologic characteristics of malignant lymphoma in Hubei, China: A single-center 5-year retrospective study. <b>2018</b> , 97, e12120	10
1362	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <b>2018</b> , 42, 1488-1494	29
1361	A Case of ALK+ Anaplastic Large-Cell Lymphoma With Aberrant Myeloperoxidase Expression and Initial Cutaneous Presentation. <b>2018</b> , 40, 519-522	2
1360	Difficulties Coding Dermatological Disorders Using the ICD-10: The DIADERM Study. <b>2018</b> , 109, 893-899	2



- 1359 Faziãle Papeln bai follikulãrem B-Zell-Lymphom. **2018**, 16, 1493-1495
- 1358 Orbital T-cell lymphoma in youngest recorded patient - early diagnosis, management, and successful outcome: a case report and review of the literature. **2018**, 12, 139 0
- 1357 Cutaneous T-cell lymphomas in the revised 4th edition of World Health Organization classification of tumors of hematopoietic and lymphoid tissues (2017). **2018**, 93, 871-873
- 1356 Chronic active Epstein-Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements. **2018**, 41, 162-169 12
- 1355 Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disease: A Case Report. **2018**, 09,
- 1354 Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma. **2018**, 9, 677-682 4
- 1353 Phototherapy of cutaneous T-cell lymphomas. **2018**, 17, 1904-1912 10
- 1352 Risk stratification of mantle cell lymphoma (MCL). **2018**, 2, 10-10 3
- 1351 Numb chin syndrome as a presenting symptom of diffuse large B-cell lymphoma with secondary myelofibrosis. **2018**, 2018, 3
- 1350 Unusual case of unilateral conductive hearing loss: chronic lymphocytic leukaemia. **2018**, 2018,
- 1349 Epidemiology. **2018**,
- 1348 Follicular dendritic cell sarcoma presenting as a painless lump in the parotid. **2018**, 2018, 2
- 1347 Post-Heart Transplantation Lymphoproliferations. **2018**,
- 1346 Intestinal Transplantation. **2018**,
- 1345 Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. **2018**, 2, pky038 11
- 1344 CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis. **2018**, 9, 16547-16556 11
- 1343 BCL6/BCL2 and MYC Alterations Drawing the Gray Zone between Diffuse Large B-cell Lymphoma and Double, Triple Hit Lymphoma. **2018**, 12,
- 1342 Epidemiological Analysis of Lymphoma Subtypes in a Reference Center in Joã Pessoa. **2018**, 06, 0

1341	Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. <b>2018</b> , 09,	4
1340	Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder. <b>2018</b> , 42, 116-129	19
1339	[Lymphoplasmacytic lymphoma or multiple myeloma: immunoglobulins may lead to misdiagnosis]. <b>2018</b> , 76, 451-457	0
1338	An unusual case report of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression involving the gastrointestinal tract and bone marrow. <b>2018</b> , 13, 82	11
1337	From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia Development. <b>2018</b> , 9, 2402	1
1336	Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric V $\beta$ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases. <b>2018</b> , 93, 1118-1124	7
1335	EBV-positive mucocutaneous ulcer on the penis. <b>2018</b> , 16, 1490-1492	1
1334	Apport du séquençage haut débit dans la prise en charge des hémopathies lymphoïdes. <b>2018</b> , 2018, 75-80	
1333	Curing diffuse large B-cell lymphomas in elderly patients. <b>2018</b> , 58, 14-21	6
1332	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). <b>2018</b> , 8, 117	35
1331	Organochlorine Levels in Plasma and Risk of Multiple Myeloma. <b>2018</b> , 60, 911-916	5
1330	How immunologic and genetic biomarkers impact Hodgkin lymphoma classification, diagnosis, and management: a huge potential that yet needs to be exploited. <b>2018</b> , 33, 137-140	1
1329	Solitärer Tumor am Unterarm. <b>2018</b> , 16, 1391-1394	
1328	B-cell follicular lymphoma presenting as facial papules. <b>2018</b> , 16, 1493-1495	2
1327	Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapies. <b>2018</b> , 9, 33482-33499	7
1326	Venous thromboembolic events during warm autoimmune hemolytic anemia. <b>2018</b> , 13, e0207218	29
1325	Long-term Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Standard Therapy. <b>2018</b> , 06,	
1324	EpsteinBarr Virus ?. <b>2018</b> ,	

1323	gene mutations are frequently detected in in situ follicular neoplasia. <i>Blood</i> , <b>2018</b> , 132, 2687-2690	2.2	18
1322	Distribution of lymphomas in Turkey: data of 4239 cases from a single institution using the WHO classification. <b>2018</b> , 48, 1013-1023		2
1321	Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. <b>2018</b> , 5, e520-e531		12
1320	Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response. <b>2018</b> , 24, 249-253		4
1319	Multiple cranial nerve palsies in immunodeficiency subtype of Burkitt lymphoma. <b>2018</b> , 8, 303-306		1
1318	Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma. <b>2018</b> , 58, 175-179		1
1317	Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report. <b>2018</b> , 2018, 2525070		2
1316	Two-way detection of image features and immunolabeling of lymphoma cells with one-step microarray analysis. <b>2018</b> , 12, 064106		2
1315	Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature. <b>2018</b> , 9, 347-349		2
1314	Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T-cell lymphoma. <b>2018</b> , 16, 4772-4778		1
1313	Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. <b>2018</b> , 47, 700-700g		26
1312	Solitary Extramedullary Plasmacytoma of the Thyroid Gland Following Head and Neck External Beam Radiotherapy. <b>2018</b> , 4, e285-e288		1
1311	Stoma formation after lymphoproliferative disorders and immunosuppression therapy. <b>2018</b> , 27, S20-S26		1
1310	Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. <b>2018</b> , 2018, 1042597		4
1309	Lymphoma in Adolescents and Young Adults: Current Perspectives. <b>2018</b> , 24, 285-300		2
1308	Primary CNS high-grade B-cell lymphoma, with rearrangements of and : a case report. <b>2018</b> , 53, 87-89		
1307	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. <b>2018</b> , 5, e609-e617		96
1306	Difficulties Coding Dermatological Disorders Using the ICD-10: The DIADERM Study. <b>2018</b> , 109, 893-899		

1305	Breast Implant-Associated Lymphoma. <b>2018</b> , 115, 628-635	24
1304	Waldenstrom's Macroglobulinemia: An Update. <b>2018</b> , 10, e2018004	15
1303	Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP. <b>2018</b> , 8, 14814	9
1302	Peripheral T-cell non-Hodgkin lymphoma manifesting as a primary lesion on the lip: A rare case report. <b>2018</b> , 38, 438-444	2
1301	Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. <b>2018</b> , 151, 362-367	2
1300	[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)]. <b>2018</b> , 143, 1318-1324	0
1299	Malignant Lymphomas Introduction. <b>2018</b> , 605-608	
1298	Solitary Extramedullary Plasmacytoma Mimicking Acute Subdural Hematoma. <b>2018</b> , 120, 521-524	2
1297	EBV infection determines the immune hallmarks of plasmablastic lymphoma. <b>2018</b> , 7, e1486950	13
1296	The role of surgery in primary central nervous system lymphomas. <b>2018</b> , 76, 139-144	5
1295	Immunosenescence and lymphomagenesis. <b>2018</b> , 15, 22	12
1294	Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas. <b>2018</b> , 10,	11
1293	External validation of the accuracy of 'CLLflow score'. <b>2018</b> , 66, e6	4
1292	Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. <b>2018</b> , 8, 14216	14
1291	Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach?. <b>2018</b> , 58, 2-6	4
1290	New perspectives in the therapeutic approach of peripheral T-cell lymphoma. <b>2018</b> , 30, 285-291	8
1289	Chronic lymphocytic leukemia treatment algorithm 2018. <b>2018</b> , 8, 93	46
1288	Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia. <b>2018</b> , 10, 7527	0

1287	North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. <i>Blood</i> , <b>2018</b> , 132, 1507-1518	2.2	44
1286	A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies. <b>2018</b> , 31, 173-179		6
1285	Novel Biomarker Approaches in Classic Hodgkin Lymphoma. <b>2018</b> , 24, 206-214		9
1284	Double hit and double expressors in lymphoma: Definition and treatment. <b>2018</b> , 124, 4622-4632		63
1283	Clinicopathological and fluorescence in situ hybridisation analysis of primary testicular diffuse large B-cell lymphoma: a single-centre case series. <b>2018</b> , 69, 136-142		2
1282	Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Diseases in Chinese Mainland. <b>2018</b> , 6, 289		3
1281	Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus 18FDG positron emission tomography/computed tomography in initial staging and restaging after treatment. <b>2018</b> , 151, 255-264		0
1280	Recent advances in understanding and managing hairy cell leukemia. <b>2018</b> , 7,		2
1279	Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!. <i>Blood</i> , <b>2018</b> , 132, 2722-2729	2.2	40
1278	Donor-derived Viral Infections in Liver Transplantation. <b>2018</b> , 102, 1824-1836		13
1277	t(14;18)-positive B cells: is it seed or soil?. <i>Blood</i> , <b>2018</b> , 132, 1631-1632	2.2	0
1276	MicroRNAs as Biomarkers of B-cell Lymphoma. <b>2018</b> , 13, 1177271918806840		18
1275	Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitro. <b>2018</b> , 11, 6605-6615		8
1274	Radiation Therapy in Diffuse Large B-Cell Lymphoma. <b>2018</b> , 1-14		
1273	Radiation Therapy in Follicular Lymphoma. <b>2018</b> , 1-10		
1272	Improvements in intestine transplantation. <b>2018</b> , 27, 267-272		11
1271	Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an African migrant: case report and review of the literature on diagnostics standards and therapeutic options. <b>2018</b> , 18, 941		5
1270	Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy. <b>2018</b> , 58, 184-187		3

1269	Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease. <b>2018</b> , 14, 306		29
1268	Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. <b>2018</b> , 53, 189-197		9
1267	Pediatric-type Follicular Lymphoma. <b>2018</b> ,		
1266	Operative R0 resection of diffuse large B-cell lymphoma of the pelvis: a case report. <b>2018</b> , 12, 293		2
1265	Bulky primary tibia mantle cell lymphoma achieved complete remission with CHOP and DHAP plus rituximab: A case report. <b>2018</b> , 16, 6116-6120		
1264	Médecine générale en oncologie : état de l'art et défis à relever. <b>2018</b> , 2018, 28-33		
1263	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. <b>2018</b> , 50, 1650-1657		74
1262	Remission of Cutaneous Involvement in Splenic Marginal Zone Lymphoma after Splenectomy. <b>2018</b> , 98, 801-802		0
1261	Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B-cell lymphoma or classical Hodgkin lymphoma: A histologic diagnostic pitfall. <b>2019</b> , 46, 102-110		6
1260	HIV-related Malignancies and Mimics: Imaging Findings and Management. <b>2018</b> , 38, 2051-2068		11
1259	Low-dose trifosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience. <b>2018</b> , 18, 1000		7
1258	IL-2R $\alpha$ -regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma. <b>2018</b> , 38, 62		10
1257	Optimal frontline management of mantle cell lymphoma: can we agree?. <b>2018</b> , 11, 911-914		
1256	Isolated hypoglossal nerve palsy as a presenting symptom of metastatic peripheral T-cell lymphoma - not otherwise specified (PTCL-NOS): a unique case & a review of the literature. <b>2018</b> , 7, IJH03		3
1255	MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma. <b>2018</b> , 16, 3169-3176		10
1254	Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-CLL 2017. <b>2018</b> , 57, 190-215		4
1253	How I treat breast implant-associated anaplastic large cell lymphoma. <i>Blood</i> , <b>2018</b> , 132, 1889-1898	2.2	44
1252	Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2040-2052	2.2	10

1251	Colorectal Lymphoma: A Review. <b>2018</b> , 31, 309-316	11
1250	Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis. <b>2018</b> , 65, e27415	1
1249	Just Beneath the Surface. <b>2018</b> , 379, 968-973	3
1248	Transcriptome Analysis and In Situ Hybridization for FcaGHV1 in Feline Lymphoma. <b>2018</b> , 10,	1
1247	Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation. <b>2018</b> , 1, e13	2
1246	Breast implant-associated anaplastic large cell lymphoma: a pictorial review. <b>2018</b> , 9, 683-686	14
1245	On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia. <b>2018</b> , 19, 1675-1684	
1244	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. <b>2018</b> , 7, 144	10
1243	Disorders of Histiocytes. <b>2018</b> , 567-616.e4	1
1242	Management of primary cutaneous CD4 small and medium pleomorphic T-cell lymphoma: A retrospective study. <b>2018</b> , 79, 772-774	4
1241	Third Eyelid T-cell-Rich Large B-cell Lymphoma Positive to EHV-5 in a MareĀ Case Report. <b>2018</b> , 70, 52-56	3
1240	Prognostic factors and primary treatment for WaldenstrĀm macroglobulinemia - a Swedish Lymphoma Registry study. <b>2018</b> , 183, 564-577	4
1239	Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma. <b>2018</b> , 19, 52	8
1238	De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas?. <b>2018</b> , 54, 80-82	1
1237	Solitary tumor of the forearm. <b>2018</b> , 16, 1391-1394	
1236	NK-Cell Enteropathy and Similar Indolent Lymphoproliferative Disorders: A Case Series With Literature Review. <b>2019</b> , 151, 75-85	12
1235	Glioblastoma Multiforme in a Patient with Multiple Myeloma: A Case Report and Literature Review. <b>2018</b> , 22, 17-125	2
1234	Usefulness of presepsin for early detection of infections in patients with hematologic disorders. <b>2018</b> , 486, 374-380	3

1233	Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. <b>2018</b> , 11, 4817-4827	28
1232	Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease. <b>2018</b> , 57, 3651-3657	3
1231	Mantle Cell Lymphoma Biology. <b>2018</b> , 18, S97-S98	0
1230	A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified. <b>2018</b> , 73, 5-11	4
1229	Molecular and Cytogenetic Studies in a Child with Burkitt Lymphoma and Ataxia-Telangiectasia Syndrome Harboring MYC Overexpression and Partial Trisomy 8. <b>2018</b> , 38, 63-66	2
1228	Recent Advances in Diffuse Large B Cell Lymphoma. <b>2018</b> ,	2
1227	Drug resistance in multiple myeloma. <b>2018</b> , 70, 199-208	122
1226	Update on posttransplant lymphoproliferative disease. <b>2018</b> , 27, 440-444	2
1225	Distinct 3D Structural Patterns of Lamin A/C Expression in Hodgkin and Reed-Sternberg Cells. <b>2018</b> , 10,	12
1224	B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. <b>2018</b> , 8, 12907	5
1223	Richter transformation in the era of novel agents. <b>2018</b> , 2018, 256-263	15
1222	Small B-Cell Lymphomas. <b>2018</b> , 213-270.e3	
1221	Genomics of aggressive B-cell lymphoma. <b>2018</b> , 2018, 69-74	10
1220	A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology. <b>2018</b> , 2, 1542-1546	7
1219	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. <b>2018</b> , 2, 2400-2411	3
1218	Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. <b>2018</b> , 2, 2533-2542	5
1217	Genomikus kiegészítő-eltérések szerepe krónikus limfoid leukémiában multiplex ligázáló szondaamplifikációval. <b>2018</b> , 51, 31-40	
1216	Aggressive B-cell lymphomas. <b>2018</b> ,	



1215	Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <b>2018</b> , 19, 33		5
1214	How I manage patients with relapsed/refractory diffuse large B cell lymphoma. <b>2018</b> , 182, 633-643		78
1213	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. <b>2018</b> , 42, 843-854		35
1212	Relapse rates in patients with unilesional primary cutaneous B-cell lymphoma treated with radiation therapy: a single-institution experience. <b>2018</b> , 179, 1172-1173		3
1211	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. <i>Blood</i> , <b>2018</b> , 132, 935-947	2.2	57
1210	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , <b>2018</b> , 132, 413-422	2.2	58
1209	A safety profile of medications used to treat Waldenström's macroglobulinemia. <b>2018</b> , 17, 609-621		2
1208	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. <b>2018</b> , 23, 111-122		14
1207	Cutaneous Lymphomas. <b>2018</b> , 155-187		
1206	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <b>2018</b> , 9, 2024		54
1205	RETRACTED ARTICLE: Primary central nervous system high-grade B-cell lymphoma, with rearrangements of and. <b>2018</b> , 31, 581-583		
1204	The future of kinase inhibitors for DLBCL?. <i>Blood</i> , <b>2018</b> , 131, 2278-2280	2.2	2
1203	Molecular Diagnosis of Hematopoietic Neoplasms: 2018 Update. <b>2018</b> , 38, 293-310		3
1202	Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus FDG positron emission tomography/computed tomography in initial staging and restaging after treatment. <b>2018</b> , 151, 255-264		2
1201	Cryoglobulinemic Glomerulonephritis Associated With Nodal and Renal Infiltration by T-Cell Lymphoma of T-Follicular Helper Phenotype: A Case Report. <b>2018</b> , 72, 606-611		1
1200	A case of post-transplant lymphoproliferative disorders that developed ten years after living renal transplantation in the parotid gland region. <b>2018</b> , 30, 457-460		
1199	Colonial monomorphic epitheliotropic intestinal T-cell lymphoma with novel phenotype of cytoplasmic CD3 expression. <b>2018</b> , 58, 102-106		5
1198	Composite cutaneous lymphoma of diffuse large B-cell lymphoma-leg type and subcutaneous panniculitis-like T-cell lymphoma. <b>2018</b> , 45, 716		4

1197	Clinical characteristics of primary intestinal NK/T cell lymphoma, nasal type: Case series and review of the literature. <b>2018</b> , 214, 1081-1086	5
1196	Historical Landmarks in an Understanding of the Lymphomas. <b>2018</b> , 675-721	1
1195	[Multiplex ligation-dependent probe amplification in oncohematological diagnostics and research]. <b>2018</b> , 159, 583-592	1
1194	Rituximab maintenance therapy of follicular lymphoma in clinical practice. <b>2018</b> , 7, 2903	5
1193	Isolated orbital mass as the primary presentation of a triple-hit lymphoma transformed from a systemic follicular lymphoma. <b>2018</b> , 10, 156-158	2
1192	EURAPS Editorial: BIA-ALCL, a brief overview. <b>2018</b> , 71, 785-787	6
1191	Cytogenetics of Lymphomas. <b>2018</b> , 853-902	
1190	T-Cell Lymphomas with T-Follicular Helper. <b>2018</b> , 747-756	
1189	Epstein-Barr virus-positive mucocutaneous ulcer of the oral cavity in a patient who had had a renal transplant. <b>2018</b> , 56, 626-628	5
1188	Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics. <b>2018</b> , 2018, 3574534	20
1187	High risk device registries: Global value, costs, and sustainable funding. <b>2018</b> , 71, 1362-1380	7
1186	Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma. <b>2018</b> , 18, 687-691	4
1185	MicroRNAs for the pediatric otolaryngologist. <b>2018</b> , 112, 195-207	5
1184	Cutavirus Infection in Primary Cutaneous B- and T-Cell Lymphoma. <b>2018</b> , 154, 965-967	6
1183	Pulmonary Pathology. <b>2018</b> ,	2
1182	An update on high grade B-cell lymphoma. <b>2018</b> , 24, 237-245	1
1181	Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review. <b>2018</b> , 13, 318-328	11
1180	A Case of Chemotherapy-Refractory "THRLBCL like Transformation of NLPHL" Successfully Treated with Lenalidomide. <b>2018</b> , 2018, 6137454	

1179	Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum. <b>2018</b> , 81, 96-104	7
1178	Reappraisal of nodal Epstein-Barr Virus-negative cytotoxic T-cell lymphoma: Identification of indolent CD5 diseases. <b>2018</b> , 109, 2599-2610	7
1177	Hydroa vacciniforme-like lymphoproliferative disorder in an elderly Chinese patient and a literature review of adult cases. <b>2018</b> , 57, 1283-1292	5
1176	Gastric Lymphoma. <b>2018</b> , 147-159	
1175	Reply to the Editor Regarding: Magnusson MR, Deva AK Letter to the Editor 2018 May 2 in Relation to: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. <i>Aesth Plast Surg</i> , 2018. <b>2018</b> , 42, 1167-1169	2
1174	Breast Implant-Associated Anaplastic Large Cell Lymphoma: Case Report and Review of the Literature. <b>2018</b> , 2018, 2414278	18
1173	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. <b>2018</b> , 9, 28866-28876	26
1172	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. <b>2018</b> , 10,	14
1171	Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint. <b>2018</b> , 11, 737-748	13
1170	The Value of T-Cell Receptor [(TRG) Clonality Evaluation by Next-Generation Sequencing in Clinical Hematolymphoid Tissues. <b>2018</b> , 150, 193-223	6
1169	Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. <b>2018</b> , 11, 2287-2293	17
1168	Epstein Barr Virus-Associated Hodgkin Lymphoma. <b>2018</b> , 10,	15
1167	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. <b>2018</b> , 138, 2365-2376	39
1166	Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. <b>2018</b> , 13, e0199708	2
1165	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. <b>2018</b> , 951-973	
1164	Tonsillar Plasmacytoma: clues on magnetic resonance imaging. <b>2018</b> , 18, 19	2
1163	Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. <b>2018</b> , 10, 615-624	13
1162	The Mediastinal Mass. <b>2018</b> ,	

1161	Mediastinal Lymphoma. <b>2018</b> , 241-249	
1160	Optimizing initial therapy in DLBCL. <b>2018</b> , 31, 199-208	13
1159	Die folliculotrope Mycosis fungoides - vielschichtiger als gedacht. <b>2018</b> , 16, 537-538	
1158	Histiocytic sarcoma of the neck: A case report. <b>2018</b> , 9, 54-57	2
1157	Management of relapsed/refractory DLBCL. <b>2018</b> , 31, 209-216	51
1156	Molecular Applications in Cytology. <b>2018</b> ,	1
1155	Oral lymphoma: a case series. <b>2018</b> , 45, 641-644	
1154	Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. <b>2018</b> , 108, 416-422	1
1153	Double hit lymphoma: How do we define it and how do we treat it?. <b>2018</b> , 31, 233-240	16
1152	Ultrasonography-guided core needle biopsy of cervical lymph nodes for diagnosing head and neck lymphoma compared with open surgical biopsy: Exploration for factors that shape diagnostic yield. <b>2018</b> , 39, 679-684	8
1151	A rare case of splenic diffuse red pulp small B-cell lymphoma (SDRPL): a review of the literature on primary splenic lymphoma with hairy cells. <b>2018</b> , 53, 74-78	3
1150	Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. <b>2018</b> , 14, 1007-1017	32
1149	"Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements. <b>2018</b> , 46, 807-811	1
1148	The Pathologic Basis for the Classification of Non-Hodgkin and Hodgkin Lymphomas. <b>2018</b> , 1187-1203	0
1147	Pediatric cutaneous T-cell post-transplant lymphoproliferative disorder: Case report and review of the literature. <b>2018</b> , 45, 858-863	7
1146	An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping. <b>2018</b> , 40, 715-720	2
1145	Primary bilateral ovarian Burkitt lymphoma; a rare issue in gynecologic oncology. <b>2018</b> , 2018, rjy113	2
1144	Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions. <b>2018</b> , 63, 1421-1438	5

1143	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. <b>2018</b> , 9, 621	16
1142	Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. <b>2018</b> , 8, 139	25
1141	New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. <b>2018</b> , 8, 198	31
1140	Y-ibrutumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. <b>2018</b> , 101, 514-521	2
1139	EBV Positive Diffuse Large B Cell Lymphoma and Chronic Lymphocytic Leukemia Patients Exhibit Increased Anti-dUTPase Antibodies. <b>2018</b> , 10,	4
1138	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. <b>2018</b> , 10,	24
1137	Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. <b>2018</b> , 6, 1508-1517	69
1136	Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing. <b>2018</b> , 20, 677-685	13
1135	How I treat primary mediastinal B-cell lymphoma. <i>Blood</i> , <b>2018</b> , 132, 782-790	2.2 40
1134	Pregnancy associated acute leukemia: Single center experience. <b>2018</b> , 16, 53-58	6
1133	Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma. <b>2018</b> , 22, 807-813	6
1132	Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia. <b>2018</b> , 23,	7
1131	Molecular Diagnosis of <i>Felis catus</i> Gammaherpesvirus 1 (FcaGHV1) Infection in Cats of Known Retrovirus Status with and without Lymphoma. <b>2018</b> , 10,	16
1130	'Blastoid' variant of Burkitt lymphoma with additional partial 1q tetrasomy. <b>2018</b> , 8, 637-639	
1129	Diffuse Large B-cell Lymphoma. <b>2018</b> , 557-570	
1128	Diffuse Large B-cell Lymphoma Subtypes. <b>2018</b> , 571-582	
1127	Other Lymphomas of Large B Cells. <b>2018</b> , 583-604	
1126	Burkitt and Burkitt-Like Lymphomas. <b>2018</b> , 605-612	

1125	Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV. <b>2018</b> , 14, e1007130	8
1124	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. <b>2018</b> , 19,	11
1123	Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. <b>2018</b> , 8, 163	118
1122	Transformation of double-hit follicular lymphoma to plasmablastic lymphoma: a partial role of MYC gene rearrangement. <b>2018</b> , 58, 128-135	3
1121	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. <b>2018</b> , 93, 953-962	53
1120	The First Year of the AEVD Primary Cutaneous Lymphoma Registry. <b>2018</b> , 109, 610-616	
1119	Advances in pathological understanding of high-grade B cell lymphomas. <b>2018</b> , 11, 637-648	9
1118	When Appearance Is Everything: Chylous Ascites. <b>2018</b> , 131, 1314-1316	
1117	Lymphomas of the Ocular Adnexa. <b>2018</b> , 513-522	
1116	The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. <b>2018</b> , 19,	19
1115	Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma. <b>2018</b> , 34, 199-206	2
1114	Biology and Pathology of B-Cell Lymphoma. <b>2018</b> , 9-31	
1113	Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives. <b>2018</b> , 10,	20
1112	The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas. <b>2018</b> , 10,	54
1111	Evolving treatment strategies in mantle cell lymphoma. <b>2018</b> , 31, 270-278	4
1110	CD3-positive diffuse large B-cell lymphoma relapses as CD3-negative large B-cell lymphoma: Loss of aberrant antigen expression in B-cell lymphoma after chemotherapy. <b>2018</b> , 214, 1738-1744	1
1109	Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. <b>2018</b> , 97, 2001-2003	
1108	Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF mutation. <b>2018</b> , 28, 4635-4642	12

1107	Fluorescent In Situ Hybridization in Surgical Pathology Practice. <b>2018</b> , 25, 223-237	4
1106	Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review. <b>2018</b> , 22, e13211	12
1105	slan Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. <b>2018</b> , 78, 3544-3559	17
1104	Primary Skull Base Lymphoma: Manifestations and Clinical Outcomes of a Great Imitator. <b>2018</b> , 159, 643-649	10
1103	A Practical Guide to Skin Cancer. <b>2018</b> ,	1
1102	Management of post-transplant lymphoproliferative disorders. <b>2018</b> , 182, 330-343	41
1101	The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms. <b>2018</b> , 40 Suppl 1, 97-103	34
1100	Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. <b>2018</b> , 13, 10	24
1099	Current trials for frontline therapy of mantle cell lymphoma. <b>2018</b> , 11, 13	10
1098	Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. <b>2018</b> , 37, 95	20
1097	Interobserver Agreement of Interim and End-of-Treatment F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. <b>2018</b> , 59, 1831-1836	14
1096	Would you think of histiocytic sarcoma in this fine-needle aspiration?. <b>2018</b> , 97, 2257-2259	
1095	Genetics in Lymphomagenesis. <b>2018</b> , 723-753	
1094	Chronic Lymphocytic Leukemia: Diagnosis and Treatment. <b>2018</b> , 93, 651-664	18
1093	Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin. <b>2018</b> , 31, 1479-1486	7
1092	Precision medicine and lymphoma. <b>2018</b> , 25, 329-334	5
1091	NHL in adolescents and young adults: A unique population. <b>2018</b> , 65, e27073	8
1090	SOX11, a key oncogenic factor in mantle cell lymphoma. <b>2018</b> , 25, 299-306	24

1089	Expression of Keap1 and Nrf2 in diffuse large B-cell lymphoma and its clinical significance. <b>2018</b> , 16, 573-578	3
1088	Breast Implant-Associated Anaplastic Large Cell Lymphoma: Immediate or Delayed Implant Replacement?. <b>2018</b> , 42, 1492-1498	6
1087	Mycophenolate Mofetil for the Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma: Case Report and Review of the Literature. <b>2018</b> , 18, e437-e440	2
1086	Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. <b>2018</b> , 183, 385-399	11
1085	Peripheral T-cell lymphoma, not otherwise specified, presenting with generalized ulcerated plaques and hypereosinophilia. <b>2018</b> , 4, 651-654	1
1084	Targeting MEK in a Translational Model of Histiocytic Sarcoma. <b>2018</b> , 17, 2439-2450	13
1083	Non-traumatic splenic rupture - a rare first presentation of diffuse large B-cell lymphoma and a review of the literature. <b>2018</b> , 18, 779	5
1082	Simultaneous occurrence of splenic diffuse large B cell lymphoma and gastrointestinal stromal tumor in the stomach: a case report. <b>2018</b> , 13, 61	1
1081	TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma. <b>2018</b> , 18, 762-768	14
1080	Update on mantle cell lymphoma. <i>Blood</i> , <b>2018</b> , 132, 1647-1656	2.2 91
1079	Integrating novel systemic therapies for the treatment of mycosis fungoides and S�ary syndrome. <b>2018</b> , 31, 322-335	6
1078	Recurrent ulceronecrotic plaques and nodules with spontaneous remission. <b>2018</b> , 16, 1155-1158	
1077	Microenvironment Cell Contribution to Lymphoma Immunity. <b>2018</b> , 8, 288	23
1076	Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells. <b>2018</b> , 97, 2353-2362	5
1075	Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia. <b>2018</b> , 6, 26	21
1074	Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study. <b>2018</b> , 98, 835-841	10
1073	High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma. <b>2018</b> , 20, 777-788	5
1072	Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. <b>2018</b> , 98, 1657-1669	60



1071	Clinicopathological features of splenic tumours of lymphoid tissue. <b>2018</b> , 214, 1952-1958		4
1070	Non-Hodgkin lymphoma. <b>2018</b> , 362, k3204		28
1069	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , <b>2018</b> , 132, 1695-1702	2.2	30
1068	Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses. <b>2018</b> , 3, 381-390		4
1067	Misdiagnosed Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Successfully Treated: A Case Report. <b>2017</b> , 10, 948-953		1
1066	Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. <b>2018</b> , 4, 29-44		5
1065	Molecular pathogenesis of cutaneous lymphomas. <b>2018</b> , 27, 1078-1083		7
1064	TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression. <b>2018</b> , 80, 145-151		13
1063	T-cell receptor- $\alpha$ expression and $\beta$ T-cell infiltrates in primary cutaneous $\gamma$ -T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. <b>2018</b> , 73, 653-662		19
1062	Hematologic and Lymphoid Neoplasia. <b>2018</b> , 107-118		
1061	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , <b>2018</b> , 132, 694-706	2.2	104
1060	Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation's 2017 classification. <b>2018</b> , 69, 1-19		5
1059	Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection. <b>2018</b> , 1045, 357-376		11
1058	Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements. <b>2018</b> , 103, 1899-1907		31
1057	Hematopoietic stem cell transplantation for T-cell lymphoma. <b>2018</b> , 1, e6		2
1056	Heightened BRAF and BRAF pseudogene expression levels in 2 Japanese patients with Erdheim-Chester disease. <b>2018</b> , 1, 16-22		
1055	GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. <b>2018</b> , 151, 39.e1-39.e17		1
1054	Concurrent Mycobacterium tuberculosis infection and nodal marginal zone lymphoma. <b>2018</b> , 50, 464-466		

1053	Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia. <b>2018</b> , 13, e0191205		3
1052	T- and NK-Cell Lymphocytosis. <b>2018</b> , 281-328		
1051	A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma. <b>2018</b> , 182, 63-70		8
1050	Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations. <b>2018</b> , 80, 192-200		5
1049	Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. <b>2018</b> , 15, 6903-6912		8
1048	Superior vena cava syndrome related to mediastinal lymphoma in late pregnancy: A case report. <b>2018</b> , 19, e00065		0
1047	Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. <b>2018</b> , 151, 362-367		10
1046	EBV in T-/NK-Cell Tumorigenesis. <b>2018</b> , 1045, 459-475		31
1045	Diagnosis of NK and cytotoxic T-cell disorders: a review. <b>2018</b> , 24, 257-266		1
1044	Clinical characteristics and outcomes of PTLD following intestinal transplantation. <b>2018</b> , 32, e13313		11
1043	A Mediastinal Mass in a Young Man. <b>2018</b> , 319, 2432-2433		
1042	Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. <i>Blood</i> , <b>2018</b> , 132, 666-670	2.2	28
1041	Gastric Cardiac Cancer. <b>2018</b> ,		2
1040	Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. <b>2018</b> , 71, 1-5		8
1039	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. <b>2019</b> , 60, 559-561		8
1038	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. <b>2019</b> , 60, 376-384		16
1037	Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound-Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes. <b>2019</b> , 38, 581-586		5
1036	Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. <b>2019</b> , 33, 63-73		26

1035	SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. <b>2019</b> , 185, 145-147	7
1034	Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. <b>2019</b> , 60, 60-64	28
1033	Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients. <b>2019</b> , 13, 229-237	12
1032	Diagnosis and classification of lymphoma: Impact of technical advances. <b>2019</b> , 56, 30-36	12
1031	Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. <b>2019</b> , 27, 98-101	5
1030	Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. <b>2019</b> , 37, 210-222	21
1029	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <b>2019</b> , 33, 696-709	25
1028	The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. <b>2019</b> , 56, 90-95	34
1027	Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome. <b>2019</b> , 187, 478-487	5
1026	Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia. <b>2019</b> , 15, 2687-2697	
1025	The Global Landscape of EBV-Associated Tumors. <b>2019</b> , 9, 713	149
1024	Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review. <b>2019</b> , 17,	3
1023	Acute Myeloid Leukemia: An Update. <b>2019</b> , 163-182	1
1022	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <b>2019</b> , 25, 2383-2387	10
1021	Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. <i>Blood</i> , <b>2019</b> , 134, 960-969	2.2 29
1020	Immunoglobulin abnormalities in 1677 solid organ transplant recipients. Implications for posttransplantation follow-up. <b>2019</b> , 57, 101229	3
1019	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. <b>2019</b> , 291, 190-213	40
1018	Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma. <b>2019</b> , 6, 407-418	

1017	Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. <b>2019</b> , 14, 563-575	7
1016	The SUMO Pathway in Hematomalignancies and Their Response to Therapies. <b>2019</b> , 20,	24
1015	Periphere T-Zell-Lymphome. <b>2019</b> , 25, 892-898	
1014	HIV-triggered lymphoma. <b>2019</b> , 12, 230-234	0
1013	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. <b>2019</b> , 25, 2490-2500	8
1012	Primary Mediastinal Large B-Cell Lymphoma: A Review for Radiologists. <b>2019</b> , 213, W194-W210	4
1011	Shift in Epstein-Barr virus (EBV)-infected cells in chronic active EBV disease. <b>2019</b> , 61, 825-826	1
1010	A six-gene-based prognostic model predicts complete remission and overall survival in childhood acute myeloid leukemia. <b>2019</b> , 12, 6591-6604	12
1009	Molekulare Klassifikatoren. <b>2019</b> , 25, 849-858	
1008	Breast implant-associated anaplastic large cell lymphoma, a systematic review and in-depth evaluation of the current understanding. <b>2019</b> , 120, 573-577	8
1007	Increasing Evidence for the Association of Breast Implant-Associated Anaplastic Large Cell Lymphoma and Li Fraumeni Syndrome. <b>2019</b> , 2019, 5647940	10
1006	Two cases of monomorphic epitheliotropic intestinal T-cell lymphoma associated with coeliac disease. <b>2019</b> , 54, 965-968	10
1005	Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <b>2019</b> , 12, 833-843	9
1004	CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. <b>2019</b> , 12, 873-881	13
1003	Unusual Clinical Presentation of a Primary Cutaneous Follicle Center Lymphoma on the Scalp of a Middle-Aged Female: Case Report and Review of the Literature. <b>2019</b> , 5, 379-385	1
1002	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <b>2019</b> , 94, 1193-1199	9
1001	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , <b>2019</b> , 134, 798-801	2.2 20
1000	Design of medical database for medical decision support system in laboratory diagnosis of acute leukaemia. <b>2019</b> , 1189, 012029	1

999	Primary Cutaneous Anaplastic Large-Cell Lymphoma. <b>2019</b> , 6, 163-169	4
998	Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. <b>2019</b> , 186, e203-e207	5
997	Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. <b>2019</b> , 12, 787-796	4
996	Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. <b>2019</b> , 14, 81	10
995	Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes. <b>2019</b> , 20,	3
994	Surgical Resection for Primary Rectal Lymphoma: Support for Local Excision?. <b>2019</b> , 244, 189-195	0
993	High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. <b>2019</b> , 4,	6
992	IMiDs New and Old. <b>2019</b> , 14, 414-425	18
991	Acute profound sensorineural hearing loss as the initial manifestation of Hairy Cell Leukemia, Case Report and literature review. <b>2019</b> , 60, 200-203	1
990	Hydroa vacciniforme-like lymphoproliferative disorder: Clinicopathologic study of 41 cases. <b>2019</b> , 81, 534-540	21
989	Mantle cell lymphoma pathology update in the 2016 WHO classification. <b>2019</b> , 3, 3-3	6
988	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes. <b>2019</b> , 9, 683	19
987	A case of intraoral plasmablastic lymphoma spontaneously regressed after biopsy in HIV-negative patient. <b>2019</b> , 31, 280-283	2
986	Somatic mutations in and associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders. <b>2019</b> , 20, 1319-1327	6
985	Investigating the self-perceived educational priorities of haematology nurses. <b>2019</b> , 41, 72-81	2
984	Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing. <b>2019</b> , 19, e496-e505	3
983	Successful treatment of nasal-type extra-nodal natural killer/T cell lymphoma with simultaneous involvement of the thyroid, liver, and pancreas. <b>2019</b> , 98, 2243-2246	1
982	Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?. <b>2019</b> , 125, 3111-3120	9

981	Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. <b>2019</b> , 60, 3569-3572		4
980	Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. <b>2019</b> , 12, 73		35
979	Imaging of Waldenström Macroglobulinemia: A Comprehensive Review for the Radiologist in the Era of Personalized Medicine. <b>2019</b> , 213, W248-W256		3
978	Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire. <b>2019</b> , 139, 2195-2203		5
977	Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases. <b>2019</b> , 14, 82		9
976	Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. <b>2019</b> , 8, 5058-5067		15
975	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 134, 1132-1143	2.2	46
974	Optimizing treatment combination for lymphoma using an optimization heuristic. <b>2019</b> , 315, 108227		0
973	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <b>2019</b> , 37, 2815-2824		93
972	CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond. <b>2019</b> , 10, 471		82
971	Gastric MALT lymphoma in a population-based study in France: clinical features, treatments and survival. <b>2019</b> , 50, 654-663		13
970	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <b>2019</b> , 24, e1236-e1250		20
969	Updates on CAR T-cell therapy in B-cell malignancies. <b>2019</b> , 290, 39-59		36
968	Post-transplant lymphoproliferative disorder presenting as T-prolymphocytic leukemia: a case report. <b>2019</b> , 13, 223		1
967	The impact of diagnostic wait time on the survival of patients with diffuse large B-cell lymphoma: effect modification by the International Prognostic Index. <b>2019</b> , 187, 195-205		
966	RHO Family GTPases in the Biology of Lymphoma. <b>2019</b> , 8,		18
965	Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. <b>2019</b> , 14, 207-218		6
964	The revised International Paediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS): a test of applicability. <b>2019</b> , 186, e201-e203		

963	Large Granular Lymphocyte Leukemia. <b>2019</b> , 167-179	
962	Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. <b>2019</b> , 19, e559-e563	4
961	Non-coding RNAs in Natural Killer/T-Cell Lymphoma. <b>2019</b> , 9, 515	12
960	Diagnostic and prognostic factors for patients with primary pulmonary non-Hodgkin's lymphoma: A 16-year single-center retrospective study. <b>2019</b> , 18, 2082-2090	4
959	PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories. <b>2019</b> , 8, 4656-4668	6
958	Drug-Induced Injury, Polyps, Congenital, and Miscellaneous Disorders. <b>2019</b> , 289-306	
957	Chronic lymphocytic leukaemia: from genetics to treatment. <b>2019</b> , 16, 684-701	85
956	Targetable genetic alterations of $\kappa$ drive immunoglobulin expression in diffuse large B cell lymphoma. <b>2019</b> , 11,	28
955	Role of Radiation Therapy in Younger and Older Adults with Primary Mediastinal Large B Cell Lymphoma in Rituximab Era: A U.S. Population-Based Analysis. <b>2019</b> , 8, 623-627	1
954	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. <b>2019</b> , 33, 639-656	5
953	Central Nervous System Lymphoma. <b>2019</b> , 33, 597-611	14
952	Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements. <b>2019</b> , 33, 587-596	7
951	The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma. <b>2019</b> , 60, 3214-3224	1
950	High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing. <b>2019</b> , 60, 3455-3460	2
949	Recent Advances in Cutaneous T-cell Lymphoma: Diagnostic and Prognostic Considerations. <b>2019</b> , 12, 783-803	9
948	Changes in EBV Association Pattern in Pediatric Classic Hodgkin Lymphoma From a Single Institution in Argentina. <b>2019</b> , 9, 881	1
947	'Piperazing' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib. <b>2019</b> , 11, 2365-2380	2
946	Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria. <b>2019</b> , 31, 144-149	2

945	A novel ALK inhibitor ZYY inhibits Karpas299 cell growth in vitro and in a mouse xenograft model and induces protective autophagy. <b>2019</b> , 383, 114781	5
944	Pruritus as a sign of systemic disease. <b>2019</b> , 37, 644-656	7
943	[Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary]. <b>2019</b> , 160, 944-951	
942	Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. <b>2019</b> , 26, 253-265	18
941	Stabilizing stretch reflexes are modulated independently from the rapid release of perturbation-triggered motor plans. <b>2019</b> , 9, 13926	4
940	Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma. <b>2019</b> , 96, 134-142	4
939	Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China. <b>2019</b> , 11, 8277-8284	
938	Actualit� dans les lymphomes � petites cellules non folliculaires. <b>2019</b> , 48, 859-870	
937	Precision Medicine Concepts in T-Cell Lymphoma. <b>2019</b> ,	
936	Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature. <b>2019</b> , 12, 1095-1105	2
935	Extranodal NK/T-Cell Lymphoma, Nasal Type: Shrouded No More. <b>2019</b> , 15, 521-522	1
934	[Hairy cell leukemia]. <b>2019</b> , 48, 842-849	1
933	RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment. <b>2019</b> , 110, 104294	3
932	Polymorphic post-transplant lymphoproliferative disorder in a gilt. <b>2019</b> , 39, 136-142	
931	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <b>2019</b> , 37, 3291-3299	116
930	A practical cytological approach to the diagnosis of breast-implant associated anaplastic large cell lymphoma. <b>2019</b> , 30, 363-369	16
929	Association of CD204 macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT. <b>2019</b> , 103, 578-587	2
928	Lymphoma genetics. <b>2019</b> , 101-110	



927	Nasopharyngeal Lymphoma: A 22-Year Review of 35 Cases. <b>2019</b> , 8,	10
926	Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. <b>2019</b> , 37, 569-577	10
925	Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. <b>2019</b> , 20,	16
924	Radiolucencies. <b>2019</b> , 159-272	
923	Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder: The first-reported Latin-American case with response to doxycycline. <b>2019</b> , 7, 2405-2409	1
922	The opportunistic effect of exosomes on Non-Hodgkin Lymphoma microenvironment modulation. <b>2019</b> , 144, 102825	5
921	[Current standard in diagnostic and therapy of peripheral T-cell lymphoma]. <b>2019</b> , 144, 1400-1404	
920	Overview of T-cell Lymphomas. <b>2019</b> ,	
919	MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. <b>2019</b> , 104, 2337-2348	22
918	Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients. <b>2019</b> , 19, 1084	6
917	Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects. <b>2019</b> , 38, 450	12
916	Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. <b>2019</b> , 9, 16495	14
915	Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. <b>2019</b> , 10, 986	10
914	Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada. <b>2019</b> , 26, e473-e481	16
913	Pediatric-type follicular lymphoma-Complete metabolic remission with radiation therapy. <b>2019</b> , 37, 638-640	
912	[Epidemiological and clinical profile and outcome in 166 mycosis fungoides patients in Casablanca]. <b>2019</b> , 146, 825-828	0
911	The Evolution of Breast Implants. <b>2019</b> , 33, 217-223	12
910	Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <b>2019</b> , 33, 270-278	14

909	Burkitt-like lymphoma in a pediatric patient with familial adenomatous polyposis. <b>2019</b> , 239, 33-35	3
908	Molecular diagnostics and risk assessment in myeloid malignancies. <b>2019</b> , 49-58	
907	CXCR4-gerichtete Endoradiotherapie von hämatologischen Erkrankungen. <b>2019</b> , 42, 36-45	0
906	The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma. <b>2019</b> , 19, 272	5
905	[Extra-nodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous and ocular involvement]. <b>2019</b> , 146, 626-633	1
904	EBVCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. <b>2019</b> , 25, 6260-6273	11
903	Proceedings of the 2019 National Toxicology Program Satellite Symposium. <b>2019</b> , 47, 913-953	6
902	Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. <b>2019</b> , 185, 1071-1085	12
901	Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA. <b>2019</b> , 10, 323-331	21
900	Lymphocyte subset at time of Epstein-Barr viremia post-allogeneic hematopoietic stem cell transplantation in children may predict development of post-transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor. <b>2019</b> , 23, e13574	2
899	Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Why Must We Learn About It?. <b>2019</b> , 5, 1-5	1
898	Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemostudy). <b>2019</b> , 98, 2367-2377	0
897	Psychoonkologischer Versorgungsbedarf bei Patienten mit Non-Hodgkin-Lymphom. <b>2019</b> , 25, 914-918	1
896	Monoclonal immunoglobulinmediated kidney disease: What is beyond amyloidosis in real practice?. <b>2019</b> , 3, 105-112	1
895	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. <b>2019</b> , 9, 33-43	3
894	Brustimplantatassoziiertes Lymphom und Laktation [eine seltene Kombination]. <b>2019</b> , 16, 105-108	
893	Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. <b>2019</b> , 12, 975-981	9
892	Klinisch-pathologische Korrelation weist den Weg. <b>2019</b> , 67, 604-615	

891	A Supraclavicular ALK-Positive Anaplastic Large-Cell Lymphoma Initially Misdiagnosed and Yet Successfully Treated with Wide Excision and Adjuvant Chemotherapy: a Case Report. <b>2019</b> , 1, 716-725	0
890	Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know. <b>2019</b> , 10, 25	8
889	A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT. <b>2019</b> , 9, 36	4
888	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. <b>2019</b> , 10, 1943	8
887	Brustimplantatassoziiertes Lymphom und Laktation [Eine seltene Kombination. <b>2019</b> , 79, 250-253	
886	[Follicular lymphoma: An update]. <b>2019</b> , 48, 850-858	
885	M1-like macrophage polarization prevails in young children with classic Hodgkin Lymphoma from Argentina. <b>2019</b> , 9, 12687	5
884	The Evolving Case Supporting Individualised Physiotherapy for Low Back Pain. <b>2019</b> , 8,	4
883	Breast implant associated anaplastic large cell lymphoma. <b>2019</b> , l4302	0
882	Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. <b>2019</b> , 20,	17
881	[Cutaneous lymphomas : Clinical presentation - diagnosis - treatment]. <b>2019</b> , 70, 815-830	0
880	Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. <b>2019</b> , 81, 970-976	9
879	Exosomal MiRNAs in Pediatric Cancers. <b>2019</b> , 20,	17
878	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. <b>2019</b> , 94, 2054-2071	60
877	Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care - Authors' reply. <b>2019</b> , 6, e120	
876	Clinical characteristics and prognostic factors in Chinese patients with classical Hodgkin's lymphoma involving extranodal sites: a retrospective single-center. <b>2019</b> , 24, 661-668	1
875	The role of obinutuzumab in the management of follicular lymphoma. <b>2019</b> , 15, 3565-3578	5
874	Ductal acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma. <b>2019</b> , 2,	17

873	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. <b>2019</b> , 12, 959-973	5
872	Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience. <b>2019</b> , 24, 623-630	2
871	Lymphomatoid Papulosis and Other Lymphoma-Like Diseases. <b>2019</b> , 37, 471-482	3
870	Long-Term Evaluation of Post-transplant Lymphoproliferative Disorders in Paediatric Heart Transplantation in Sao Paulo, Brazil. <b>2019</b> , 40, 1655-1662	1
869	Nonproliferative and Proliferative Lesions of the Rat and Mouse Hematolymphoid System. <b>2019</b> , 47, 665-783	31
868	Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. <i>Blood</i> , <b>2019</b> , 134, 2159-2170	2.2 45
867	Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis. <b>2019</b> , 2019, 1586328	5
866	FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma. <b>2019</b> , 11,	6
865	Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets. <b>2019</b> , 10, 780	2
864	Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition. <b>2019</b> , 8,	10
863	Ancillary Studies in the Diagnostic Evaluation of Large B-Cell Lymphoma. <b>2019</b> , 143, 1464-1471	0
862	Approach to lymphoma diagnosis and management in South Africa. <b>2019</b> , 109, 715	1
861	Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. <b>2019</b> , 19, 791-798	7
860	Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma. <b>2019</b> , 12, 1053-1062	5
859	[Histopathological classification of chronic B-lymphoproliferative disorders]. <b>2019</b> , 48, 792-806	0
858	Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the L265P Gene Mutation. <b>2019</b> , 11, e2019057	0
857	A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC. <b>2019</b> , 12, 595-602	1
856	Primary central nervous system lymphoma of the optic chiasm. <b>2019</b> , 54, e134-e140	2

855	Gastric MALT lymphoma and Helicobacter pylori. <b>2019</b> , 152, 65-71	3
854	[Extra-ganglionic non-Hodgkin mucosa-associated lymphoid tissue lymphoma presenting as acute appendicitis in a nonagenarian patient]. <b>2019</b> , 54, 55-56	
853	An unexpected diagnosis of histiocytic sarcoma. <b>2019</b> , 106, 60-62	2
852	Defective Epstein-Barr virus in chronic active infection and haematological malignancy. <b>2019</b> , 4, 404-413	80
851	Various initial presentations of Epstein-Barr virus infection-associated post-transplant lymphoproliferative disorder in pediatric liver transplantation recipients: Case series and literature review. <b>2019</b> , 23, e13357	4
850	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. <b>2019</b> , 33, 1687-1699	57
849	B-cell depleting immunotherapies: therapeutic opportunities and toxicities. <b>2019</b> , 15, 497-509	2
848	Is True Whole-Body F-FDG PET/CT Required in Pediatric Lymphoma? An IAEA Multicenter Prospective Study. <b>2019</b> , 60, 1087-1093	4
847	Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma. <b>2019</b> , 11,	27
846	Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders. <b>2019</b> , 8, 1013-1023	13
845	Primary immune regulatory disorders for the pediatric hematologist and oncologist: A case-based review. <b>2019</b> , 66, e27619	19
844	Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. <b>2019</b> , 9, 895	14
843	2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). <b>2019</b> , 39, S3-S13	135
842	Combined Pathology-Driven Algorithmic Testing and Integrated Reporting for Bone Marrow Examination. <b>2019</b> , 143, 732-737	0
841	Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients. <b>2019</b> , 19, 81	2
840	Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma. <b>2019</b> , 78, 1-2	
839	DNA copy number imbalances in primary cutaneous lymphomas. <b>2019</b> , 33, 1062-1075	3
838	BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker. <b>2018</b> , 8, 645	27

837	Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma. <b>2019</b> , 109, 622-626	1
836	Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. <b>2019</b> , 104, 1428-1439	15
835	Non-odontogenic Bone Pathology. <b>2019</b> , 555-626	1
834	Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis. <b>2019</b> , 9, 335	3
833	Unusual transformation of primary extranodal marginal zone B cell lymphoma of the uterus into a nodal follicular lymphoma grade IIIB. <b>2019</b> , 98, 797-799	
832	EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. <b>2019</b> , 44, 90-93	16
831	Association Between Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk and Polyurethane Breast Implants: Clinical Evidence and European Perspective. <b>2019</b> , 39, S49-S54	14
830	Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma. <b>2019</b> ,	3
829	Development of BTK inhibitors for the treatment of B-cell malignancies. <b>2019</b> , 42, 171-181	28
828	Alopecic patches of the scalp: a variant of primary cutaneous follicle centre B-cell lymphoma reported in a series of 14 cases. <b>2019</b> , 33, e209-e211	2
827	Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study. <b>2019</b> , 33, 518-530	18
826	Lymphomatoid granulomatosis: a rare lymphoproliferative disease in the pediatric age. <b>2019</b> , 61, 179-180	
825	Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas. <b>2019</b> , 43, 102-109	6
824	Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach. <b>2019</b> , 21, 63	2
823	The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. <b>2019</b> , 19, 471	11
822	Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma. <b>2019</b> , 14, 45	3
821	Radioimmunotherapy of Lymphomas. <b>2019</b> , 113-121	3
820	An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. <b>2019</b> , 10, 56	36

819	Prognostic significance of peripheral blood absolute lymphocyte count and derived neutrophil to lymphocyte ratio in patients with newly diagnosed extranodal natural killer/T-cell lymphoma. <b>2019</b> , 11, 4243-4254	8
818	Aggressive B-cell lymphomas from morphology to molecular pathogenesis. <b>2019</b> , 3, 1-1	9
817	Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma. <b>2019</b> , 60, 3092-3093	
816	C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges. <b>2019</b> , 142, 64-70	6
815	A decision-tree approach for the differential diagnosis of chronic lymphoid leukemias and peripheral B-cell lymphomas. <b>2019</b> , 178, 85-90	14
814	Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy. <b>2019</b> , 72, 630-635	3
813	MANTLE CELL LYMPHOMA: TWO REFERENCE CENTER'S RESULTS. <b>2019</b> , 37, 407-408	
812	Surgical management of primary colonic lymphoma: Big data for a rare problem. <b>2019</b> , 120, 431-437	1
811	Primary lymphomas of the intraabdominal solid organs and the gastrointestinal tract: spectrum of imaging findings with histopathological confirmation. <b>2019</b> , 44, 2988-3005	4
810	A transcriptional signature associated with non-Hodgkin lymphoma in the blood of patients with Q fever. <b>2019</b> , 14, e0217542	9
809	Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study. <b>2019</b> , 94, 992-1001	2
808	The role of cytology in the diagnosis of haematological malignancies. <b>2019</b> , 30, 345-347	
807	The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. <b>2019</b> , 103, 200-207	28
806	SOX11: friend or foe in tumor prevention and carcinogenesis?. <b>2019</b> , 11, 1758835919853449	14
805	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. <b>2019</b> , 9, 443	20
804	Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus. <b>2019</b> , 81, 23-41	9
803	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. <b>2019</b> , 60, 3266-3271	2
802	Malignant Lymphoma or Metastatic Epithelial Tumors. <b>2019</b> , 297-302	1

801	Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <b>2019</b> , 33, e13652		93
800	Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With / Hypomorphic Gene Variants. <b>2019</b> , 7, 183		11
799	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. <b>2019</b> , 20, 1160-1170		64
798	T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. <b>2019</b> , 32, 207-216		14
797	Predictive value of soluble interleukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy. <b>2019</b> , 98, 2121-2129		3
796	Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge. <b>2019</b> , 7, 11		1
795	Epidural Tumors and Metastases. <b>2019</b> , 671-693		
794	Breast implant-associated anaplastic large cell lymphoma, an under-recognised entity. <b>2019</b> , 63, 630-638		6
793	High-grade B-cell lymphoma: how to diagnose and treat. <b>2019</b> , 12, 497-506		5
792	Immunophenotyping of Murine Precursor B-Cell Leukemia/Lymphoma: A Comparison of Immunohistochemistry and Flow Cytometry. <b>2019</b> , 56, 950-958		2
791	Combined inhibition of Bcl-2 and NF $\kappa$ B synergistically induces cell death in cutaneous T-cell lymphoma. <i>Blood</i> , <b>2019</b> , 134, 445-455	2.2	6
790	Prevention and Treatment of EBV-Related Complications. <b>2019</b> , 81-91		1
789	A novel surgical approach with peritonectomy to extranodal multisystemic histiocytic sarcoma: A case report and literature review. <b>2019</b> , 59, 213-216		1
788	Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. <b>2019</b> , 33, 2662-2672		10
787	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. <b>2019</b> , 139, 2334-2342.e8		16
786	Unusual lymphoid malignancy and treatment response in two children with Down syndrome. <b>2019</b> , 66, e27822		0
785	Long-Term Outcomes in Survivors of Childhood and Adolescent Non-Hodgkin Lymphoma. <b>2019</b> , 353-366		
784	Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. <b>2019</b> , 186, 409-419		3



783	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease. <b>2019</b> , 195-211	0
782	Epidemiology of Non-Hodgkin Lymphomas in Childhood and Adolescence. <b>2019</b> , 15-22	0
781	Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL. <b>2019</b> , 14, e0216898	10
780	Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). <b>2019</b> , 9, 300	26
779	Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia. <b>2019</b> , 26, 108-113	5
778	Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma. <b>2019</b> , 8, 3831-3845	4
777	The role of HLA variation in lymphoma aetiology and survival. <b>2019</b> , 286, 154-180	6
776	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. <b>2019</b> , 75, 787-796	26
775	Clinicopathologic correlates of L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. <b>2019</b> , 60, 2880-2889	8
774	Clinical Significance of , C-, and Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients. <b>2019</b> , 16, 556-566	7
773	Rare mature B-cell lymphomas in children and adolescents. <b>2019</b> , 37 Suppl 1, 53-61	10
772	Laboratory Diagnosis of Chronic Lymphocytic Leukaemia. <b>2019</b> , 21-35	2
771	Cutaneous lymphomas-An update 2019. <b>2019</b> , 37 Suppl 1, 43-47	29
770	Hepatosplenic T-Cell Lymphoma: Who Is on Your Speed Dial?. <b>2019</b> , 15, 307-312	4
769	Variant form of hairy cell leukemia. <b>2019</b> , 7, 1161-1166	5
768	Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. <b>2019</b> , 17, 198	5
767	TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas. <b>2019</b> , 11, 4743-4756	6
766	Double-hit lymphoma: So what?. <b>2019</b> , 37 Suppl 1, 19-23	10

765	Primär kutanes diffus-großzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede. <b>2019</b> , 17, 275-286	1
764	Treatment outcome and prognostic factors in PCNSL. <b>2019</b> , 14, 56	15
763	Cutaneous lymphoma and important differential diagnoses: emphasis on cases with a cytotoxic phenotype. <b>2019</b> , 25, 240-248	1
762	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. <b>2019</b> , 9, 50	45
761	Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. <b>2019</b> , 94, 929-946	29
760	Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis. <b>2019</b> , 12, 2751-2766	5
759	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. <b>2019</b> , 8, 3131-3141	7
758	Hairy cell leukemia: present and future directions. <b>2019</b> , 60, 2869-2879	18
757	Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin. <b>2019</b> , 5, 1-8	2
756	Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. <b>2019</b> , 39, 446-453	12
755	Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. <b>2019</b> , 20,	17
754	History of Diagnoses and Treatment Strategies in Pediatric Non-Hodgkin Lymphomas. <b>2019</b> , 3-13	
753	Clinical and Prognostic Significance of Cell Sensitivity to Chemotherapy Detected in vitro on Treatment Response and Survival of Leukemia Patients. <b>2019</b> , 9,	3
752	Copy number aberrations in B-cell lymphoma: A call for consideration in prognosis determination and therapy. <b>2019</b> , 11, 38-40	1
751	Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. <b>2019</b> , 24, 440-445	6
750	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. <b>2019</b> , 90, 1027-1038	32
749	Grey zones in the differential diagnosis of lymphoma pathology. <b>2019</b> , 25, 191-216	2
748	[Fast-evolving necrotic ulcer]. <b>2019</b> , 51, 656-657	

747	A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. <b>2019</b> , 66, e27798	10
746	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. <b>2019</b> , 39, 2591-2598	
745	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <b>2019</b> , 9, 48	13
744	Non-implant associated primary cutaneous anaplastic large cell lymphoma of the breast. <b>2019</b> , 2019, rjz139	3
743	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. <b>2019</b> , 21, 1039-1048	12
742	Hematopoietic Stem Cell Transplantation. <b>2019</b> , 305-313	
741	Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma. <b>2019</b> , 14, e0215765	5
740	Substantial improvement in immune thrombocytopenic purpura associated with T-cell/histiocyte-rich B-cell lymphoma treated with chemotherapy: A case report. <b>2019</b> , 10, 441-445	1
739	Marginal Zone Lymphoma. <b>2019</b> , 221-227	
738	Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations. <b>2019</b> , 58, 698-704	5
737	Actinic Prurigo and Hydroa Vacciniforme. <b>2019</b> , 8, 63-72	1
736	Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study. <b>2019</b> , 80, 1704-1711	5
735	Lymphomatoid granulomatosis: A rare lymphoproliferative disease in the pediatric age. <b>2019</b> , 61, 179-180	
734	Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients. <b>2019</b> , 98, 1937-1946	3
733	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. <b>2019</b> , 133-188	1
732	Lymph node fine-needle cytology in the era of personalised medicine. Is there a role?. <b>2019</b> , 30, 348-362	7
731	Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors. <b>2019</b> , 25, 4443-4454	47
730	Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIIE extranodal natural killer/T-cell lymphoma, nasal type. <b>2019</b> , 8, 3349-3358	5

729	Usefulness of Flow Cytometry for the Detection of Cutaneous Localization in Malignant Hematologic Disorders. <b>2019</b> , 96, 283-293	2
728	Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. <b>2019</b> , 145, 3078-3088	6
727	Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma. <b>2019</b> , 203, 154-161	4
726	Serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels may be associated with lymphoma: An exploratory study with haematological diseases. <b>2019</b> , 9, 6308	3
725	A Rare Case of a Transgender Female With Breast Implant-Associated Anaplastic Large Cell Lymphoma Treated With Radiotherapy and a Review of the Literature. <b>2019</b> , 7, 2324709619842192	8
724	Cytological diagnosis of vitreoretinal lymphomas: A case series. <b>2019</b> , 30, 385-392	1
723	Vitamin D status and risk of non-Hodgkin lymphoma: An updated meta-analysis. <b>2019</b> , 14, e0216284	19
722	Genetic Predisposition to Non-Hodgkin Lymphoma. <b>2019</b> , 97-110	1
721	Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma. <b>2019</b> , 37, 303-307	0
720	A case of pulmonary lymphoproliferative disorder presenting rapidly progressive respiratory failure. <b>2019</b> , 7, e00422	
719	Double-hit pancreatic B-lymphoblastic lymphoma with a variant translocation t(2;18)(p11;q21). <b>2019</b> , 110, 107-114	1
718	Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. <b>2019</b> , 60, 128-133	6
717	Optimizing treatment of HIV-associated lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1385-1394	2.2 28
716	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. <b>2019</b> , 37, 253-260	2
715	Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. <b>2019</b> , 60, 2622-2634	7
714	Chronic Lymphocytic Leukemia. <b>2019</b> ,	
713	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. <b>2019</b> , 37, 548-558	4
712	Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review. <b>2019</b> , 139, 7-15	7

711	Posttransplant lymphoproliferative disorder in pediatric patients: Survival rates according to primary sites of occurrence and a proposed clinical categorization. <b>2019</b> , 19, 2764-2774	8
710	Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. <b>2019</b> , 94, 641-649	13
709	Molecular Diagnostics in Non-Hodgkin Lymphoma. <b>2019</b> , 103-127	
708	Global patterns and trends in the incidence of non-Hodgkin lymphoma. <b>2019</b> , 30, 489-499	53
707	Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. <b>2019</b> , 14, 149-158	10
706	Overexpression of survivin in pediatric Hodgkin lymphoma tumor cells: Characterization of protein expression and splice-variants transcription profile. <b>2019</b> , 108, 24-31	2
705	MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities. <b>2019</b> , 288, 178-197	22
704	Aktualisierte S2k-Leitlinie Zölkakie der Deutschen Gesellschaft ff Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). <b>2022</b> , 60, 790-856	1
703	Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality. <b>2022</b> , 14, 2392	0
702	A Case of Upper Gastrointestinal Bleeding Due to Metastatic High-Grade B-Cell Lymphoma Successfully Treated With Chemotherapy. <b>2022</b> ,	
701	Targeting MYC and BCL2 by a Natural Compound for "Double-Hit" Lymphoma.. <b>2022</b> ,	
700	Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies. <b>2022</b> , 12,	0
699	Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.. <b>2022</b> ,	
698	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.	
697	Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.. <b>2022</b> ,	
696	CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.. <b>2022</b> , 54, 637-648	0
695	A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.. <b>2022</b> , e15816	0
694	CAR T-cell Therapy in Highly-Aggressive B-Cell Lymphoma: Emerging Biological and Clinical Insights.. <i>Blood</i> , <b>2022</b> ,	2.2 1

- 693 Single-cell profiling-guided combination therapy of c-Fos and histone deacetylase inhibitors in diffuse large B-cell lymphoma.. **2022**, 12, e798 2
- 692 Lymphoma Nomenclature - What's in a name?. **2022**, 0
- 691 Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions. **2022**, 11, 2699 1
- 690 Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.. **2022**, 125, 105848 0
- 689 Clinical Features and Immunophenotypes of Double-Hit Diffuse Large B-Cell Lymphoma. **2022**, 12, 1106 0
- 688 Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study. **2022**, 103786
- 687 Dihydroorotate dehydrogenase inhibition acts synergistically with tyrosine kinase inhibitors to induce apoptosis of mantle cell lymphoma cells.
- 686 Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents: A Prospective Cohort Study of the AGMT Study-Group. **2022**, 14, 2459 2
- 685 B-Cell Lymphoma Producing IgM Anti-B Antibody: A Case Report. **2022**, 9, 0
- 684 Orbital manifestations of B-cell acute lymphoblastic leukemia/lymphoma.. **2022**, 1-5
- 683 Follicular dendritic cell sarcoma of the thigh: a clinicopathological report and management approach.. **2022**, 15,
- 682 Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinical Presentations.. **2022**,
- 681 TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study. 1-8 0
- 680 Enhancement of the International prognostic index with  $\beta_2$ -microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. **2022**, 22, 0
- 679 Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. **2022**, 14, 2532
- 678 Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma. **2022**, 13, 0
- 677 Primary mediastinal large B-cell lymphoma is characterized by large-scale copy-neutral loss of heterozygosity.
- 676 Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia.

- 675 Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. **2022**, 14, 2516 2
- 674 Immunoglobulin/T Cell Receptor Capture Strategy for Comprehensive Immunogenetics. **2022**, 133-152
- 673 Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas. **2022**, 119-132
- 672 Marked Response to Chemoimmunotherapy in a Patient with Follicular Lymphoma of Huge Mesenteric Lymphadenopathy. **2022**, 9, 77
- 671 CAR-T????B?????????????????. **2022**,
- 670 Diagnosis of Primary Hepatic Lymphoma in a 55-Year-Old Male Patient Presented With Pain in the Right Hypochondrium: A Very Rare Case. **2022**, 0
- 669 Spontaneous Regression of Plasmablastic Lymphoma in an Immunocompetent Patient: Case Report and Review of the Literature. **2022**, 2022, 1-6
- 668 Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma. 1
- 667 Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. **2022**, 11, 1812 1
- 666 A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). 0
- 665 Leukemic Presentation of Anaplastic Large Cell Lymphoma: A Diagnostic Challenge Mimicking T-Cell Prolymphocytic Leukemia. **2022**, 27, 119-122
- 664 CD8-positive indolent T-Cell lymphoproliferative disorder of the gastrointestinal tract: A case report and review of literature. **2022**, 10, 4971-4984 0
- 663 The EHA Research Roadmap: Malignant Lymphoid Diseases. **2022**, 6, e726 0
- 662 Overview of pediatric kidney transplantation. **2022**, 151194
- 661 2022 Practice Recommendation Updates from the World Consensus Conference on BIA-ALCL. 3
- 660 Tumor infiltrating lymphocytes predict survival in solid organ transplant recipients with monomorphic post-transplant lymphoproliferative disorders. **2022**, 0
- 659 Efficacy of brentuximab vedotin in patients with CD30-positive lymphoproliferative skin diseases: results of the first prospective study in the Russian Federation. **2022**, 98, 53-62
- 658 High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.

- 657 The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. *Blood*, 2.2 18
- 656 Plasma Metabolites Forecast Occurrence and Prognosis for Patients With Diffuse Large B-Cell Lymphoma. 12, 1
- 655 Pulmonary lymphomatoid granulomatosis in a 4-year-old girl: A case report. **2022**, 10, 5380-5386
- 654 HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib. 13, 1
- 653 The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas. **2022**, 14, 2799 0
- 652 A Multi-scale, Multiomic Atlas of Human Normal and Follicular Lymphoma Lymph Nodes. 1
- 651 Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. 12, 1
- 650 Primary Dural Mucosa-associated Lymphoid Tissue Lymphoma Mimicking Falx Meningioma: A Case Report. **2022**, 9, 123-128 1
- 649 Febrile neutropenia risk factors in actively treated diffuse large B-cell lymphoma patients. **2022**, 11, 7
- 648 COVID-19 and its impact on cancer, HIV, and mentally ill patients. **2022**, 95-137
- 647 Oral manifestation of lymphomatoid papulosis: systematic review. **2022**, 28, 30 0
- 646 Use of benzodiazepines is the risk factor for infection in patients aged 80 years or older with diffuse large B-cell lymphoma: A single-institution retrospective study. **2022**, 17, e0269362
- 645 In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
- 644 The use of diagnostic patterns for interventional cytopathology during rapid on-site evaluation and final classification. **2022**,
- 643 Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives. **2022**, 14, 3019 0
- 642 Development and Characterization of 3D Hybrid Spheroids for the Investigation of the Crosstalk Between B-Cell Non-Hodgkin Lymphomas and Mesenchymal Stromal Cells. Volume 15, 683-697 0
- 641 Hemophagocytic Syndrome-Associated Intravascular Large B-cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease Treated With Autologous Stem Cell Transplantation Using a Modified TEAM Regimen. **2022**,
- 640 Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis. **2022**, 29, 4245-4259



639	Genomic characterization of lymphomas in patients with inborn errors of immunity.	4
638	Utility of EpsteinBarr viral load in blood for diagnosis and predicting prognosis of lymphoma: A comparison with EpsteinBarr virusEncoded RNA in-situ hybridization. <b>2022</b> ,	1
637	Direct-Acting Antivirals as Primary Treatment for Hepatitis C VirusAssociated Indolent Non-Hodgkin Lymphomas: The BAiT Study of the Fondazione Italiana Linfomi.	0
636	C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma. <a href="#">jnumed.122.264207</a>	1
635	Follicular lymphoma presenting like marginal zone lymphoma: A case report. <b>2022</b> , 10, 5877-5883	
634	Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomized, phase 3 trial. <b>2022</b> , 300, e2291-2300	16
633	Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters. 12,	0
632	High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up. <b>2022</b> , 12,	
631	Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. <b>2022</b> , 10, e004984	2
630	Clinicopathological factors affecting prognosis in marginal zone lymphoma in Asian patients: a cohort study. 1-4	
629	Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas. <b>2022</b> , 12, 964	
628	Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease. 12,	0
627	Factors Associated with Discontinuation of Statin Therapy in Patients with Lymphoma Aged 80 Years and Older: A Retrospective Single-Institute Study.	
626	De-escalating Chemotherapy for Advanced Extranodal Natural Killer/T-Cell Lymphoma.	
625	Pralatrexate for Peripheral T-cell lymphoma (PTCL): Chance only supports the prepared mind. Systematic review. <b>2022</b> , 22,	0
624	ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment. <b>2022</b> , 14, 2939	1
623	Epidermotropic cutaneous T-cell lymphoma with follicular helper T-cell phenotype limited to one anatomical region.	
622	Unusually swift response of relapsed Burkitt leukemia to R-DHAP.	

- 621 Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. **2022**, 14, 2912 1
- 620 Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case Series. **2022**, 14, 2921
- 619 Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas. 0
- 618 Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma. **2022**, 15, e249631 0
- 617 Acute kidney injury due to direct infiltration by lymphoplasmacytic lymphoma secreting IgG paraproteins. **2022**, 101, e29449
- 616 B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.
- 615 Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes. 12,
- 614 Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. 1-14 0
- 613 Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL). **2022**, 14, 2899 1
- 612 Implants and Safety. **2022**, 21-37
- 611 Clinicopathological and Prognostic Analysis of 21 Children with Epstein-Barr Virus Positive T and NK-Cell Lymphoproliferative Disease. **2022**, 12, 6207-6214
- 610 Efficacy and Safety of Pola-BR Combination in Relapsed/Refractory Aggressive B-cell Non-Hodgkin's Lymphomas: A Russian Multi-Center Study. **2022**, 15, 232-239
- 609 Oncohematology. **2022**, 365-407
- 608 LBD: a manually curated database of experimentally validated lymphoma biomarkers. **2022**, 2022,
- 607 Lymphomes splhiques : diagnostic et prise en charge. **2022**,
- 606 IgM monoclonal gammopathies of clinical significance: diagnosis and management. 0
- 605 Personalized treatment of malignant tumors during pregnancy. **2022**, 101, e29803
- 604 Up-front therapy with CHOP plus etoposide in Brazilian nodal PTCL patients: increased toxicity and no survival benefit compared to CHOP regimen - results of a real-life study from a middle-income country. **2022**, 0

603	Patterns of utilization and outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 rearrangements. <b>2022,</b>		
602	Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion. <b>2022,</b> 14, 3126		1
601	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. <b>2022,</b> 14, 3229		0
600	International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. <i>Blood,</i>	2.2	50
599	R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. <b>2022,</b>		1
598	Mantle-Cell Lymphoma. <b>2022,</b> 386, 2495-2506		1
597	Multimodal Sonographic Appearance and Survival Outcomes of 69 Cases of Primary Thyroid Lymphoma Over 10 Years.		0
596	Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report. <b>2022,</b> 17,		
595	Discovery, Optimization, and Evaluation of Potent and Selective PI3K $\beta$ Dual Inhibitors for the Treatment of B-cell Malignancies.		
594	High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma. <b>2022,</b> 10,		1
593	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.		
592	Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. <b>2022,</b>		1
591	Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study. <b>2022,</b> 3, e481-e490		0
590	Functional genomics for curation of variants in telomere biology disorder associated genes, a systematic review.		
589	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. <b>2022,</b> 13,		1
588	Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. <b>2022,</b> 15,		0
587	Causes of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study.		
586	Formation of Lymphoma Hybrid Spheroids and Drug Testing in Real Time with the Use of Fluorescence Optical Tweezers. <b>2022,</b> 11, 2113		

585	Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. <b>2022</b> ,	4
584	The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.	0
583	Physical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint).	
582	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.	1
581	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma. 12,	0
580	Association of ATG16L1 rs2241880 and TP53 rs1042522 with characteristics and course of diffuse large B-cell lymphoma. <b>2022</b> , 154033	
579	Burkitt Lymphoma Incidence in Five Continents. <b>2022</b> , 3, 434-453	0
578	Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline. <b>2022</b> , 6, e746	
577	Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. <b>2022</b> , 23, 417-423	0
576	CC chemokine receptor 2 (CCR2) expression promotes diffuse large B-Cell lymphoma survival and invasion.	0
575	Epidemiological Characteristics of Peripheral T-Cell Lymphoma: A Population-Based Study. 12,	
574	Thymic Extranodal Marginal-Zone Lymphoma of Mucosa-Associated Lymphoid Tissue: Pathological Features, 18F-FDG PET/CT Findings and Prognosis in 12 Cases. 9,	
573	Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China. <b>2022</b> ,	0
572	Case Report: Pathogenesis With a Rare RHOA A161E Mutation in a Patient With Angioimmunoblastic T-Cell Lymphoma. 13,	0
571	Classifying Germinal Center Derived Lymphomas: Navigate a Complex Transcriptional Landscape. <b>2022</b> , 14, 3434	0
570	RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma. 13,	1
569	Primary cutaneous gamma delta T-cell lymphoma masquerading as leukemia cutis in a patient recently diagnosed with small lymphocytic lymphoma: clues to the diagnosis.	
568	Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience. 107815522211104	

567	Developing a Classification of Hematologic Neoplasms in the Era of Precision Medicine. <i>Blood</i> ,	2.2	○
566	Pediatric-Type Indolent B-Cell Lymphomas With Overlapping Clinical, Pathologic, and Genetic Features. Publish Ahead of Print,		○
565	9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions. <b>2022</b> , 46, 1017-1024		○
564	Breast lymphomas, breast implants and capsules The timeline of BIA-ALCL with respect to surgical consent: the UK perspective. <b>2022</b> ,		
563	Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.		
562	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> ,	2.2	○
561	Falsely positive HIV test due to Interference by heterophile antibodies in a patient with Mantle cell lymphoma treated with Rituximab. <b>2022</b> , 7, 100178		
560	Hematologic Malignancy: The Lymphomas. <b>2023</b> , 529-554		
559	Case Report: Immune Microenvironment and Mutation Features in a Patient With EpsteinBarr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma. 13,		○
558	Hairy Cell Leukemia.		
557	High-Throughput CRISPR Screening in Hematological Neoplasms. <b>2022</b> , 14, 3612		○
556	A Simple-to-Perform ifn- $\gamma$ mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation. 13,		
555	Evolution in the Definition of Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: A Model for the Future of Personalized Medicine. <b>2022</b> , 3, 466-474		○
554	Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. <b>2022</b> , 219,		1
553	Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. Volume 12, 81-98		○
552	Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study.		
551	Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT. 12,		○
550	Breast Plasmacytoma as Extra-Medullary Lesion of Multiple Myeloma: A Case Report. <b>2022</b> , 10, 232470962211117		

- 549 Refractory Primary Mediastinal B-Cell Lymphoma: A Case Report of Conventional Chemotherapies, Immune Checkpoint Inhibitors, Polatuzumab Vedotin, Transplantation, and Post-Transplant Large Granular Lymphocytosis.
- 548 Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma. **2022**, 14, 3716
- 547 Successful early diagnosis of monomorphic epitheliotropic intestinal T-cell lymphoma manifesting as chronic diarrhea and hypokalemia using video capsule endoscopy and double-balloon enteroscopy. ○
- 546 Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment. **2022**, 34, 413-421 ○
- 545 Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas. 1
- 544 EBV-associated NK and T-cell lymphoid neoplasms. **2022**, 34, 422-431 ○
- 543 Solitary Extramedullary Plasmacytoma of the Larynx and Secondary Laryngeal Involvement in Plasma Cell Myeloma: Single-Centre Retrospective Analysis and Systematic Literature Review. **2022**, 11, 4390 ○
- 542 Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement.
- 541 A phase 2, multicentre, open-label trial ( ACE-LY -003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. 1
- 540 EBV positive mucocutaneous ulcer (EBVMCU) in pediatric Crohn's disease - the Importance of pathology. Publish Ahead of Print, ○
- 539 Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment. ○
- 538 Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review. 1-15 1
- 537 Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study.
- 536 Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature. 28, ○
- 535 A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma. **2022**, 36, 2177-2179 ○
- 534 Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice. Volume 12, 107-117 ○
- 533 Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
- 532 Hodgkin Lymphoma and Hairy Cell Leukemia Arising from Chronic Lymphocytic Leukemia: Case Reports and Literature Review. **2022**, 11, 4674 1

- 531 Role of microRNAs in B-Cell Compartment: Development, Proliferation and Hematological Diseases. **2022**, 10, 2004 1
- 530 Detection of a monoclonal component after pediatric liver transplantation: a case report. **2022**, 1
- 529 A Novel Integrated Approach for Cytogenomic Evaluation of Plasma Cell Neoplasms. **2022**,
- 528 Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients. **2022**, 12,
- 527 Analysis of the Diagnosis of Burkitt-Like Lymphoma in a Patient With Atypical Cytogenetics and Molecular Markers. **2022**,
- 526 Characteristics and Outcomes of Alberta Lymphoma Patients with a History of Immunosuppressive therapy for Autoimmune Conditions. **2022**,
- 525 Identification of three small nucleolar RNAs ( snoRNAs ) as potential prognostic markers in diffuse large B-cell lymphoma.
- 524 Neues zu Pathogenese und molekularem Verständnis bei kutanen T-Zell-Lymphomen.
- 523 Management of Peripheral T-cell Lymphomas and the Role of Transplant. 0
- 522 Gastrointestinal symptoms and endoscopy findings after pediatric solid organ transplantation: A case series. 0
- 521 CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. **2022**, 10, 1960 1
- 520 PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma. **2022**, 42, 754-768
- 519 Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma. 0
- 518 Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. 13, 0
- 517 The Methylation of the p53 Targets the Genes MIR-203, MIR-129-2, MIR-34A and MIR-34B/C in the Tumor Tissue of Diffuse Large B-Cell Lymphoma. **2022**, 13, 1401 0
- 516 Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
- 515 Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
- 514 Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia.

- 513 Combined Immune Defect in B-Cell Lymphoproliferative Disorders Is Associated with Severe Infection and Cancer Progression. **2022**, 10, 2020 ○
- 512 HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. **2022**, 23, 666-681 ○
- 511 Subdural anaplastic large-cell lymphoma presenting as a subacute epidural hematoma on imaging: A case report. **2022**, 101, e30012
- 510 Whole transcriptome sequencing reveals a TCF4-ZNF384 fusion in acute lymphoblastic leukemia. **2022**, 12, 1-11 ○
- 509 Análisis de supervivencia en pacientes con micosis fungoide foliculotropa de un centro latinoamericano. **2022**, 10, 1-11 ○
- 508 Acquired von Willebrand syndrome and lymphoid neoplasms: A review of malignancy management, and propositions of practical recommendations. **2022**, 10, 1-11 ○
- 507 Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkin's Lymphoma in Children. **2022**, 9, 1279
- 506 Primary Colorectal Diffuse Large B-cell Lymphoma: a Report of Eighteen Cases in a Tertiary Care Center. **2022**, 10, 1-11 ○
- 505 Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. **2022**, 10, 1-11 ○
- 504 The Clinical Impact of Precisely Defining Mantle Cell Lymphoma: Contributions of Elaine Jaffe. **2022**, 3, 508-517
- 503 Intraparenchymal Mucosa-Associated Lymphoid Tissue Lymphoma: A Case Report. **2022**, 10, 1-11 ○
- 502 Myeloid/Lymphoid Neoplasms with Platelet Derived Growth Factor Receptor Alpha (PDGFRA) Rearrangement. **2022**, 10, 1-11 ○
- 501 Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study. **2022**, 10, 1-11 ○
- 500 TCF3-HLF-Positive Acute Lymphoblastic Leukemia Resembling Burkitt Leukemia: Cell Morphologic and Immunophenotypic Findings. **2022**, 10, 1-11 ○
- 499 The burden and trends of multiple myeloma worldwide from 1990 to 2019. **2022**, 10, 1-11 ○
- 498 Case 26-2022: A 48-Year-Old Woman with Cystic Lung Disease. **2022**, 387, 738-747
- 497 Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice. **2022**, 626, 51-57
- 496 Treatment strategies for patients with diffuse large B-cell lymphoma. **2022**, 110, 102443 1



- 495 Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group. **2022**, 268-269, 1-21
- 494 Leukemias, Lymphomas, and Plasma Cell Disorders. **2023**, 237-300
- 493 Follicular lymphoma: 2023 update on diagnosis and management. 1
- 492 Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk. 0
- 491 FOXP3+/CD68+ ratio within the tumor microenvironment may serve as a potential prognostic factor in classical Hodgkin lymphoma. **2022**, 0
- 490 The Clonal Diversity of Peripheral B Cell Receptor Immune Repertoire Impaired by Residual Malignant B Cells Predicts Treatment Efficacy in B Cell Lymphoma Patients. **2022**, 14, 4628 0
- 489 Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. 1-11 0
- 488 Complications in lymph node excision in the head and neck area. 1-5 0
- 487 Primary diffuse large B-cell lymphoma of orbit: A population-based analysis. 9, 0
- 486 Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. 0
- 485 A rare case of post-transplant lymphoproliferative disorder (Hodgkins lymphoma) post autologous stem cell transplantation: A case report and review of literature. **2022**, 82, 104738 0
- 484 Primary diffuse large B-Cell lymphoma of the uterine cervix with severe lower urinary tract Symptoms: A rare case report and review of the literature. **2022**, 43, 101066 0
- 483 EXABS-111-NHL Challenging Cases in Rare T-Cell Lymphomas. **2022**, 22, S10-S11 0
- 482 Multiple disciplinary team management of rare primary splenic malignancy: Two case reports. 10, 10535-10542 0
- 481 18F-FDG PET/CT prognostic role in predicting response to salvage therapy in relapsed/refractory Hodgkin's lymphoma. **2022**, 92, 25-31 0
- 480 Molecular Pathogenesis of Hodgkin's Lymphoma: Advances Through the Key Player LMP1 and 3D Nanotechnology. **2022**, 0
- 479 Chronic lymphocytic leukemia: Current approach to lab diagnosis. **2022**, 5, 39 0
- 478 A rare case of mantle cell lymphoma of nasopharynx and larynx with synchronous presentation treated with volumetric modulated arc technique radiotherapy. **2022**, 0 0

- 477 The role of B cells in the development, progression, and treatment of lymphomas and solid tumors. **2022**, 71-117 ○
- 476 Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification. **2022**, 62, 127-135 1
- 475 Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study. **2022**, 18, 704 ○
- 474 Widespread myeloid sarcoma with KMT2A rearrangement involving the testis, oral cavity, heart, kidney and gallbladder without bone marrow involvement. **2022**, 18, 100349 ○
- 473 Diagnostic Applications of Nuclear Medicine: Pediatric Cancers. **2022**, 1271-1307 ○
- 472 Role of interleukin-10 (1082G/A) and splicing factor 3B subunit 1 (2098A/G) gene polymorphisms in chronic lymphocytic leukemia. **2022**, 13, 76 ○
- 471 Hodgkin-Lymphome und Non-Hodgkin-Lymphome. **2022**, 860-885 ○
- 470 Genetic and immunophenotypic diversity of acute leukemias in children. **2022**, 76, 369-379 ○
- 469 Renal Transplantation: Infectious Complications. **2022**, 1973-1988 ○
- 468 Experience with the Use of B-RAF Inhibitor Vemurafenib in the Treatment of Hairy Cell Leukemia. **2022**, 15, 349-355 ○
- 467 Successful treatment with tirabrutinib for relapsed Bing-Neel syndrome following high-dose methotrexate and craniospinal irradiation. **2022**, 62, 181-186 ○
- 466 Diagnostic Applications of Nuclear Medicine: Leukemias. **2022**, 529-567 ○
- 465 Epstein-Barr Virus Upper Gastrointestinal Tract Mucocutaneous Ulceration in a Renal Transplant Recipient with Leucopenia and Hypogammaglobulinaemia. **2022**, 11, 355-359 ○
- 464 Case Report: Rare Systemic and Aggressive ALK-Positive Histiocytosis With Recurrent Pancreatitis Treating by Alectinib. 9, ○
- 463 Physical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint). ○
- 462 A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma. ○
- 461 PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma. **2022**, 21, ○
- 460 Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy. 13, 1

- 459 Clinical and Cytogenetic Characteristics of Children With Leukemia 20-Year Retrospective Study. Publish Ahead of Print, ○
- 458 Digital system augmented by artificial intelligence to interpret bone marrow samples for hematological disease diagnosis. ○
- 457 Recurrent primary cutaneous anaplastic large cell lymphoma in young female patient from Ethiopia: A Case Report. **2022**, 7, 019-022 ○
- 456 A new approach to the study of Hodgkin lymphoma by flow cytometry. **2022**, ○
- 455 Differential diagnosis of non-diffuse primary thyroid lymphoma and papillary thyroid carcinoma by ultrasound combined with computed tomography. **2022**, 22, ○
- 454 Clinical Application of Biomarkers for Hematologic Malignancies. **2022**, 150-212 ○
- 453 Response to the WHO classification of haematolymphoid tumours (Editorial). ○
- 452 An Update on Viral Induced Cutaneous Lymphoproliferative Disorders. A Review from the Ibero-American Society of Dermatopathology (SILADEPA). CME Part I. **2022**, ○
- 451 TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients. **2022**, 1-13 ○
- 450 Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma. ○
- 449 Emerging Therapies for the Management of Richter Transformation. ○
- 448 Plasmablastic lymphoma: An update. **2022**, 44, 54-63 ○
- 447 Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder. 13, ○
- 446 Hämatologische Labordiagnostik 2022. **2022**, 20, 172-176 ○
- 445 Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: A case report and literature review. ○
- 444 Multimodality imaging findings of infection-induced tumors. ○
- 443 Case report: Common clonal origin of concurrent langerhans cell histiocytosis and acute myeloid leukemia. 12, ○
- 442 Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China. ○

- 441 An unusual case of hepatosplenic T-cell lymphoma-like unclassifiable T/NK-cell lymphoma accompanied by acute myeloid leukemia. ○
- 440 Sex differences in lymphoma incidence and mortality by subtype: a population-based study. ○
- 439 Circulating tumor DNA in Hodgkin lymphoma. **2022**, 101, 2393-2403 ○
- 438 High Plasma EBV-DNA Load and Positive EBER Status Associated with Viral Recurrence and Persistent Infection in Early Treatment of Lymphoma. ○
- 437 Deep morphology learning enhances ex vivo drug profiling-based precision medicine. 1
- 436 Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. **2022**, 23, 11145 ○
- 435 Clinical features of type 1 and 2 refractory celiac disease: Results from a large cohort over a decade. **2022**, 1
- 434 Extra copy number of BCL2 is correlated with increased BCL-2 protein expression and poor survival in diffuse large B-cell lymphoma treated with chemoimmunotherapy. 1-10 ○
- 433 A novel predictive model for distinguishing mediastinal lymphomas from thymic epithelial tumors. ○
- 432 Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording. ○
- 431 DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis. **2022**, 101, e30620 ○
- 430 Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition). ○
- 429 The burden and trends of multiple myeloma worldwide from 1990 to 2019. ○
- 428 Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. 13, ○
- 427 Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study. ○
- 426 Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice. Volume 15, 1899-1907 ○
- 425 The first case of peripheral T cell lymphoma with a CSF3R variant resulted in relapsing febrile neutropenia and aplastic anemia. ○
- 424 Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients. **2022**, 14, 4485 ○

423	Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a Prospective Case-Control Analysis. <b>2022</b> , 12, 1536	1
422	Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis. <b>2022</b> , 2022, 1-12	0
421	Periampullary Nodularity in an Asymptomatic Patient. <b>2022</b> ,	0
420	Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. <b>2022</b> , 41, 4560-4572	1
419	A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signaling. 12,	0
418	Comment on Kieslinger et al. A Recurrent STAT5BN642H Driver Mutation in Feline Alimentary T Cell Lymphoma. <i>Cancers</i> 2021, 13, 5238. <b>2022</b> , 14, 4593	0
417	High plasma EBV-DNA load and positive EBER status associated with viral recurrence and persistent infection in early treatment of lymphoma.	0
416	EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma. <b>2022</b> , 2022, 1-16	0
415	A Systematic Review of Outcomes Following Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). <b>2022</b> ,	2
414	Cytomegalovirus infection may be oncoprotective against neoplasms of B-lymphocyte lineage: single-institution experience and survey of global evidence. <b>2022</b> , 19,	0
413	The diagnosis and management of suspected lymphoma in general practice.	0
412	Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemia. 1-4	0
411	Diagnostics in Waldenström Macroglobulinemia: a consensus statement of the European Consortium for Waldenström Macroglobulinemia.	0
410	EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. <b>2022</b> , 22,	0
409	Nasal Lymphoma with Low Mitotic Index in Three Cats Treated with Chlorambucil and Prednisolone. <b>2022</b> , 9, 472	1
408	Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies. <b>2022</b> , 23, 1443-1456	0
407	Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma. <b>2022</b> ,	0
406	A Case of Angioimmunoblastic T-cell Lymphoma (AITL). <b>2022</b> , 44, 293-299	0

405	CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma. 12,	0
404	Ocular adnexal lymphoma: Subtype-specific clinical and genetic features. <b>2022</b> , 100, 3-37	0
403	Hematologic Malignancies Patients Face High Symptom Burden and Are Lately Referred to Palliative Consultation: Analysis of a Single Center Experience. 104990912211322	0
402	Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.	0
401	BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. <b>2022</b> , 15,	1
400	Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.	0
399	Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing.	1
398	Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing.	0
397	Diffuse Large B-Cell Epstein-Barr Virus-Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics.	0
396	The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship.	0
395	Prognostic impact of the controlling nutritional status score in patients with hematologic malignancies: A systematic review and meta-analysis. 13,	0
394	Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma. 12,	1
393	Tumor-associated macrophages in lymphoma: From mechanisms to therapy. <b>2022</b> , 112, 109235	0
392	Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. <b>2022</b> , 54, 101674	2
391	II. The Update of the Classification of Malignant Lymphomas. <b>2021</b> , 110, 1392-1403	0
390	VIII. Immunodeficiency and Malignant Lymphoma. <b>2021</b> , 110, 1441-1446	0
389	Grey zone lymphoma - diagnostic and therapeutic challenge. <b>2022</b> , 75, 101-105	0
388	Marrow Replacement Disorders. <b>2022</b> , 227-236	0

- 387 Double expressor Diffuse large B-cell lymphoma: A case report and literature review. **2022**, 75, 106-110 ○
- 386 High-grade B-cell lymphoma. **2022**, 75, 88-95 ○
- 385 Current principles of follicular lymphoma treatment. **2022**, 75, 62-65 ○
- 384 Non-Hodgkin's Lymphoma. 1-20 ○
- 383 Hematopoietic Cell Transplantation. 1-13 ○
- 382 New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. 1
- 381 Interim results of the PML-16, PML-19 protocols for primary mediastinal large B-cell lymphoma therapy. **2022**, 67, 328-350 ○
- 380 Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. ○
- 379 Lymphoplasmacytic Lymphoma with IgG or IgA Paraprotein: A Study of 29 Cases including Cases that Can Mimic Plasma Cell Neoplasms. **2022**, ○
- 378 Mantle cell lymphoma in human immunodeficiency virus -infected patients. ○
- 377 Clinical Features, Phenotypic Markers and Outcomes of Diffuse Large B-Cell Lymphoma between HIV-Infected and HIV-Uninfected Chinese Patients. **2022**, 14, 5380 ○
- 376 Optimizing Palliative Focal Radiation Therapy Dose in Cutaneous T-Cell Lymphoma: How Low Can You Go?. **2022**, ○
- 375 Examining potential mechanisms of testicular fibrosis in Klinefelter Syndrome: A review of current understanding. 1
- 374 Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells. **2022**, 22, ○
- 373 First-Line Treatment of Waldenström Macroglobulinaemia: Considerations Based on the Dutch National Guideline. **2022**, 3, 704-717 ○
- 372 The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. 12, ○
- 371 Postibrutinib relapse outcomes for patients with marginal zone lymphoma. ○
- 370 Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment. 13, ○

- 369 Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?. **2022**, 3, 689-703 ○
- 368 Plasmacytic Pleural Effusion as a Major Presentation of Angioimmunoblastic T-Cell Lymphoma: A Case Report. **2022**, 29, 7637-7644 ○
- 367 Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia. ○
- 366 Thymic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: A case report and literature review. **2022**, ○
- 365 Análisis de supervivencia en pacientes con micosis fungoide foliculotropa de un centro latinoamericano. **2022**, ○
- 364 Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era. ○
- 363 Radiological Features of Bone Lymphoma on CT and MRI. A Retrospective Monocentric Series of 56 Patients. **2022**, ○
- 362 The inflammasomes: crosstalk between innate immunity and hematology. ○
- 361 Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis. ○
- 360 Biological and clinical significance of epigenetic alterations in B-cell lymphomas. ○
- 359 Indolent T-Cell Lymphoproliferative Disease: A Rare Case of a Benign Lymphoma of the Gastrointestinal Tract With Extra-Gastrointestinal Involvement. **2022**, 9, e00879 ○
- 358 Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. ○
- 357 Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD. 12, ○
- 356 Current Understanding of Breast Implant-Associated Anaplastic Large Cell Lymphoma. **2022**, ○
- 355 Activation induced cytidine deaminase: An old friend with new faces. 13, 3
- 354 Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. 1-7 ○
- 353 Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities. ○
- 352 Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. 115-122 ○



351	BIA [ALCL - Horizon Scanning. <b>2022,</b>	o
350	Maladie de Waldenström : actualité et perspectives en 2022. <b>2022,</b>	o
349	5-Hydroxymethylation alterations in cell-free DNA reflect molecular distinctions of diffuse large B cell lymphoma at different primary sites. <b>2022, 14,</b>	o
348	Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma. <b>2022, 14, 4893</b>	o
347	A prospective analysis of red blood cell membrane polyunsaturated fatty acid levels and risk of non-Hodgkin lymphoma. 1-11	o
346	Impact of EpsteinBarr virus infection in patients with inflammatory bowel disease. 13,	o
345	Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.	o
344	The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy. <b>2022, 15,</b>	o
343	Genetics of Transformed Follicular Lymphoma. <b>2022, 3, 615-633</b>	o
342	Autophagy in Hematological Malignancies. <b>2022, 14, 5072</b>	1
341	Minimum Information for Reporting a Genomics Experiment.	o
340	Dominant susceptibility-weighted imaging features of intravascular large B-cell lymphoma with central nervous system involvement.	o
339	Chronic Lymphocytic Leukemia. 1-11	o
338	Treatment of relapsed and refractory Waldenstrom Macroglobulinemia. 1-12	o
337	Prognostic Impact of Systemic Therapy and Radiation Therapy in Stage I Nodal Marginal Zone Lymphoma. <b>2022,</b>	o
336	Primary hepatic interdigitating dendritic cell sarcoma: A case report. <b>2022,</b>	o
335	Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.	o
334	The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?. <b>2022, 17,</b>	o

- 333 Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels. **2022**, 14, 5318 1
- 332 Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma. 0
- 331 Gastric CD56-negative Extranodal Natural Killer/T-cell Lymphoma: A Case Report. **2022**, 80, 190-194 0
- 330 B-Lymphoid Blast Phase Chronic Myeloid Leukemia: Current Therapeutics. **2022**, 23, 11836 0
- 329 Subtype distribution of lymphomas in northwestern Iran: a retrospective analysis of 659 cases according to World Health Organization classification. **2022**, 22, 0
- 328 Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino Amfca (GELL)]. **2022**, 27, 1208-1216 0
- 327 Aggressive Lymphome (DLBCL, MCL) Was ist neu?. **2022**, 147, 1449-1456 0
- 326 Outcomes of coronavirus disease 2019 ( COVID -19) and risk factors associated with severe COVID -19 in patients with mature B-cell non-Hodgkin lymphomas: a US electronic health record cohort study. 0
- 325 Challenges in Differentiating Chronic Enteropathy from Low-Grade Gastrointestinal T-cell Lymphoma in Cats. **2022**, 3, 121-131 0
- 324 Molecular Advances in Nodal Peripheral T-Cell Lymphoma. **2022**, 5, 51-58 0
- 323 Incorporation of ultrasound-guided core biopsy with flow cytometry to assist the diagnosis of cervical lymphoma. 0
- 322 Extracellular Vesicles in Diffuse Large B Cell Lymphoma: Characterization and Diagnostic Potential. **2022**, 23, 13327 0
- 321 A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. 1-12 0
- 320 Extramedullary T-lymphoblastic blast crisis in chronic myeloid leukemia: A very rare case associated with comutation of ABL1 T315I and H396R. 0
- 319 The value of ultrasound-guided fine needle aspiration in the diagnosis of diffuse large B-cell lymphoma: A single center experiment. **2022**, 157, 110567 0
- 318 Development of a new risk scoring system based on spleen involvement and the lymphocyte/monocyte ratio for follicular lymphoma patients. **2022**, 123, 106980 0
- 317 Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. **2022**, 113, 109299 0
- 316 Identification of prognostic factors in classic Hodgkin lymphoma by integrating whole slide imaging and next generation sequencing. 0

- 315 Utility of reverse transcriptase Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO). **2022**, 0 ○
- 314 Characteristic endoscopic findings of gastrointestinal malignant lymphomas other than mucosa-associated lymphoid tissue lymphoma. **2022**, 85, 477-483 ○
- 313 Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies. **2022**, 35, 779-786 ○
- 312 Analytical study of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1p210, and KMT2-MLLT3 in Mexican children with acute myeloid leukemia: A multicenter study of the Mexican interinstitutional group for the identification of the causes of childhood leukemia (MIGICCL). 10, ○
- 311 Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis. 12, ○
- 310 Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma. **2022**, 11, 6574 ○
- 309 Diagnosis of acute myelomonocytic leukemia in a patient with extramedullary testicular lesion. **2022**, 17, 81-87 ○
- 308 Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL). ○
- 307 Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review. **2022**, 10, 2917 ○
- 306 Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. ○
- 305 Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies. ○
- 304 Bruton tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review. 12, ○
- 303 Das wachsende Interesse an Breast Implant Illness und dessen Einfluss auf das Verhalten der Patientinnen. ○
- 302 Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes. Volume 13, 663-671 ○
- 301 Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma. **2022**, 14, 5601 1
- 300 The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia. ○
- 299 Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database. 13, ○
- 298 Surgical management of monomorphic epitheliotropic intestinal T-cell lymphoma followed by chemotherapy and stem-cell transplant: A case report and review of the literature. 14, 2273-2287 ○

- 297 Evaluation of Diagnostic Efficacy of NRP-1/CD304 in Hematological Diseases. ○
- 296 Evaluation of Breast Implant-associated Anaplastic Large Cell Lymphoma With Whole Exome and Genome Sequencing. ○
- 295 mTOR inhibition amplifies the anti-lymphoma effect of PI3K/IL-2 blockage in diffuse large B-cell lymphoma. ○
- 294 Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma. 12, ○
- 293 Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. ○
- 292 58/m mit schmerzloser Lymphknotenschwellung, Nachtschweiß und Fieber. ○
- 291 Cyclin D1 expression, cell proliferation and clonal persistence characterize primary cutaneous CD4 + small or medium T-cell lymphoproliferative disorder. ○
- 290 Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance. 12, ○
- 289 Triple Expressor Lymphoma: Presentation With Acute Paraparesis Due to Spinal Cord Compression. 2022, ○
- 288 Types of T-cell lymphoma-a cytogenetic perspective. 2022, 84, 104844 ○
- 287 Utility of Fluorescence In Situ Hybridization in Clinical and Research Applications. 2022, 42, 573-586 ○
- 286 Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma. ○
- 285 Molecular and clinical diversity in primary central nervous system lymphoma. 2022, ○
- 284 Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients. 2022, 2022, 1-11 ○
- 283 Integrated single cell analysis reveals co-evolution of malignant B cells and the tumor microenvironment in transformed follicular lymphoma. ○
- 282 A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. ○
- 281 Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. ○
- 280 Study of the Effect of Different Breast Implant Surfaces on Capsule Formation and Host Inflammatory Response in an Animal Model. ○

- 279 Rituximab Monotherapy for Grade 2-3 Lymphomatoid Granulomatosis with Central Nervous System Involvement in a Patient Receiving Methotrexate for Rheumatoid Arthritis. **2023,** ○
- 278 The Need for Greater Reporting of Medical Device Incidents. 56-63 1
- 277 Modern aspects of the diagnosis and treatment of primary central nervous system lymphomas. **2022,** 11, 49 ○
- 276 Central Nervous System Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation. **2022,** 313-318 ○
- 275 CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. **2022,** 13, 204062072211421 ○
- 274 An update on molecular features and therapeutic perspectives of pediatric classical Hodgkin Lymphoma. What the clinician needs to know?. **2023,** 66, 104672 ○
- 273 Shifting Treatment Paradigms in Non-Hodgkin Lymphomas. 35-43 ○
- 272 Double-Hit and Triple-Hit Lymphomas: New Perspectives for Their Classification. 95-103 ○
- 271 Intraocular Lymphoma. **2022,** ○
- 270 Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase. **2022,** 16, 117955492211393 1
- 269 Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?. 109-119 ○
- 268 Hematopoietic and Lymphoid Tumors. **2021,** 377-521 ○
- 267 EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Szary syndrome: Real-world data in Spanish patients (MICADOS Study). **2022,** 1, 438-449 ○
- 266 Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. ○
- 265 BIA-ALCL Epidemiological Findings From a Retrospective Study of 248 Cases Extracted from Relevant Case Reports and Series: A Systematic Review. ○
- 264 Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study. **2022,** 6, e803 ○
- 263 Interim FDG18-PET SUVmax Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma. **2022,** ○
- 262 Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program. 1-7 ○

- 261 Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2022**, 11, 6983 ○
- 260 Feasibility of oral doxycycline as first-line therapy for conjunctival mucosa-associated lymphoid tissue lymphoma. ○
- 259 Post-Transplant Lymphoproliferative Disorder: A Rare Case of CNS Involvement following Renal Transplant. **2022**, 11, 7058 ○
- 258 Diagnostics in Waldenström macroglobulinemia: a consensus statement of the European Consortium for Waldenström Macroglobulinemia. ○
- 257 Bing-Neel Syndrome: Update on Diagnosis and Treatment. **2022**, 3, 758-770 ○
- 256 Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma. 10, ○
- 255 Plasma cell neoplasms and related entities—evolution in diagnosis and classification. ○
- 254 Primary gastric Burkitt lymphoma mimicking gastric cancer: a case report. ○
- 253 A series of heterogeneous lymphoproliferative diseases with CD3 and MUM1 co-expressed in cats and dogs. **2023**, 35, 22-33 ○
- 252 High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project. **2022**, 12, ○
- 251 DQA1\*0102 DQB1\*0602 haplotype distinguishes coeliac disease and its complications from gluten unrelated enteropathies. **2023**, 35, 64-72 ○
- 250 PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies. **2022**, 14, 5941 1
- 249 Registro de linfomas cutáneos primarios (RELCP) de la AEDV: datos tras 5 años de funcionamiento. **2022**, ○
- 248 Effect of miR-27b on the proliferation and apoptosis of diffuse large b-cell lymphoma cells by targeting the regulation of MET/PI3K/AKT pathway. **2022**, 13, ○
- 247 Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter Syndrome. **2022**, 14, 6035 ○
- 246 Enhancing diagnosis of T-cell lymphoma using non-recombined T-cell receptor sequences. 12, ○
- 245 T-cell acute lymphoid leukemia after BMT of AML: Case report. **2022**, ○
- 244 Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. Volume 15, 1481-1501 ○

- 243 The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis. 12, ○
- 242 Post-transplant lymphoproliferative disease after pediatric kidney transplant. 10, ○
- 241 Nicotinamide N -methyltransferase (NNMT): A potential biomarker for differential diagnosis of anaplastic large cell lymphoma (ALCL). ○
- 240 Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder. **2022**, 14, 5949 ○
- 239 Recurrent Mantle Cell Lymphoma Isolated to the Testis After 19-Year Remission: A Case Report and Review of the Literature. **2022**, ○
- 238 Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options. **2022**, 11, 7542 1
- 237 SLP76 Mutation Associated with Combined Immunodeficiency and EBV-Related Lymphoma. ○
- 236 Single-cell profiling identifies clinically relevant interactions between tumor associated macrophages and blood endothelial cells in diffuse large B cell lymphoma. ○
- 235 Lymphomatoid Granulomatosis Presents With Nodal and Bone Marrow Invasion: A Case Report and Literature Review. **2022**, 1, ○
- 234 Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study). ○
- 233 Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children’s Oncology Group Trial ANHL12P1. ○
- 232 Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas. **2022**, 14, ○
- 231 Age- and Sex-Matched Normal Leukocyte Subset Ranges in the General Population Defined with the EuroFlow Lymphocyte Screening Tube (LST) for Monoclonal B-Cell Lymphocytosis (MBL) vs. Non-MBL Subjects. **2023**, 15, 58 ○
- 230 High-dose chemotherapy and autologous stem cell transplantation in primary lymphomatoid granulomatosis of the central nervous system. ○
- 229 Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström Macroglobulinemia. ○
- 228 Pediatric-type follicular lymphoma: a short review. **2022**, 11, ○
- 227 Subcutaneous panniculitis-like T-cell lymphoma: an unusual cause of right thigh hypertrophy. **2022**, 15, e253469 ○
- 226 Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma. **2022**, 27, 1272-1281 ○

225	The current state of knowledge about evolution of multiple myeloma to plasma cell leukemia. <b>2022</b>	0
224	Management of marginal zone lymphomas. <b>2022</b> , 2022, 676-687	0
223	High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma. 13,	0
222	Anti-myelocytomatosis tag antibody detects myelocytomatosis oncogene expression in Burkitt lymphoma. 6,	0
221	An integrative bioinformatics investigation and experimental validation of Chromobox family in Diffuse large B-cell lymphoma.	0
220	Molecular Characterisation of EpsteinBarr Virus in Classical Hodgkin Lymphoma. <b>2022</b> , 23, 15635	0
219	A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.	2
218	EBV Association with Lymphomas and Carcinomas in the Oral Compartment. <b>2022</b> , 14, 2700	0
217	Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell lymphoma/leukemia.	0
216	Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL. <b>2022</b> , 66, 332-341	1
215	Une transformation, mais laquelle?. <b>2022</b> , 2022, 77-78	0
214	Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. <b>2022</b> , 101, e32333	0
213	Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-CellEngaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.	2
212	Functional genomics for curation of variants in telomere biology disorder associated genes, a systematic review.. <b>2022</b> ,	0
211	EpsteinBarr Viral Load Monitoring Strategy and the Risk for Posttransplant Lymphoproliferative Disease in Adult Liver Transplantation.	0
210	Early orbital involvement in a rare diagnosis of Burkitt-like lymphoma with 11q aberration. 1-3	0
209	Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.	0
208	Comprehensive analysis of clinicalf eatures, treatment options, overall survival, and prognostic factors in lymphoma cell leukemia patients: A retrospective study. <b>2022</b> , 18, 1961	0



- 207 Genetic Profiling in Diffuse Large B-Cell Lymphoma: The Promise and the Challenge. **2023**, 36, 100007 ○
- 206 Extranodal Location of Lymphoma: Presentation and Evolutionary in Senegalese Patients. **2023**, 13, 1-10 ○
- 205 Prognostic significance of absolute monocyte count and lymphocyte to monocyte ratio in mucosa-associated lymphoid tissue (MALT) lymphoma. ○
- 204 Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404). ○
- 203 Successful Treatment of Large B-Cell Lymphoma in a Child with Compound Heterozygous Mutation in the ATM Gene. **2023**, 24, 1099 ○
- 202 Age-period-cohort analysis of gender differential trends in incidence and mortality of non-Hodgkin lymphoma in China, 1990-2019. 12, ○
- 201 Role of Notch2 pathway in mature B cell malignancies. 12, ○
- 200 Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis. 13, ○
- 199 Análise dos Critérios Imunofenotípicos por Citometria de Fluxo para Definição das Doenças Linfoproliferativas Crônicas de Células B. **2022**, 69, ○
- 198 Hematologic imaging. **2023**, 225-244 ○
- 197 Intravascular Large B-Cell Lymphoma: Two Cases Observed at a Single Institution. **2023**, 3, 50-58 ○
- 196 RNA Extraction Method Impacts Quality Metrics and Sequencing Results in Formalin-Fixed, Paraffin-Embedded Tissue Samples. **2023**, 100027 ○
- 195 Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. **2023**, 98, 300-308 ○
- 194 Diagnosis and management of rare paediatric Non-Hodgkin lymphoma. **2023**, 101440 ○
- 193 Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2/BCL6 Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma. **2023**, 100043 ○
- 192 Different situations of identifying second primary malignant tumors in lymphoma patients with synchronous solid tumors. ○
- 191 Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study. ○
- 190 Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review. 13, ○

- 189 Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma. 12, ○
- 188 Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. ○
- 187 Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health-Foundation Medicine Clinico-Genomic Databases, Flatiron Health Research Databases, and the National Cancer Institute SEER Population-Based Cancer Registry. ○
- 186 Artificial Intelligence-Assisted Diagnosis of Hematologic Diseases Based on Bone Marrow Smears Using Deep Neural Networks. **2023**, 107343 ○
- 185 Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies. **2023**, 113, 102510 ○
- 184 Overlapping Features of Primary Cutaneous Marginal Zone Lymphoproliferative Disorder and Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder. Publish Ahead of Print, ○
- 183 Acute Promyelocytic Leukemia with Rare Genetic Aberrations: A Report of Three Cases. **2023**, 14, 46 ○
- 182 Histiocytic Sarcoma Secondary to Gastrointestinal Stromal Tumors: A Literature Review. **2022**, ○
- 181 Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cells. ○
- 180 Intravascular large B-cell lymphoma with isolated bone marrow involvement. **2022**, 67, 579-585 ○
- 179 Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. **2022**, 11, ○
- 178 Oncogenic viruses and mechanism of oncogenesis: study of oncogenic characteristics of HTLV-1 and HHV-8 viruses. **2023**, 227-242 ○
- 177 The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review. 12, ○
- 176 Successful Diagnosis by Video-Assisted Thoracoscopic Surgical Lung Biopsy in a Case of Progressive Primary Pulmonary Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Case Report. **2023**, ○
- 175 Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. **2023**, 102, 393-402 ○
- 174 High risk of infection in Real-world patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma. ○
- 173 Isolated bone marrow gamma-delta T-Cell lymphoma: Another challenge to the WHO lymphoid neoplasm classification. **2023**, 19, 100363 ○
- 172 Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma. 14, ○

- 171 Tonsillectomy Outcomes in Children After Solid-Organ Transplantation: A 15-Year Single-Center Experience. ○
- 170 The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis. 12, ○
- 169 Evolution of viruses: tumor complications. **2023**, 197-222 ○
- 168 Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study. **2023**, 15, 750 ○
- 167 Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study. **2023**, 7, e833 ○
- 166 The Rory Morrison WMUK Registry for Waldenström macroglobulinaemia: The growth of a national registry for a rare disorder. ○
- 165 Primary Effusion Lymphoma: A Rare and Challenging Diagnosis for Recurrent Pleural Effusion. **2023**, 13, 370 ○
- 164 NK/T-cell Lymphoma With Orbital Involvement: A Case Report and Systematic Review of the Literature. Publish Ahead of Print, ○
- 163 Blastoid B-Cell Neoplasms: Diagnostic Challenges and Solutions. **2023**, 15, 848 ○
- 162 Case report: Oral ulceration of buccal mucosa. ○
- 161 Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies. ○
- 160 Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. **2023**, 2023, 1-17 ○
- 159 Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources. **2023**, 2023, 1-16 ○
- 158 Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients. **2023**, 15, 976 ○
- 157 Morphological abnormalities of erythrocytes and platelets [selected issues]. **2022**, 57, 204-212 ○
- 156 Identification of MYC/BCL2 Double-expressers Lymphomas in Diffuse Large B Cell Lymphoma Patients and Association with their Prognostic Parameters and Survival Rates: A Single Centre Experience. **2022**, 18, 87-92 ○
- 155 Retrochiasmatic Optic Pathway. **2023**, 309-332 ○
- 154 Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit. **2023**, 49, 291-301 ○

- 153 Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. **2023**, 11, e006113 ○
- 152 Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques. **2023**, 15, 1931 ○
- 151 Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi. 13, ○
- 150 Intestinal Microbes and Hematological Malignancies. **2023**, 15, 2284 ○
- 149 Anaplastic Large-Cell Lymphoma (ALCL) First Manifested as a Rapidly Progressive Acute Respiratory Failure (RF): Lymph Node Biopsy Negative Presentation Posing a Diagnostic Challenge. **2023**, ○
- 148 Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England. **2023**, 183, 162-170 ○
- 147 The role of splenectomy in management of splenic B-cell lymphomas. **2023**, 128, 107053 ○
- 146 Survey of genomic and physiological characteristics for survival in lymphoma: The NCI genomic data portal. **2023**, 47, 100955 ○
- 145 IDO1 Protein Is Expressed in Diagnostic Biopsies from Both Follicular and Transformed Follicular Patients. **2023**, 24, 7314 ○
- 144 Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment. **2023**, 7, e863 ○
- 143 A Review on the Role of Molecular Genetics in the Diagnostic Workup of BCR::ABL1-Negative Myeloproliferative Neoplasms. ○
- 142 Clinicopathological and molecular genetic characteristics of primary gastric follicular lymphoma?,?,???. **2023**, ○
- 141 IONIZING RADIATION AND CYTOKINES: THE ROLE IN THE PATHOGENESIS OF PLASMA CELL MYELOMA (LITERATURE REVIEW). **2022**, 27, 120-130 ○
- 140 Recent Developments in the Management of Orbital and Periocular Neoplasms. **2022**, 311-325 ○
- 139 Gastrointestinal Lymphoma. **2024**, 613-655 ○
- 138 Pathology of Liver, Small Bowel, and Pancreas Transplantation. **2024**, 657-689 ○
- 137 Epidermotropic B-Cell Lymphoma: A Case of Secondary Cutaneous Splenic Marginal Zone B-Cell Lymphoma With Autoinvolutive and Recurrent Cutaneous Lesions. **2023**, 45, 81-85 ○
- 136 Subgroups and precision in myeloma. **2023**, 35, 100407 ○

- 135 Treatment approaches for patients with TP53-mutated mantle cell lymphoma. **2023**, 10, e142-e154 ○
- 134 Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Natural History, and Management in the Current Era. **2023**, ○
- 133 Primary Cutaneous T-Cell/Histiocyte-Rich B-Cell Lymphoma: A Case Report and Literature Review. Volume 16, 309-316 ○
- 132 Central Nervous System Progression/Relapse in Mature T- and NK-Cell Lymphomas. **2023**, 15, 925 ○
- 131 Role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and treatment response assessment of primary bone lymphoma. **2023**, 44, 318-329 ○
- 130 Management der Langerhans-Zell-Histiozytose bei erwachsenen Patienten. **2023**, 44, 59-65 ○
- 129 Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults. **2023**, 36, 101446 ○
- 128 Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective Elderly Project by the Fondazione Italiana Linfomi. ○
- 127 Transformation of recurrent ALK-positive anaplastic large-cell lymphoma from common pattern to composite pattern (lymphohistiocytic and small-cell pattern) with a change in CD30 expression. ○
- 126 Autoimmune Neutropenias: Update on Clinical and Biological Features in Children and Adults. **2023**, 7, e814 ○
- 125 Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia. **2023**, 30, 1903-1915 ○
- 124 Body Composition in Patients with Follicular Lymphoma: Associations between Changes in Radiomic Parameters in Patients Treated with R-CHOP-like and R-B Regimens: LyRa 01F. **2023**, 15, 999 ○
- 123 Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of MYD88 Mutations. **2023**, 24, 3177 ○
- 122 Molecular profiling of large B-Cell lymphomas : A retrospective observational pilot study. **2022**, 2, 125 ○
- 121 Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype. **2023**, 64, 734-737 ○
- 120 Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. ○
- 119 DNTT activation, TdT-aided gene length mutation, and better prognosis in ATG-based regimen allo-HSCT in AML. **2023**, 62, 665-675 ○
- 118 Comparison of Primary B/NKT Non-Hodgkin Lymphomas in Nasopharynx, Nasal Cavity, and Paranasal Sinuses. **2023**, 168, 1107-1118 ○

- 117 PTCL, NOS: An update on classification, risk-stratification, and treatment. 13, ○
- 116 Nomograms for predicting overall survival and cancer-specific survival in patients with head and neck non-Hodgkin lymphoma: A population-based study. **2023**, 102, e32865 ○
- 115 Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA). **2023**, 36, 101448 ○
- 114 A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma. 13, ○
- 113 Delayed diagnosis of oral lymphoma: a case series. **2023**, 234, 151-154 ○
- 112 Angioimmunoblastic T-cell lymphoma induced hemophagocytic lymphohistiocytosis and disseminated intravascular coagulopathy: A case report. 11, 1086-1093 ○
- 111 Comprehensive Analysis of Gene Expression Profiling to Explore Predictive Markers for Eradication Therapy Efficacy against Helicobacter pylori-Negative Gastric MALT Lymphoma. **2023**, 15, 1206 ○
- 110 Mutations in latent membrane protein 1 of Epstein-Barr virus are associated with increased risk of posttransplant lymphoproliferative disorder in children. **2023**, ○
- 109 Violaceous Lesions on the Leg: What Else Apart from Kaposi Sarcoma? Differential Diagnosis with a Narrative Review of the Literature. **2023**, 3, 56-68 ○
- 108 Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK /T-cell lymphoma: A French retrospective study. ○
- 107 Differential diagnosis of a local form of granulomatosis with polyangiitis: nasal cavity and paranasal sinuses lesions (part 1). **2023**, 17, 7-15 ○
- 106 Haemophagocytic Lymphohistiocytosis Associated With Anaplastic Large-Cell Lymphoma in a Young Woman. **2023**, ○
- 105 The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma. 14, ○
- 104 SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. **2023**, 22, ○
- 103 Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution. **2023**, 136, 167-175 ○
- 102 A Spectrum of Disease. **2023**, 50, 249-257 ○
- 101 How I manage mantle cell lymphoma: indolent versus aggressive disease. **2023**, 201, 185-198 ○
- 100 Prognostic value of interim 18F-FDG PET/CT in adult follicular lymphoma treated with R-CHOP. **2023**, 102, 795-800 ○

- 99 Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis. ○
- 98 Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. **2023**, 15, 1362 ○
- 97 Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer's ring in adults. **2023**, 482, 551-560 ○
- 96 Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis. **2023**, 64, 884-888 ○
- 95 ABO Blood Group and the Risk and Prognosis of Lymphoma. Volume 16, 769-778 ○
- 94 Hystosfinaire «apport des nouvelles techniques de biologie molculaire dans le diagnostic des lymphomes: mythe ou ralit?». Cas no 5 & 6. **2023**, 43, 139-145 ○
- 93 Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation. ○
- 92 Immunogenic Cell Death in Hematological Malignancy Therapy. 2207475 ○
- 91 Peripheral immune cell profiling of double-hit lymphoma by mass cytometry. **2023**, 23, ○
- 90 Up-front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra-nodal NKT cell lymphoma: A multicenter real-world study in China. ○
- 89 Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL. Volume 15, 245-255 ○
- 88 A Rare Case of Ovarian Double-Hit/Diffuse Large B-Cell Lymphoma: A Case Report and Review of Literature. **2023**, 11, 232470962311546 ○
- 87 [Translated article] Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. **2023**, 114, T291-T298 ○
- 86 Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma. 55, jrm004816 ○
- 85 Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen. **2023**, 102, 897-906 ○
- 84 Myeloid and Lymphoid Disorders in Geriatric Patients. **2023**, 427-444 ○
- 83 Application of CD27 AND CD44 expression for prediction of ETV6::RUNX1 fusion gene presence in pediatric B-CELL precursor acute lymphoblastic leukemia. **2022**, 11, 21 ○
- 82 Potential Prognostic and Predictive Role of Monocyte and Lymphocyte Counts on Presentation in Patients Diagnosed With Diffuse Large B-Cell Lymphoma. **2023**, ○

- 81 Virological Markers in EpsteinBarr Virus-Associated Diseases. **2023**, 15, 656
- 80 Prognostic Nomogram and Competing Risk Analysis of Death for Primary Thyroid Lymphoma. **2022**, 3, e226
- 79 Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis. **2023**, 11, 42
- 78 Radiologic and histopathology features of follicular dendritic cell sarcoma in the stomach and abdominal cavity: a case report.
- 77 Post-Transplant Lymphoproliferative Disorders. **2023**, 269-276
- 76 Intestinal and Multivesicular Transplantation in Children: Outcomes and Complications. **2023**, 319-329
- 75 Paediatric Lung Transplantation. **2023**, 525-542
- 74 Monomorphic epitheliotropic T-cell lymphoma of the small intestine. **2023**, 11, 307-309
- 73 The implication of Epstein-Barr virus latent membrane protein 1 on the composition and prognostic significance of the tumor microenvironment of classical Hodgkin lymphoma.
- 72 Integrated Genomic DNA/RNA Profiling vs Fluorescence in Situ Hybridization in the Detection ofMYCandBCL2(andBCL6) Rearrangements in Large B-Cell Lymphomas: Updates Amid the New WHO Classification of Lymphoid Neoplasms.
- 71 Differential diagnosis of lymphoma with 18F-FDG PET/CT in patients with fever of unknown origin accompanied by lymphadenopathy.
- 70 CD30 -positive lymphoproliferative disordersAn Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
- 69 Orbit. **2023**, 119-165
- 68 Pituitary Gland. **2023**, 255-278
- 67 Quimioterapia en linfoma y su estrecha relaci3n con el virus de la inmunodeficiencia humana /sndrome de inmunodeficiencia adquirida. **2023**, 32, 17-22
- 66 Cavernous Sinus. **2023**, 279-307
- 65 Marginal zone lymphoma-associated membranous nephropathy: a rare presentation.
- 64 KRAB zinc finger proteins ZNF587/ZNF417 protect lymphoma cells from replicative stress-induced inflammation.



- 63 Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis. 14, ○
- 62 Lymphoma and Myeloma Correlative Imaging. **2023**, 772-787 ○
- 61 The value of 18 F-FDG PET / CT quantitative indexes in the diagnosis of nondestructive posttransplant lymphoproliferative disorders after pediatric liver transplantation. ○
- 60 Nomogram model predicting the overall survival for patients with primary gastric mucosa-associated lymphoid tissue lymphoma. 15, 533-545 ○
- 59 Mutational Profile and Pathological Features of a Case of Interleukin-10 and RGS1-Positive Spindle Cell Variant Diffuse Large B-Cell Lymphoma. **2023**, 15, 188-200 ○
- 58 Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease. **2023**, ○
- 57 How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19 -directed chimeric antigen receptor T cells. **2023**, 201, 396-410 ○
- 56 Lymphomes hodgkiniens et non hodgkiniens. **2022**, 826-849 ○
- 55 NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma. 13, ○
- 54 Co-Detection of EBV and Human Polyomavirus JCPyV in a Case of AIDS-Related Multifocal Primary Central Nervous System Diffuse Large B-Cell Lymphoma. **2023**, 15, 755 ○
- 53 Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada. ○
- 52 Clinical and Pathological Features of Hydroa Vacciniforme-Like Lymphoproliferative Disorder Along with Risk Factors Indicating Poor Prognosis. Volume 16, 1545-1559 ○
- 51 Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era. **2023**, ○
- 50 SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL. **2023**, ○
- 49 Leukemic phase follicular lymphoma in a young adult. **2023**, 37, ○
- 48 Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials. **2023**, 32, 311-324 ○
- 47 LymphoML: An interpretable artificial intelligence-based method identifies morphologic features that correlate with lymphoma subtype. ○
- 46 Contagem de Reticulócitos e suas Frações Imaturas como Indicador Precoce de Alteração Medular em Trabalhadores de Postos de Combustíveis. **2023**, 69, ○

- 45 Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors. **2023**, 11, 964 ○
- 44 Application of the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice: a retrospective analysis apart from the clinical trial at two centers in Brazil. **2023**, ○
- 43 Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma. ○
- 42 Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma. **2023**, 16, 371-381 ○
- 41 Lymphoplasmacytic Lymphoma with Paraprotein IgG. **2022**, 18, 131-134 ○
- 40 Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies. **2023**, 201, 383-395 ○
- 39 Screening and Management of PTLD. Publish Ahead of Print, ○
- 38 Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma. **2023**, 102, 1141-1148 ○
- 37 Invasive Cutaneous Candidiasis, Autoimmune Hemolytic Anemia and Pancytopenia: A Challenging Scenario for Waldenström Macroglobulinemia in an Elderly Patient. **2023**, 11, 1007 ○
- 36 The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms. ○
- 35 T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma. **2023**, 2, ○
- 34 Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia. **2023**, 7, e870 ○
- 33 Potential Pathogenic Impact of Cow Milk Consumption and Bovine Milk-Derived Exosomal MicroRNAs in Diffuse Large B-Cell Lymphoma. **2023**, 24, 6102 ○
- 32 Evaluation of diagnostic efficacy of NRP -1/ CD304 in hematological diseases. ○
- 31 Benefit of prednisolone alone in nodal peripheral T-cell lymphoma with T follicular helper phenotype. **2023**, 63, 37-42 ○
- 30 Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation. 1-14 ○
- 29 High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma. ○
- 28 Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?. **2023**, 13, 604 ○

- 27 A Comparison of Smooth and Microtextured Breast Implants in Breast Augmentation: A Retrospective Study. **2023**, 50, 160-165 ○
- 26 Intravascular diffuse large B-cell lymphoma with acquired ichthyosis: A case report. **2023**, 11, 2050313X2311636
- 25 Comparison of efficacies of haploidentical transplantation and matched sibling donor transplantation in treating T-cell lymphoblastic lymphoma. ○
- 24 Clinical analysis of 20 cases of cutaneous extranodal NK/T-Cell lymphoma. 1-7 ○
- 23 Ocular adnexal lymphomas. **2023**, 275-278 ○
- 22 Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial. **2023**, ○
- 21 Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study. 14, ○
- 20 EBV and Lymphomagenesis. **2023**, 15, 2133 ○
- 19 Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. **2023**, 7, e837 ○
- 18 Tumours and Tumour-Like Lesions. **2024**, 842-946 ○
- 17 Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review. Volume 14, 261-277 ○
- 16 Lymphomas. **2023**, 1000-1013 ○
- 15 Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. **2023**, 8, ○
- 14 Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort. ○
- 13 Gamma heavy chain disease: a retrospective analysis of 6 cases. **2023**, 18, ○
- 12 First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology. ○
- 11 Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group. **2023**, 15, 2305 ○
- 10 An immunohistochemical study of double-expressor lymphomas and its correlation with cell of origin. **2023**, 19, 0 ○

- 9 Primary mediastinal/thymic diffuse large B-cell lymphoma: a population-based study on incidence and survival. ○
- 8 AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas. 1-11 ○
- 7 Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes. Volume 15, 367-375 ○
- 6 A nuclear NKRF interacting long noncoding RNA controls EBV eradication and suppresses tumor progression in natural killer/T-cell lymphoma. **2023**, 166722 ○
- 5 Application of circulating tumour DNA in terms of prognosis prediction in Chinese follicular lymphoma patients. 14, ○
- 4 Primary Gastric Lymphoma. **2023**, 507-515 ○
- 3 Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances. 13, ○
- 2 Chest Pain Caused by Thoracic Spine Plasmacytoma: A Case Report. **2023**, ○
- 1 Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways. **2023**, 36, 100198 ○